

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/057021 A2

(51) International Patent Classification⁷:

C12Q 1/68

(72) Inventor; and

(21) International Application Number:

PCT/CA2003/001994

(75) Inventor/Applicant (for US only): BOIVIN, Guy [CA/CA]; 2531 Montbray, Sainte-Foy, Québec G1V 1E7 (CA).

(22) International Filing Date:

19 December 2003 (19.12.2003)

(74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(25) Filing Language:

English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language:


English

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]


(54) Title: MOLECULAR METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING RESPIRATORY VIRUSES

A



(57) Abstract: There is provided compositions and methods for the detection and/or quantification of respiratory viruses using specific nucleic acid sequences. In particular methods and composition are provided to detect human Metapneumovirus (hMPV). The invention also provides with multiplex assays for detecting respiratory viruses in test samples.

B



WO 2004/057021 A2



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

- 1 -

MOLECULAR METHODS AND COMPOSITIONS FOR DETECTING AND
QUANTIFYING RESPIRATORY VIRUSES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority on Canadian applications serial number 2,411,264 filed on December 19, 2002 entitled "Sequences for detection and identification of the human metapneumovirus" and serial number 2,418,004 filed on January 24, 2003 entitled "Multiplex assays for detection and identification of viral respiratory pathogens.

10

TECHNICAL FIELD

This application relates to the field of microorganisms detection and more particularly to the detection of respiratory tract viruses using virus specific nucleic acids.

15

BACKGROUND OF THE INVENTION

Respiratory tract infections are a significant cause of morbidity and mortality in all age groups but especially in young children, elderly subjects, and immunocompromised patients. Most of these infections are caused by viruses with

20 influenza A and B and the human respiratory syncytial virus (hRSV) being associated with the most frequent and severe complications i.e. pneumonitis and death (Dowell et. al., 1996, J. Infect. Dis. 174:456-462; Simonsen et al., 2000, J. Infect. Dis. 181:831-837; Han et al., 1999, J. Infect. Dis. 179:25-30; Neuzil et al., 2000, N. Engl. J. Med. 342:225-231; Simoes, 1999, Lancet 354:847-852.). Other viruses such as

25 adenoviruses (> 50 serotypes), parainfluenza viruses (PIV) (4 serotypes), rhinoviruses (> 100 serotypes), and coronaviruses also contribute to acute respiratory tract infections (Tregonor, 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 7-26). Also, recent studies by the inventor and others have suggested that the new human metapneumovirus (hMPV) should be added to the list of human respiratory

30 viral pathogens in all age groups (van den Hoogen et al., 2001, Nat. Med. 7:719-724;

2
Peret et al., 2002, J. Infect. Dis. 185:1660-1663; Boivin et al., 2002, J. Infect. Dis. 186:1330-1334).

5 The hMPV was initially isolated from nasopharyngeal aspirates recovered from 28 children suffering from respiratory tract infections. Based on partial nucleic acid sequences, gene organization, and electron microscopy (EM) findings, this virus was preliminary assigned to the *Paramyxoviridae* family, subfamily *Pneumovirinae*, genus *Metapneumovirus*. Since then, hMPV has been isolated in North America by our group (Peret et al., 2002, J. Infect. Dis. 185:1660-1663), in Australia (Nissen et al., 2002, Med. J. Aust. 176:188), and in England (Stockton et al., 2002, Emerg. Infect. 10 Dis. 8:897-901).

Preliminary virological characteristics of hMPV.

15 The initial report by Van Den Hoogen et al. (van den Hoogen et al., 2001, Nat. Med. 7:719-724) indicated that the new virus replicated slowly in tertiary monkey kidney (TMK) cells with cytopathic effects (CPE) consisting of syncytium formation appearing 10-14 days post inoculation. Notably, the virus grew very poorly in Vero and A549 cells and could not be propagated in Madin Darby canine kidney (MDCK) cells. Virus-infected TMK cell-culture supernatants also did not display any 20 hemagglutinating activity. The supernatants of infected TMK cells were used for EM studies, which revealed the presence of paramyxovirus-like pleomorphic particles in the range of 150-600 nm with short envelope projections in the range of 13-17 nm. However, RT-PCR studies with primer sets specific for known paramyxoviruses were initially all negative. Using a random PCR amplification procedure known as RAP- 25 PCR (Welsh et al., 1990, Nucleic Acids Res. 18:7213-7218; Ralph et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:10710-10714), the Dutch investigators identified differentially displayed bands (compared to human parainfluenza-1 virus) which, upon sequencing, were found to be most closely related to the avian pneumovirus (APV).

APV, the agent of turkey rhinotracheitis, has been the sole member of the recently assigned *Metapneumovirus* genus within the *Pneumovirinae* subfamily (Taxonomy Virus, 2000, Seventh Report of the International Committee on Taxonomy of Viruses. San Diego. 551, 557, 559-560). The latter virus is a major respiratory pathogen of 5 turkeys and other domestic fowl worldwide (Yu et al., 1992, *Virology*. 186:426-434; Jones et al., 1987, *Vet. Rec.* 120:301-302; Jones, 1996, *Avian Pathol.* 25:639-648; Seal et al., 2000, *Virus Res.* 66:139-147). There are four serotypes of APV with serotype C (present in US) being the most closely related to hMPV (van den Hoogen et al., 2001, *Nat. Med.* 7:719-724). The metapneumoviruses (including APV and 10 hMPV) are structurally similar to the human respiratory syncytial virus (hRSV), which also belongs to the *Pneumovirinae* subfamily, except for two features: they lack the two non-structural proteins (NS1 and NS2) and they have a different genomic organization (Yu et al., 1992, *Virology*. 186:426-434). Recently, an almost complete 15 hMPV sequence (13.4 kb) was reported in GenBank (accession number: AF371337) (van den Hoogen et al., 2002, *Virology*. 295:119-132). The overall percentage of amino acid sequence identity for the N (nucleoprotein), P (phosphoprotein), M (matrix), F (fusion), M2 (membrane), and L (polymerase) proteins is in the range of 56-88% between hMPV and APV whereas it is 18-44% between hMPV and hRSV. However, the G (glycoprotein) and SH (small hydrophobic) proteins of hMPV do not 20 possess significant amino acid sequence identity with those of any other viruses. In contrast to APV, hMPV was shown to be unable to replicate in turkeys and chickens but the human virus replicated efficiently in the respiratory tract of cynomolgous macaques inducing upper respiratory tract symptoms that correlated with peak viral replication in throat samples between 2 to 8 days post infection (van den Hoogen et 25 al., 2001, *Nat. Med.* 7:719-724). Thus, these preliminary data indicated that hMPV was a primate pathogen associated with respiratory diseases.

Clinical importance of hMPV.

There is little information about the clinical presentation of hMPV infection. In the original report by Van Den Hoogen *et al.*, 27 of the 28 infected children from the 5 Netherlands were below the age of five (van den Hoogen *et al.*, 2001, *Nat. Med.* 7:719-724). It was mentioned that those infected patients were diagnosed with a range of acute respiratory tract infections (ARTI) from mild to severe including bronchiolitis and pneumonia although no detailed clinical data were provided. In a limited study conducted in the winter of 2000, the same authors found that 7 ($\approx 10\%$) 10 of 68 pediatric patients with unexplained ARTI had evidence of acute hMPV infection by RT-PCR (van den Hoogen *et al.*, 2001, *Nat. Med.* 7:719-724). In addition, Australian investigators reported the detection of hMPV by RT-PCR in 3/200 (1.5%) nasopharyngeal aspirates from children whose specimens were negative for the common respiratory viruses during the winter of 2001 (Nissen *et al.*, 2002, *Med. J. 15 Aust.* 176:188). Recently, hMPV RNA was detected by RT-PCR in 9/405 (2.2%) of nasopharyngeal swabs from English patients who consulted for influenza-like illnesses and had negative tests for other pathogens (Stockton *et al.*, 2002, *Emerg. Infect. Dis.* 8:897-901). These studies, however, suffer from major limitations such as their small size (in most cases), the superficial description of clinical features, the lack 20 of morbidity/mortality data, their retrospective nature, the exclusion of patients who tested positive for other viruses, and the absence of a control group.

Thus far, seroprevalence studies have been limited to the Dutch population. An indirect immunofluorescence assay (IFA) using infected TMK cells has revealed that 25 25% of the children aged between 6 and 12 months had hMPV antibodies and 70% had become seropositive by the age of 5 years (n=60) (van den Hoogen *et al.*, 2001, *Nat. Med.* 7:719-724). Retrospective serological testing also indicates that hMPV has been circulating in the Dutch population for at least half a century.

30 Diagnosis of hMPV infections

Our laboratory was the first to report the presence of hMPV in America and the second in the world following the initial report from the Netherlands (Peret et al., 2002, *J. Infect. Dis.* 185:1660-1663). Our first 11 hMPV strains were isolated on LLC-MK2 cells, a continuous cell line from rhesus monkey kidneys that is used in our center to recover parainfluenza viruses (PIV). Electron microscopy studies of these isolates revealed pleomorphic, spherical and filamentous particles with characteristics (nucleocapsid diameter and pitch spacing, length of projections) that were consistent with paramyxoviruses. RT-PCR and immunofluorescent assays for paramyxoviruses (PIV 1-3, hRSV) and other respiratory viruses (adenoviruses, 5 coronaviruses, influenza viruses A and B, rhinoviruses) were negative for all 11 isolates. In contrast, amplification of the hMPV F (fusion) and M (matrix) genes based on published partial sequences (van den Hoogen et al., 2001, *Nat. Med.* 7:719-724; van den Hoogen et al., 2002, *Virology*, 295:119-132) was positive for all isolates 10 (Peret et al., 2002, *J. Infect. Dis.* 185:1660-1663).

15 Subsequently, the virological features and clinical findings associated with a larger set of 38 hMPV strains from subjects hospitalized at our institution (CHUL, Québec City) since 1993 were examined in our laboratory (Boivin et al., 2002; *J. Infect. Dis.* 186:1330-1334). With all cell lines used in our laboratory, we were able to determine that the previously unidentified hMPV strains only consistently grew on LLC-MK2 20 cells after a mean incubation time of 17.3 days (range 3-23 days). Interestingly, most isolates recovered before 2002 produced only limited syncytia on LLC-MK2 cells, whereas some of the recent strains produced large syncytia typical of those induced by hRSV. Notably, we also observed a seroconversion for hMPV in two adult patients 25 for whom acute and convalescent sera were available using an IFA test designed in our laboratory. Such seroconversion episodes (titers from < 1/10 to 1/80 and from < 1/10 to 1/160 over 2 and 4 weeks, respectively) occurred during the course of the patients' illness suggesting that hMPV was a true respiratory pathogen. A phylogenetic analysis of hMPV Canadian strains based on F gene sequences identified two major phylogenetic groups. At the nucleotide level, we found a 30 similarity of 94.2-100% and 92.6-100% for isolates of groups 1 and 2, respectively, whereas the similarity at the amino acid level was higher i.e. 96.8-100% (group 1) and

97.2-100% (group 2) suggesting a functional/immunological conservation of the F protein. Interestingly, co-circulation of the two hMPV groups during some years was observed.

5 Over the past 9 years, most (86.7%) hMPV strains from our center were isolated during a 5-month period, from December to May. As an indication of the relative frequency of detection of hMPV compared to other respiratory viruses, we reviewed all respiratory samples (n = 862) sent to our virology laboratory for viral culture during the winter season (Dec. to May) of 2000-01. During this period, hMPV was 10 recovered in 2.3% of all respiratory samples tested by viral culture compared to 2.3% for PIV, 3.4% for adenoviruses, 4.8% for hRSV, and 19.8% for influenza A or B viruses. Overall, hMPV represented 7.1% of all positive cultures from respiratory samples during that winter season with percentages of 4.1%, 2.8%, and 29.3% for patients aged 0-5, 5-65, and > 65 years, respectively. A retrospective review of the 15 clinical charts from hMPV-infected subjects identified for the first time the role of this virus as a cause of severe lower respiratory tract infections in all age groups but especially in young children, elderly subjects, and immunocompromised patients. More specifically, the most frequent diagnoses associated with hMPV infection in hospitalized children were pneumonitis (66%) and bronchiolitis (58.3%) whereas 20 bronchitis/bronchospasm (60%) and pneumonitis (40%) were most commonly seen in elderly subjects (Boivin et al., 2002, *J. Infect. Dis.* 186:1330-1334). Although no histopathological studies were available, hMPV was the only pathogen identified in respiratory tract secretions of 3 subjects (including 2 with immunosuppressive conditions) who died of respiratory insufficiency.

25

We recently studied in greater details one of the cases associated with a fatal hMPV infection (Pelletier et al., 2002, *Emerg. Infect. Dis.* 8:976-978). Interestingly, this child with acute lymphoblastic leukemia was successively infected by two genetically-distinct hMPV strains on two consecutive winter seasons. On each 30 occasion, hMPV was the only pathogen isolated from a nasopharyngeal aspirate obtained during the course of lower respiratory tract infections (bronchiolitis in the

7

first year, bronchiolitis followed by fatal pneumonitis in the second year). Comparative sequence analysis of the amplified F gene products (759 bp) revealed that the two viral isolates differed by 114 nucleotides (10 amino acids) and belonged to two different hMPV groups. Overall, our data suggest that many hMPV strains may 5 co-circulate in a specific population during a given period and such viral diversity coupled with a waning immunity (as found in elderly subjects and immunocompromised patients) may lead to multiple and sometimes fatal reinfections similar to those reported with hRSV (Hall, 2001, *N. Engl. J. Med.* 344:1917-1928; Couch et al., 1997, *Am. J. Med.* 102:2-9).

10 The role and relative contribution of hMPV were recently further expanded in a prospective case-control study performed at our institution during the winter of 2001-02 (Dec. 15-April 20). All children \leq 3 years were eligible as cases if they were hospitalized for a lower respiratory tract infection (bronchiolitis, croup, pneumonitis) 15 whereas controls consisted of children matched for age and hospitalized for an elective surgery during the same period with no respiratory symptoms. Nasopharyngeal aspirates were obtained from all participants for real-time PCR studies performed on a LightCycler (Roche). The latter included a multiplex RT-PCR for common respiratory viruses (influenza A, influenza B, hRSV) and a real-time RT-PCR assay for hMPV (analytical sensitivity of 100 copies per PCR reaction). No 20 viruses were detected in samples from the 51 control patients. In contrast, at least one virus was identified in samples from 163 (78.4%) of the 208 cases (51% hRSV, 21.6% influenza A, 0% influenza B, 5.8% hMPV, and 5.9% co-infections). hRSV and influenza A infections occurred predominantly in the period between January and 25 March 2002, whereas hMPV infections increased after February. In fact, 11/12 hMPV cases occurred within a 4-week period from mid-March to mid-April accounting for 18.9% of all ARTI in children during this period. Data collected from our virology laboratory indicated that the hMPV outbreak extended after the end of the study protocol (April 20) which suggests that hMPV seasonal pattern may differ from that 30 of other respiratory viruses. A bronchiolitis was diagnosed in 67% of hMPV-infected children whereas 16.7% developed a pneumonia. In brief, there was no statistical

difference between the different viruses with regard to the symptomatology and reported diagnoses. Similarly, the median duration of hospitalization for the 3 viruses was identical (4-5 days).

5 In view of the above, it will be appreciated that diagnosis assay that can rapidly detect the presence of many respiratory viruses is needed.

Respiratory viruses have been classically identified by viral culture using a variety of permissive cell lines. However, viral culture is not convenient for clinical 10 management due to the need of specialized techniques (cell culture, immunofluorescence methods), the long turnaround time before appearance of typical cytopathic effects for many viruses (up to a few weeks), and the need for rapid inoculation of an infectious virus into multiple cell lines for optimal sensitivity (Speeter et al., 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 243-15 272).

Antigenic detection kits for some respiratory viruses (influenza viruses and hRSV) have been developed by many companies. Most are immunoenzymatic assays (ELISA) based on the capture of a viral antigen by a specific monoclonal antibody. 20 Although such assays eliminate many of the problems inherent to viral cultures (no need for specialized equipment, rapid turnaround time in < 30 min, no need to recover an infectious virus), they have not been widely adopted due to poor sensitivity and/or specificity compared to viral culture. For instance, the sensitivity and specificity of some rapid antigenic tests for influenza has varied from 46 to 96 % and from 52 to 99 25 %, respectively, compared to viral culture. The performance of these tests is dependent on many variables such as the patient's age, the type of specimen and the duration of the disease (Hayden et al., 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 891-920). The performance of the rapid antigenic tests for hRSV has been considered quite good in children with sensitivity and specificity varying 30 from 80 to 95 % (Piedra et al., 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 763-790) but poor in adults (Englund et al., 1996, J. Clin.

9

Microbiol. 34:1649-1653). Detection of antibodies against viral pathogens (serology) has a limited value in the diagnosis of acute viral infections since two serums, collected at a 2 to 3 week interval, are required in order to document a significant rise in viral antibody titers.

5

More recently, PCR or RT-PCR assays have been developed for many respiratory viruses allowing detection of small amounts of viral DNA or RNA in a clinical sample. In the so-called "multiplex" format, PCR assays have been designed to amplify more than one viral target in the same PCR reaction (Ellis et al., 1997, J. Clin. Microbiol. 35:2076-2082; Fan et al., 1998, Clin. Infect. Dis. 26:1397-1402; Liolios et al., 2001, J. Clin. Microbiol. 39:2779-2783; Grondahl et al., 1999, J. Clin. Microbiol. 37:1-7). However, most multiplex PCR assays reported to date do not allow the simultaneous detection of all viruses involved in acute respiratory tract infections of humans and they require separate steps for the amplification and detection of viral genes, greatly increasing the assay's turnaround time and preventing reliable quantification of the amplicons. At present, only one multiplex PCR assay (the Hexaplex test from Prodesse, Waukesha, WI) is commercially-available. The Hexaplex detects 6 respiratory viruses (influenza A and B, PIV 1-3 and hRSV) using specific viral probes in a microplate format (Fan et al., 1998, Clin. Infect. Dis. 26:1397-1402; Kehl et al., 2001, J. Clin. Microbiol. 39:1696-1701). This assay does not use real-time amplification methodologies and has a turnaround time of about one full working day. Thus, there is a need for developing more rapid molecular assays that permit detection of a larger panel of respiratory viral pathogens.

10

15

20

25

30

Rapid and sensitive detection of respiratory viruses is an important clinical goal to help physicians select the most appropriate antiviral, reduce nosocomial transmission of pathogens, decrease the length of hospitalization, and reduce antibiotic use and bacterial resistance. The present invention relates to the development of multiplex assays based on nucleic acids detection for sensitive and rapid diagnosis of most viral respiratory pathogens of humans.

10

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a rapid and sensitive method using amplification primers and/or probes for determining the presence and/or the amount in a test sample of nucleic acids from clinically important respiratory viral pathogens 5 including human metapneumovirus.

In another aspect there is provided multiplex assays aimed at detecting conserved genes of common respiratory viral pathogens such as influenza A and B, human respiratory syncytial virus (hRSV) A and B, human metapneumovirus (hMPV), 10 parainfluenza viruses (PIV) types 1-4, adenoviruses, rhinoviruses, enteroviruses, and coronaviruses.

The nucleic acid amplification method is preferably but not exclusively PCR. In a preferred embodiment, identification of the amplicons produced by the amplification 15 of nucleic acids from respiratory viruses is achieved by verifying the specific melting temperature of amplified viral products or by hybridization with specific viral probes. Other amplification technologies including target and probe amplification techniques as well as signal amplification techniques performed in liquid phase or onto solid supports may also be used.

20

It is an object of the present invention to provide a method using nucleic acid amplification and/or detection for determining the presence and/or the amount of nucleic acids of the human metapneumovirus (hMPV).

25

In a preferred embodiment, the nucleic acid amplification method is PCR. However, other amplification technologies including target and probe amplification techniques as well as signal amplification performed in liquid phase or onto solid support may also be used.

11

This invention provides a method to detect the presence of hMPV in a test sample based on the detection of a nucleotide sequence from either the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G), and small hydrophobic (SH) genes. In a particularly preferred 5 embodiment, the method to detect the presence of hMPV in a test sample is based on the detection of a nucleotide sequence from the nucleoprotein (N) or polymerase (L) genes.

In another embodiment, identification of amplified hMPV products is achieved by 10 verifying the specific melting temperature of amplified viral products or by hybridization with hMPV-specific probes.

It is another object of this invention to provide a method for typing hMPV strains which comprises the steps of reproducing the above amplification method followed 15 by either hybridization using type-specific probes, DNA sequencing or restriction enzyme analysis. Typing is done preferentially, but not exclusively, on the most variable hMPV genes i.e. the fusion (F) and glycoprotein (G) genes.

All the proprietary DNA fragments and oligonucleolides useful in the detection or 20 identification of a hMPV strain are further objects of this invention as well as any composition of matters that include them (recombinant vectors, hosts, diagnostic kits...).

25 **BRIEF DESCRIPTION OF THE DRAWINGS**

Further features and advantages of the present invention will become apparent from the following detailed description, taken in combination with the appended drawings, in which:

12

Figure 1 represents a melting curve analysis of amplified hMPV strains using specific nucleoprotein primers (Sequence ID Nos. 92 and 94);

5 Figure 2 shows an ethidium bromide-stained agarose gel showing restriction fragment length polymorphism of amplified hMPV fusion (F) gene sequences digested with enzymes ApaL I and Avr II. PCR products of the hMPV F gene (amplified with primers sequence ID Nos. 97 and 98) were digested with ApaL I and Avr II. Strains belonging to hMPV genotype F-1 were digested only by ApaL I resulting in two fragments of 532 bp and 227 bp whereas strains belonging to hMPV genotype F-2 10 were digested only by Avr II resulting in fragments of 447 and 312 bp.;

Figure 3 shows the age at admission of children hospitalized for acute respiratory tract infections (ARTI) caused by hMPV (A), hRSV (B), and influenza A (C) as well as for the whole study population (D) described in example 4;

15

Figure 4 represents the biweekly distribution of virologically cases with acute respiratory tract infections and their controls in the study reported in example 4;

20 Figure 5 represents the biweekly distribution of hMPV isolates in the study group (hospitalized children) described in example 4 and in respiratory specimens tested at the regional virology laboratory (RVL);

25 Figure 6 illustrates a phylogenetic tree of hMPV strains recovered as part of the study described in example 4 also including the prototype strain from the Netherlands (GenBank af371367) and a Canadian isolate from season 2000-01 (hMPV35-2001). The dates of sample collection are in parentheses;

30 Figure 7 is a melting curve analysis of viral strains amplified using the respiratory-1 multiplex real-time PCR assay. A- Multiplex real-time PCR assay using hMPV N primers (SEQ ID NOS. 95 and 96). B- Multiplex real-time PCR assay using hMPV L

13
primers (SEQ ID NOS. 112 and 114). Note: the internal control is apparent (Tm: 91°C) in the absence of amplification of specific viral products.;

Figure 8 is a melting curve analysis of viral strains amplified using the respiratory-2
5 multiplex real-time PCR assay. Note: The internal control is apparent (Tm: 91°C) in
the absence of amplification of specific viral products;

Figure 9A is a fluorescence signal as a function of elongation step for the
determination of the hMPV load in clinical samples using quantitative real-time PCR;
10

Figure 9B is a standard curve for determination of the hMPV using quantitative real-
time PCR;

Figure 10A is a phylogenetic tree for the F gene of hMPV;

15
Figure 10B is a phylogenetic tree for the G gene of hMPV;

Figure 11 is a melting curve analysis of amplified viral genes and of an internal
control as determined by the LightCycler instrument. Note that high amounts of
20 amplified viral products may preclude detection of the internal control in some PCR
runs; and

Figure 12 is a melting curve analysis SARS-coronavirus using a real time PCR assay.

25 It will be noted that throughout the appended drawings, like features are identified by
like reference numerals.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention provides nucleic acid based diagnostic methods and compositions to detect and quantify respiratory viruses.

5

In a preferred embodiment respiratory viral pathogens targeted by the diagnostic assays include all genotypes of influenza A and B viruses, hRSV, hMPV, PIV, adenoviruses, rhinoviruses, and enteroviruses. Other less common (coronaviruses, reoviruses) and yet to be discovered respiratory viruses are also targets under the 10 scope of the present invention.

In the description of this invention, the terms «nucleic acids» and «sequences» might be used interchangeably. However, «nucleic acids» are chemical entities while «sequences» are the pieces of information encoded by these «nucleic acids». Both nucleic acids and sequences are equivalently valuable sources of information for the 15 matter pertaining to this invention.

In one embodiment the method targets conserved hMPV nucleotide sequences for diagnostic purposes and variable hMPV sequences for epidemiological typing purposes. Nucleotide sequences were selected either from a number of hMPV viral 20 sequences obtained in the inventor's laboratory or from public databases (GenBank accession number AF371337).

Our proprietary DNA fragments and oligonucleotides (a non-restrictive list of primers and probes) are listed in the following tables.

25

It will be understood by those skilled in the art that sequences that can selectively hybridize to the sequences of the present invention are also comprised in the scope of the invention. By selectively hybridizing it is meant that a nucleic acid molecule binds to a given target in a manner that is detectable in a different manner from non-target

15

sequence under moderate, or more preferably under high, stringency conditions of *hybridization*. "Complementary" or "target" nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid molecule. Proper annealing conditions depend, for example, upon a nucleic acid molecule's length, base composition, and the number of mismatches and their position on the molecule, and must often be determined empirically. For discussions of nucleic acid molecule (probe) design and annealing conditions, see, for example, Sambrook et al. 1989 (Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)) or Ausubel et al. 1987 (Ausubel, F., et al., Current Protocols in Molecular Biology, New York (1987)).

The detection of the viruses including the hMPV is conducted through compositions of matters such as diagnostic kits comprising the amplification primers or probes of this invention.

15

In the methods and kits of the present invention, probes and primers are not limited to nucleic acids and may include, but are not restricted to, analogs of nucleotides. The diagnostic reagents constituted by the probes and the primers may be present in any suitable form (bound to a solid support, liquid, lyophilized, etc.) for detection and/or amplification of nucleic acid sequences of the viruses.

In the methods and kits of the present invention, amplification reactions may include but are not restricted to: a) polymerase chain reaction (PCR), b) ligase chain reaction (LCR), c) nucleic acid sequence-based amplification (NASBA), d) self-sustained sequence replication (3SR), e) strand displacement amplification (SDA), f) branched DNA signal amplification (bDNA), g) transcription-mediated amplification (TMA), h) cycling probe technology (CPT), i) nested PCR, j) multiplex PCR, k) solid phase amplification (SPA), l) nuclease dependent signal amplification (NDSA), m) rolling circle amplification technology (RCA), n) anchored strand displacement amplification, o) solid-phase (immobilized) rolling circle amplification.

In the methods and kits of the present invention, detection of the nucleic acids of target genes may include real-time or post-amplification technologies. These detection technologies can include, but are not limited to, the use of intercalating agents such as SYBR green, fluorescence resonance energy transfer (FRET)-based methods such as adjacent hybridization of probes (including probe-probe and probe-primer methods), *TaqMan* probe, molecular beacon probe, Scorpion probe, nanoparticle probe and Amplifluor probe. Other detection methods include target gene nucleic acids detection via immunological methods, solid phase hybridization methods on filters, chips or any other solid support. In these systems, the hybridization can be monitored by fluorescence, chemiluminescence, potentiometry, mass spectrometry, plasmon resonance, polarimetry, colorimetry, flow cytometry or scanometry. Nucleotide sequencing, including sequencing by dideoxy termination or sequencing by hybridization (e.g. sequencing using a DNA chip) represents another method to detect and characterize the nucleic acids of target genes.

Amplification of hMPV sequences

In one aspect of the invention there is provided methods and compositions for detecting hMPV in a sample.

In a preferred embodiment, a reverse-transcription (RT)-PCR protocol is used for nucleic acid amplification. The single-stranded viral RNA is converted to complementary DNA using an enzyme possessing a reverse transcriptase activity and a specific hMPV primer. Alternatively, random hexamer primers can be substituted to the specific hMPV primer. In a preferred embodiment, viral RNA was prealably extracted from 200 µl of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN). Complementary DNA was synthesized using 10 µl of eluted RNA, 0.75 µM of a specific hMPV primer (Table 2, sequences ID Nos. 91, 97, 100, 102, 109, 112), and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's recommendations.

For DNA amplification by the widely used PCR method, primer pairs were derived from our proprietary DNA fragments or from public database sequences (Table 1).

During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-denatured target DNA from the microbial genome are used

5 to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109).

10 In a preferred embodiment, complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation (Sigma-Aldrich, Oakville, ON) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2
15 μ l of RT mixture and 18 μ l of a reaction mixture containing 4 mM MgCl₂, 2 μ l of Faststart DNA SYBR Green Master Mix or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation, 3% DMSO, and 0.5 μ M of each hMPV primer (see Tables 2 and 4 for sequence ID Nos. and specific combinations of primers for amplification, respectively). Cycling conditions typically included an initial
20 denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. However, the cycling conditions could slightly vary according to the hMPV gene to amplify.

25 The person skilled in the art of nucleic acid and/or signal amplification knows the existence of other rapid amplification procedures such as ligase chain reaction (LCR), reverse transcriptase PCR (RT-PCR), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling circle
30 amplification technology (RCA), solid phase RCA, anchored SDA and nucleic acid dependent signal amplification (NDSA) (Persing, 1993, Diagnostic Molecular

18

Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109; Lee, 1997, Nucleic Acid Amplification Technologies: Applications to Disease Diagnosis, Eaton Publishing, Boston, MA. 61-125; Westin et al., 2000, Nat. Biotechnol. 18:199-204). The scope of this invention is not limited to the use of amplification by PCR, but rather includes the use of any nucleic acid amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acid and/or signal amplification and detection technology including real-time or post-amplification detection technologies, any amplification technology combined with detection, any hybridization nucleic acid chips or array technologies, any amplification chips or combination of amplification and hybridization chip technologies. Detection and identification by any nucleotide sequencing method is also under the scope of the present invention.

15

Any oligonucleotide, useful for diagnosis, and which are derived from hMPV sequences and used with any nucleic acid amplification and/or hybridization technologies are also under the scope of this invention.

20

Detection of amplification products

Classically, the detection of PCR amplification products is performed by standard ethidium bromide-stained agarose gel electrophoresis. Using this approach, primers specific for a nucleotide sequence from either the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), polymerase (L), glycoprotein (G), genes generated amplicons of various lengths depending on the selected primers pairs (Table 4). It is however clear that other detection methods of amplified products may be faster, more sensitive, and more practical. Amplicon detection may also be performed by solid support or liquid hybridization using strain-specific internal DNA probes hybridizing to an amplification product. Such probes may be generated from sequences from our repertory (Table 1) and designed to specifically hybridize to DNA amplification

19

products which are objects of the present invention. Amplicons can also be characterized by DNA sequencing. Alternatively, a rapid detection method developed with real-time PCR assays consists of determining the specific melting temperature of amplicons at the end of the amplification reaction.

5

In a preferred embodiment, detection of hMPV amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler instrument, the internal temperature was rapidly increased to 94°C then decreased to 60°C for 30 seconds, followed by slowly increasing to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture. Using this procedure, the specific melting temperature obtained with the specific amplicons produced by the pairs of primers specific for the N (SEQ ID No 92+94), M (SEQ ID No 100+101), F (SEQ ID 97+98), P (SEQ ID No 102 +103) and L (SEQ ID No 112 + 113) gene sequences was found to be $82.63^{\circ}\text{C} \pm 0.87^{\circ}\text{C}$, $82.75^{\circ}\text{C} \pm 0.80^{\circ}\text{C}$, $83.29^{\circ}\text{C} \pm 0.45^{\circ}\text{C}$, $80.48^{\circ}\text{C} \pm 0.46^{\circ}\text{C}$, and $77.99 \pm 0.33^{\circ}\text{C}$, respectively (Table 5 and see also Figure 1 for example of the melting temperature obtained for different hMPV strains with the N primers). Alternatively, we also designed specific adjacent and TaqMan fluorescent probes for the various hMPV gene products (N, M, F, G, P and L) that can be used for real-time detection and quantification of amplicons (Table 3). Here, quantification of hMPV gene products is achieved through fluorescence resonance energy transfer (FRET) when the two probes hybridize nearby on a complementary DNA sequence. Other types of detection methods including the use of TaqMan or molecular beacon probes specific for the hMPV sequences described above are also under the scope of this invention.

25

Typing of hMPV

Previous studies have shown that two major genotypes of hMPV circulate in North America and Europe (van den Hoogen et al., 2001, Nat. Med. 7:719-724; Boivin et al., 2002, J. Infect. Dis. 186:1330-1334). We also designed a rapid molecular typing method for epidemiologic studies based on amplification of a portion of the F (fusion)

20

glycoprotein (primer sequence ID Nos. 97 and 98, Tables 2 and 4) followed by DNA sequencing or digestion with restriction enzymes (ApaL I and Avr II). Table 6 summarizes the size of the F fragments obtained for different hMPV isolates following enzymatic digestion and the corresponding genotype (see also Figure 2 for 5 an example of the band pattern following electrophoresis on an agarose gel). Alternative typing methods based on the use of type-specific hMPV F primers and/or probes as well as DNA sequencing of amplified products are also within the scope of this invention. hMPV subtyping using similar methodologies for the other surface glycoprotein (i.e. the G gene) may also be used.

10

A method for detection of a plurality of potential hMPV strains having different genotypes may be conducted in separate reactions and physical enclosures, one type at the time. Alternatively, it could be conducted simultaneously for different types in separate physical enclosures, or in the same physical enclosures. In the latter scenario 15 a multiplex PCR reaction could be conducted which would require that the oligonucleotides are all capable of annealing with a target region under common conditions. Since many probes or primers are specific for a determined genotype, typing an hMPV strain is under the scope of the present invention. When a mixture of oligonucleotides annealing together with more than one type of hMPV is used in a 20 single physical enclosure or container, different detection labels would be used to distinguish one type from another.

The diagnostic kits, primers and/or probes mentioned above can be used to detect and/or identify hMPV, whether said diagnostic kits, primers and probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: 25 any clinical sample, any environmental sample, any viral culture, any tissue, or any cell line.

It is also an object of the present invention that said diagnostic kits, primers and/or probes can be used alone or in combination with any other assay suitable to detect 30 and/or identify other microorganisms (i.e. viruses, bacteria, fungi, and parasites) including but not limited to: any assay based on nucleic acids detection, any

21

immunoassay, any enzymatic assay, any biochemical assay, any lysotypic assay, any serological assay, any culture on specific cell lines, and any infectivity assay on animals.

- 5 In the methods and kits described herein below, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). All DNA sequences have been obtained either from our proprietary sequences (Table 1) or from SEQ ID No. 1 from public databases.
- 10 It is clear to the individual skilled in the art that oligonucleotide sequences other than those described in the present invention and which are appropriate for detection and/or identification of hMPV may also be derived from the proprietary fragment sequences or selected public database sequences. For example, the oligonucleotide primers or probes may be shorter but of a length of at least 10 nucleotides or longer than the ones chosen; they may also be selected anywhere else in the proprietary DNA fragments or in the sequences selected from public databases; they may also be variants of the same oligonucleotide. If the target DNA or a variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true: a given target
- 15 20 DNA may hybridize to a variant oligonucleotide probe or be amplified by a variant oligonucleotide PCR primer. Alternatively, the oligonucleotides may be designed from said DNA fragment sequences for use in amplification methods other than PCR. Consequently, the core of this invention is the detection and/or identification of hMPV by targeting DNA sequences which are used as a source of specific and
- 25 30 ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes require much effort, it is quite possible for the individual skilled in the art to derive, from the selected DNA fragments, oligonucleotides other than the ones listed in Tables 2 and 3 which are suitable for diagnostic purposes. When a proprietary fragment or a public database sequence is selected for its specificity and ubiquity (i.e. ability to detect all

hMPV strains), it increases the probability that subsets thereof will also be specific and ubiquitous.

5 The proprietary DNA fragments have been obtained as a repertory of sequences created by amplifying hMPV nucleic acids with proprietary primers. These primers and the repertory of nucleic acids as well as the repertory of nucleotide sequences are further objects of this invention (Tables 1-3).

10 As part of the design rules, all oligonucleotides were evaluated for their suitability for hybridization or PCR amplification by computer analysis using standard programs (i.e. the GCG Wisconsin package programs, the primer analysis software Oligo™ 6 and MFOLD 3.0). The potential suitability of the PCR primer pairs was also evaluated prior to their synthesis by verifying the absence of unwanted features such as long stretches of the same nucleotide and a high proportion of G or C residues at 15 the 3' end (Persing, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109). Oligonucleotide amplification primers were synthesized using an automated DNA synthesizer (Applied Biosystems).

20 The oligonucleotide sequence of primers or probes may be derived from either strand of the duplex DNA. The primers or probes may consist of the bases A, G, C, or T or analogs and they may be degenerated at one or more chosen nucleotide position(s) (Nichols et al., 1994, Nature. 369:492-493). Primers and probes may also consist of nucleotide analogs such as Locked Nucleic Acids (LNA) (Koskin et al., 1998, 25 Tetrahedron Lett. 54:3607-3630), and Peptide Nucleic Acids (PNA) (Egholm et al., 1993, Nature. 365:566-568). The primers or probes may be of any suitable length and may be selected anywhere within the DNA sequences from proprietary fragments, or from selected database sequences which are suitable for the detection of hMPV.

30 Variants for a given target microbial gene are naturally occurring and are attributable to sequence variation within that gene. For example, different strains of the same viral

23

species may have a single or more nucleotide variation(s) at the oligonucleotide hybridization site. The person skilled in the art is well aware of the existence of variant nucleic acids and/or sequences for a specific gene and that the frequency of sequence variations depends on the selective pressure during evolution on a given 5 gene product. The detection of a variant sequence for a region between two PCR primers may be demonstrated by sequencing the amplification product. In order to show the presence of sequence variations at the primer hybridization site, one has to amplify a larger DNA target with PCR primers outside that hybridization site. Sequencing of this larger fragment will allow the detection of sequence variation at 10 this primer hybridization site. A similar strategy may be applied to show variations at the hybridization site of a probe. Insofar as the divergence of the target nucleic acids and/or sequences or a part thereof does not affect significantly the sensitivity and/or specificity and/or ubiquity of the amplification primers or probes, variant microbial DNA is under the scope of this invention. Variants of the selected primers or probes 15 may also be used to amplify or hybridize to a variant target DNA.

In an other aspect of the invention there is also provided newly isolated human metapneumoviruses deposited with International Depository Authority of Canada on December 11 2003 and bearing IDAC numbers 111203-01 and 111203-02 (also 20 referred herein as CAN 97-83 and CAN 98-75 respectively).

In a further aspect of the invention the diagnostic method is designed at performing simultaneous detection of nucleic acids from a variety of respiratory viruses using specific primers and/or probes. The method is aimed at detecting and/or quantifying 25 conserved viral sequences from respiratory viruses for diagnostic purposes. Target nucleotide sequences were selected public databases and from viral strain sequences obtained in the inventor's laboratory.

The specific respiratory viral pathogens targeted by the diagnostic assays include all 30 genotypes of influenza A and B viruses, hRSV, hMPV, PIV, adenoviruses, rhinoviruses, and enteroviruses. Other less common (coronaviruses, reoviruses) and

24

yet to discover respiratory viruses are also targets under the scope of the present invention.

5 The specific combination of oligonucleotides (primers and/or probes) in a multiplex format is also another object of this invention.

Composition of matters such as diagnostic kits comprising amplification primers and/or probes for the detection of respiratory viruses are also objects of the present invention.

10

Amplification of viral sequences

In a preferred embodiment, a PCR protocol is used for nucleic acid amplification. Multiplex assay, aimed at amplifying a plurality of respiratory viruses in the same 15 physical enclosure, is an object of the present invention.

We aim at developing DNA-based tests or diagnostic kits to detect and identify most respiratory viruses in a limited number of amplification reactions using specific primers (Table 10) and/or probes (Table 11). Although some of the primer sequences 20 used for amplification of the various respiratory viruses, with the exception of hMPV (SEQ. ID. Nos. 95 and 96 or 112 and 114), PIV-1 (SEQ. ID. Nos. 147 and 148), PIV-3 (SEQ. ID. Nos. 151 and 152), and adenovirus (SEQ. ID. Nos. 153), have been described previously by others (Fouchier et al., 2000, J. Clin. Microbiol. 38:4096-4101 for influenza A virus / SEQ. ID. Nos. 139 and 140; Li et al., 2001, J. Clin. 25 Microbiol. 39:696-704 for influenza B virus / SEQ. ID. Nos. 141 and 142; Mazulli et al., 1999, J. Infect. Dis. 180:1686-1689 for hRSV / SEQ. ID. Nos. 143 and 144; Osiowy et al., 1998, J. Clin. Microbiol. 36: 3149-3154 for PIV-1, PIV-3, and adenovirus / SEQ. ID. Nos. 145 and 146, 149 and 150, and 154 and 155, respectively; Atmar et al., 1993, J. Clin. Microbiol. 31: 2544-2546 for rhinovirus and enterovirus / 30 SEQ. ID. Nos. 160 and 161) and that one influenza A primer (SEQ. ID. No. 139) is

25

almost identical to the one described in another patent (U.S. patent number 6,015,664), the object of the present invention is to combine many sets of primers and/or probes in the same physical enclosure (multiplex format).

5 Briefly, viral RNA was extracted from 200 μ l of naso-pharyngeal aspirates or other respiratory tract samples using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). Complementary DNA (cDNA) was then synthesized using 10 μ l of the RNA preparation, 0.75 μ M of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), 300 copies of an internal control 10 template, and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's instructions. The internal control template consisted of a 554 or 558 bp (depending on the multiplex assay) transcribed region of an herpes simplex virus type 2 DNA polymerase region flanked by either influenza B or rhinovirus/enterovirus complementary primer sequences (depending on the 15 multiplex assay) cloned in the pDrive plasmid (QIAGEN).

For DNA amplification by the widely used PCR method, primer pairs were mostly derived from public database sequences (Table 10). During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-20 denatured target DNA from the viral genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing, 1993, Diagnosis Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C., 88-109).

25

In a preferred embodiment, cDNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation (Sigma-Aldrich, Oakville, ON) in a LightCycler instrument (Roche 30 Diagnostics). Each reaction had a total volume of 20 μ l including 2 μ l of cDNA and 18 μ l of a reaction mixture containing 4 mM MgCl₂, 2 μ l of LC Faststart DNA SYBR

26

Green 1 Master Mix or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation, 3% DMSO, and 0.3-1.0 μ M of each viral primer (see Tables 10, 12, and 13 for primer sequence ID NOs., length of amplicons, and specific combination of primers, respectively). Cycling conditions typically included an initial 5 denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. However, the cycling conditions could vary slightly according to the multiplex PCR assay.

In a preferred embodiment, two real-time multiplex PCR assays were used to amplify 10 and detect the panel of common respiratory viruses (Table 13). The respiratory-1 multiplex assay combines 4 sets of primers for amplification of influenza A and B viruses, hRSV, hMPV, and an internal control template. The respiratory-2 multiplex assay comprises 4 other sets of primers for amplification of PIV-1, PIV-3, adenoviruses, rhinoviruses/enteroviruses, and an internal control template. The use of 15 any other combinations of the same or similar primer sequences in two or more than two multiplex assays for detection of common respiratory viral pathogens is also under the scope of this invention.

The person skilled in the art of nucleic acid amplification knows the existence of other 20 rapid amplification procedures such as ligase chain reaction (LCR), reverse transcriptase PCR (RT-PCR), solid phase PCR, transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling 25 circle amplification technology (RCA), solid phase RCA, anchored SDA, and nuclease dependent signal amplification (NDSA) (Pershing, 1993, *Diagnosis Molecular Microbiology: Principles and Applications*, American Society for Microbiology, Washington, D.C., 88-109; Lee, 1997, *Nucleic Acid Amplification Technologies: Application to Disease Diagnosis*, Eaton Publishing, Boston, MA., 61-125; Westin et 30 al., 2000, *Nat. Biotechnol.* 18:199-204). The scope of this invention is not limited to the use of amplification by PCR, but rather includes the use of any nucleic acid

27

amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acids amplification and detection technology including real-time or post-amplification detection technologies, any 5 amplification technology combined with detection, any hybridization nucleic acid chips or array technologies, any amplification chips or combination of amplification and hybridization chip technologies. Detection and identification by any nucleotide sequencing method is also under the scope of the present invention.

1.0 Detection of amplification products

Classically, the detection of PCR amplification products is performed by standard ethidium bromide-stained agarose gel electrophoresis. Using this approach, the amplicons may be discriminated based on their size. In the present invention, the 15 length of the different amplicons varies from 84 to 929 bp (Table 12). It is however clear that other detection methods of amplified products may be faster, more sensitive, and more practical. Amplicon detection may also be performed by solid support or liquid hybridization using strain-specific, internal DNA probes hybridizing to an amplification product. Such probes may be generated from sequences designed to 20 specifically hybridize to DNA amplification products which are objects of the present invention. Amplicons can be also characterized by DNA sequencing. Alternatively, a rapid detection method developed with real-time PCR assays consist of determining the specific melting temperature of amplicons at the end of the amplification reaction.

25 The detection of viral amplicons was first characterized using the melting curve analysis feature of a real-time PCR instrument. Using this procedure, the different viral targets amplified in each of the multiplex PCR assays could be differentiated by their specific melting temperature (Table 13 and Fig. 7 and 8). Alternatively, specific 30 fluorescent probes (Table 11) for each viral target can be used for real-time detection and quantification of amplicons in a single amplification/detection assay. Real-time quantification of viral products can be performed through a variety of fluorescence-

based technologies such as adjacent probes, Taqman probes, and molecular beacons. Alternatively, these probes may be used in a separate post-amplification step.

The diagnostic kits, primers and probes mentioned above can be used to detect and/or

5 identify respiratory viruses, whether said diagnostic kits, primers and/or probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: any clinical sample, any environmental sample, any viral culture, any tissue, and any cell line.

10 It is also an object of the present invention that said diagnostic kits, primers and/or probes can be used alone or in combination with any other assay suitable to detect and/or identify and /or quantify microorganisms, including but not limited to: any assay based on nucleic acids detection, any immunoassay, any enzymatic assay, any biochemical assay, any serological assay, any culture on specific cell lines, and any

15 infectivity assay on animals.

In the methods and kits described herein, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). It is clear to the individual skilled in the art that oligonucleotide sequences other than those described in the present invention and which are appropriate for detection and/or identification of any respiratory viruses may also be derived from those selected in the present invention. For example, the oligonucleotide primers or probes may be shorter but of a length of at least 10 nucleotides or longer than the ones chosen; they may also be variants of the same oligonucleotide. If the target DNA or a variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true; a given target DNA may hybridize to a variant oligonucleotide probe or be amplified by variant oligonucleotide PCR primers. Alternatively, the oligonucleotides may be designed for use in amplification methods other than PCR. Consequently, one aspect of the present invention is the simultaneous detection and/or identification of various respiratory viruses by targeting nucleic acid sequences which are used as a

29

source of specific and ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes require much effort, it is quite possible for the individual skilled in the art to derive, from the selected oligonucleotides (listed in Tables 10 and 11), other oligonucleotides which are suitable for diagnostic purposes.

5 Thus, the specific primers and/or probes selected for amplification and detection of respiratory viruses and their specific combination in multiplex assays are objects of this invention (Tables 10-13).

10

EXAMPLES:

Example 1: Evaluation of different primers for hMPV detection

15

An evaluation of the sensitivity of different hMPV primer sets in a real-time PCR assay was performed using 20 positive hMPV cultures grown in LLC-MK2 cells and 10 naso-pharyngeal aspirate specimens. These samples were collected in the Québec City area (QC, Canada) over a period of 3 years (2000-2002). Viral RNA was prealably extracted from 200 µl of viral culture supernatants or naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN). Complementary DNA was synthesized using 10 µl of eluted RNA, 0.75 µM of a specific hMPV primer (Table 2, sequences ID Nos. 91, 97, 100, 102, 112), and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's recommendations. Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of RT mixture and 18 µl of a reaction mixture containing 4 mM MgCl₂, 2 µl of Faststart DNA SYBR Green Master Mix, 3% DMSO, and 0.5 µM of each hMPV primer (Table 4: sequence ID Nos.: 92 and 94; 100 and 101; 97 and 98; 102 and 103; and 112 and 113, for the nucleoprotein (N),

30

matrix (M), fusion (F), phosphoprotein (P), and polymerase (L) genes respectively).

Cycling conditions typically included an initial denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. However, the cycling conditions could slightly vary according to the hMPV gene to amplify.

5 Detection of hMPV amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler instrument, the internal temperature was rapidly increased to 94°C then decreased to 60°C for 30 seconds, followed by slowly increasing to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture.

10

Using this procedure, the specific melting temperature obtained with the hMPV amplicons produced by the primers specific for target genes coding for N, M, F, P and L proteins was found to be 82.63°C ± 0.87°C, 82.75°C ± 0.80°C, 83.29°C ± 0.45°C, 80.48°C ± 0.46°C, and 77.99 ± 0.33°C, respectively. As shown in Table 5, a real-time

15 PCR assay using primers complementary to the N gene successfully amplified RNA from all 20 cultures and 10 clinical specimens. In contrast, hMPV primers specific for the M, F, P, and L genes had sensitivities of only 70%, 63.3%, 50%, and 89.7% respectively. Thus, primers aimed at amplifying the hMPV N gene appear to target more conserved regions of the hMPV genome and, consequently, were selected for

20 further detailed evaluation (see example 2).

Example 2: Validation of a real-time PCR assay for the hMPV nucleoprotein (N) gene in a pediatric population

25 An hMPV N plasmid was constructed by subcloning the amplified hMPV N region in the plasmid pDrive (QIAGEN, Mississauga, ON, Canada). The new plasmid was transcribed using the RNA Transcription Kit (Stratagene, Vancouver, BC, Canada) for sensitivity analysis. Using the previously described RT procedure (N primer, sequence ID No. 91) and real-time PCR protocol (N primers, sequence ID Nos. 92

30 and 94) reported in example 1, the sensitivity of the assay was estimated at 100 copies per reaction with a specific melting temperature of 82 °C. The assay was found to be

31

specific with no amplification signal observed when viral cultures positive for the human respiratory syncytial virus, the parainfluenza viruses, the influenza viruses A and B, and the adenoviruses were tested. The real-time PCR assay for the hMPV N gene was subsequently validated in a prospective case-control study in children below 5 the age of 3 years hospitalized at Laval University Hospital Center (CHUQ-CHUL) in Québec City, Canada, during the winter season of 2001-02. Cases consisted of children hospitalized for a respiratory syndrome whereas controls consisted of children hospitalized during the same period for a surgery with no respiratory symptoms. At admission, a nasopharyngeal aspirate was collected for viral antigen 10 tests, viral cultures, and RT-PCR studies for influenza A and B viruses, the human respiratory syncytial virus (hRSV), and the hMPV N gene.

No virus was detected in any of the samples from the 51 control children. Among the 208 cases tested by real-time PCR for hMPV, hRSV, influenza A and B viruses, the 15 positivity rates were 5.8%, 51.0%, 21.6%, and 0%, respectively. Viral culture was positive for hMPV in only 2 cases whereas the real-time hMPV PCR assay for the N gene was positive for 12 cases including the 2 positive by viral culture. All positive hMPV PCR results for the N gene were confirmed by a second PCR assay targeting the hMPV fusion (F) gene and by the use of DNA sequencing which indicated the 20 presence of multiple hMPV strains clustering in the two previously-reported F genotypes. Thus, the real-time PCR assay described in this invention appears to be much more sensitive than conventional viral culture for the detection of hMPV in clinical samples.

32

Example 3: Typing of hMPV clinical strains using restriction enzyme analysis

We designed a rapid molecular typing method for hMPV epidemiological studies based on amplification of a portion of the fusion (F) gene which is then digested with specific restriction enzymes. Briefly, a 759-bp fragment of the hMPV F gene was 5 amplified by a real-time PCR procedure as described in example 1 using specific primers (sequence ID Nos. 97 and 98). After PCR amplification, two aliquots (10 μ L) of the PCR product were digested during 2 hours at 37°C with 10 units of ApaL I and 4 units of Avr II (New England Biolabs, Mississauga, ON, Canada) according to the manufacturer's recommendations. Digested products were then loaded on an 1% 10 agarose gel for electrophoresis.

Table 6 summarizes the size of the F fragments obtained for different hMPV isolates following enzymatic digestion and the corresponding genotype as defined by DNA sequencing and phylogenetic studies. In brief, all hMPV isolates belonging to the 15 genotype F-I were digested by ApaL I (fragments of 532 and 227 bp) but not by Avr II whereas those belonging to the genotype F-II were digested by Avr II (fragments of 447 and 312 bp) but not by ApaL I (see Figure 2 for an example of the band pattern following electrophoresis on an agarose gel).

20 **Example 4 : A prospective case-control study for defining the role of respiratory viruses in children hospitalized for acute respiratory tract infections**

Summary

The human metapneumovirus (hMPV) is a new paramyxovirus recently isolated from 25 young children with respiratory syndromes. The objectives of this study were to estimate the relative contribution of hMPV in children's hospitalization for acute respiratory tract infections (ARTI) and to define its clinical presentation and seasonal pattern.

33

We evaluated the percentage of hospitalizations for ARTI in children aged 0-3 years attribute to hMPV and other respiratory viruses in a prospective case-control study during the winter/spring seasons of 2002. We used multiplex real-time PCR assays and other conventional diagnostic methods to detect hMPV, the human respiratory syncytial virus (hRSV), and the influenza viruses in nasopharyngeal aspirates of children.

HMPV was detected in 12 (5.8%) of the 208 children hospitalized for ARTI as compared to 118 (56.7%) for hRSV and 49 (23.6%) for influenza A. In contrast, none of the 51 controls harbored any of the respiratory viruses. Most hRSV and influenza infections occurred in January and February whereas the peak hMPV activity was in March and April. The peak age for hospitalizations for hRSV and hMPV infections was < 3 months and 3-5 months, respectively. Diagnoses of bronchiolitis and pneumonitis were made in respectively 67% and 17% of hMPV-infected children compared to 84% and 25% for those with hRSV infection. None of the hMPV-infected children was admitted to the intensive care unit compared to 15% for those with hRSV or influenza A infections.

HMPV causes significant morbidity in young children and its clinical presentation is similar although less severe than that of hRSV.

Introduction

The human metapneumovirus (hMPV) is the first human member of the new *Metapneumovirus* genus within the *Paramyxoviridae* family (van den Hoogen BG, de Jong JC, Groen J, et al.. Nat Med 2001;7:719-24; van den Hoogen BG et al. Virology 2002;295:119-32.) The human respiratory syncytial virus (hRSV) belongs to a separate genus within the same family (Taxonomy V. Seventh Report of the International Committee on Taxonomy of Viruses. Academic, San Diego, 2000.).

30 HMPV has been recently identified in nasopharyngeal aspirates of children and adults suffering from a range of respiratory tract infections in various parts of the world (van

34

den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Nissen MD, et al. *Med J Aust* 2002;176:188; Peret TC, Boivin G, Li Y, et al. *J Infect Dis* 2002;185:1660-3; Stockton J, et al. *Emerg Infect Dis* 2002;8:897-901). The clinical syndrome of the infected children encompasses mild respiratory problems to 5 bronchiolitis and pneumonitis (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Pelletier G, et al. *Emerg Infect Dis* 2002;8:976-8; Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4).

Using reverse-transcription polymerase chain reaction (RT-PCR), the rate of hMPV 10 detection in nasopharyngeal aspirates (NPA) of pediatric patients with unexplained ARTI varied between 1.5 and 10% (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Nissen MD, et al. *Med J Aust* 2002;176:188). These retrospective studies are small, excluded patients who tested positive for other viruses, only superficially describe the clinical features of the disease and lack 15 morbidity/mortality data. In absence of a control group, these studies cannot differentiate if hMPV is a colonizing or a pathogenic virus. More recently, Stockton et al. identified hMPV RNA in 2.2% of 405 specimens from patients with influenza-like illnesses who consulted general practitioners in England although few swabs were collected from children < 5 years (Stockton J, et al. *Emerg Infect Dis* 2002;8:897-20 901).

The objectives of this study were to estimate the relative contribution of hMPV in children's hospitalization for acute respiratory tract infections (ARTI) and to define its clinical presentation and seasonal pattern.

Materials and Methods

Study design. Participants were children aged \leq 3 years hospitalized between December 15, 2001 and April 20, 2002 at Laval University Hospital Center (CHUQ-CHUL) in Québec City, Canada. Cases were admitted for an ARTI (bronchiolitis, 5 pneumonitis, laryngotracheobronchitis, etc...) whereas controls were hospitalized for an elective surgery and had no respiratory symptoms or fever. Children hospitalized twice were counted as two cases. At admission, after signed consent was obtained from their parents, all children had an NPA (1-2 ml) collected and tested for hRSV antigen (TestPack, Abbott Laboratories, Abbott Park, IL). The specimen was frozen at 10 -80°C until subsequent RT-PCR studies. Additionally, viral cultures, direct immunofluorescence staining, and microbiological testing were performed according to the treating physician. A standardized questionnaire was completed at admission by 15 a single research nurse with the parents. At the end of the hospitalization, the children's charts were reviewed to collect clinical and laboratory data. The study was approved by the CHUQ-CHUL research ethics board.

RNA extraction and cDNA synthesis. Viral RNA was extracted from 200 μl of NPA specimens using the QIAamp viral RNA Mini Kit (QIAGEN, Mississauga, ON, Canada). Complementary cDNA was synthesized using 10 μl of eluted RNA and the 20 Omniscript Reverse Transcriptase kit (QIAGEN). Random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfe, QC, Canada) were used in the RT step of the multiplex respiratory PCR assay whereas a specific primer (5'-TGGGACAAGTGAAATGTC-3') serves to synthesize hMPV cDNA in a separate PCR assay. An internal control (300 copies) consisting of a 534-bp transcribed region 25 of the pDrive plasmid (QIAGEN) flanked by influenza B complementary primer sequences (see below) was spiked in the RT reaction of the multiplex respiratory PCR assay to verify the presence of PCR inhibitors.

RT-PCR assays and phylogenetic studies. The multiplex respiratory PCR assay 30 was designed to amplify conserved regions of the influenza A (SEQ. ID Nos.139-140) (Fouchier RA, et al. J Clin Microbiol 2000;38:4096-101) and B (SEQ. ID Nos. 141-

36

142) (Li J, Chen S, Evans DH. *J Clin Microbiol* 2001;39:696-704) matrix genes as well as the fusion gene of hRSV (SEQ. ID Nos. 143-144) (Mazzulli T, Peret TC, McGeer A, et al. *J Infect Dis* 1999;180:1686-9).

5 Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, Québec, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2 μ l of cDNA and 18 μ l of a reaction mixture containing 2.4 mM MgCl₂, 2 μ l of Faststart DNA SYBR Green Master Mix, 3% DMSO, 0.3 mM 10 each of influenza A and B primers, and 0.8 mM of hRSV primers. The thermal cycling incubations consisted of an initial denaturation step at 94°C for 10 min, followed by 50 cycles of 15 s at 94°, 5 s at 58°C, and 25 s at 72°C. At the end of each cycle, the fluorescent signal was measured at a wavelength of 530 nM using the LightCycler Fluorimeter. The melting curve analysis program of the LightCycler was 15 used to identify specific PCR products of influenza A (Tm: 85°C), influenza B (Tm: 83°C), hRSV (Tm: 79°C), and the internal control (Tm: 92°C). The sensitivity of the multiplex respiratory PCR assay was estimated at 50 copies for each viral target when mixed with 300 copies of the internal control.

20 A specific PCR assay was designed for amplification of the hMPV Nucleoprotein (N) gene in the LightCycler instrument. The sequences of the forward (MPV-NCS) and reverse (MPV-NCA) primers were respectively 5'-GAGTCTCAGTACACAATTAA-3' (SEQ ID NO 92) and 5'-GCATTTCCGAGAACACAC-3' (SEQ ID NO 94). The specific cDNA was amplified using conditions similar to those of the multiplex 25 respiratory PCR assay except that 0.5 mM of each primer was added to the master mix. Cycling conditions included an initial denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. The melting temperature of the amplified hMPV N fragment was 82°C and the sensitivity of the PCR assay was 100 copies. For phylogenetic studies, nucleotide sequences were 30 determined from amplified hMPV F (fusion) gene products then analyzed using the

37

neighbor joining algorithm and Kimura-2 parameters. (Boivin G, Abed Y, Pelletier G, et al. J Infect Dis 2002;186:1330-4).

hMPV in the general population. To further assess the seasonal distribution,

5 affected age groups and frequency of hMPV, we compared data from the study to those of the general population derived from the viral cultures found positive for hMPV in our regional virology diagnostic laboratory, the only one performing viral cultures for the Québec City area (population approximately 600 000). Respiratory specimens were inoculated in 96-well plates containing ten cell lines (MDCK, LLC-
10 MK2, Hep-2, human foreskin fibroblast, Vero, mink lung, A-549, rhabdomyosarcoma, 293, and HT-29) then incubated for a period of 21 days. A positive cytopathic effect was confirmed by immunofluorescence testing using monoclonal antibodies or by RT-PCR (hMPV).

15 Statistical analyses. Proportions were compared by the χ^2 test.

Results

The study population included a total of 208 hospitalized cases with ARTI (including 8 children who were admitted twice) and 51 children who served as controls.

20

Description of the study population and viral etiologies. The age distribution of children with ARTI is presented in Fig. 3: 56% (116) were male and 44% (92) were female. Hospitalization was the highest in infants \leq 3 months of age and steadily decreased thereafter. Most (90%) children had no underlying medical conditions at admission.

25 All 208 cases had an NPA. The mean delay between the onset of symptoms and collection of NPA was 6 days (median 4 days). This delay did not differ for the different viruses detected. All 208 cases were tested by PCR, 204 had an hRSV

antigen detection test, 100 had a direct examination procedure for other viruses, and 100 had a viral culture. At least one respiratory virus was detected in 164 (79%) cases whereas none was detected in 44. Twelve children (5.8%) were positive for hMPV, 118 (56.7%) for hRSV, 49 (23.6%) for influenza A, and none for influenza B (Table 7). There was no PCR testing for adenoviruses and PIV type 2 but these two viruses were found in 6% and 2%, respectively, of the 100 viral cultures or antigenic assays. Single virus infections occurred in 141 (86%) of the 164 positive cases and mixed infection was present in 23 (14%). Two of the 12 hMPV infections were mixed (hMPV-influenza and hMPV-hRSV). The other combinations were hRSV-influenza A (18 cases), hRSV-adenovirus (2), and influenza A-adenovirus (1).

Among the 208 cases tested by PCR for hMPV, hRSV, influenza A and B viruses, the positivity rates were 5.8%, 51.0%, 21.6%, and 0%, respectively (Table 7). In addition, 16 other cases had one of the four latter respiratory viruses identified only by culture (3 influenza A and one hRSV), only by an antigen detection test (10 hRSV and one influenza A) or by both culture and antigen detection test (1 hRSV). Among the 8 children hospitalized twice, none had the same viral infection at both admissions. The combinations observed were hMPV - hRSV (2), hMPV - no virus (1), hRSV - no virus (2), hRSV - influenza (2), no virus - no virus (1).

The biweekly distribution of cases with respiratory tract viruses is shown in Fig. 4. hRSV and influenza A infections occurred predominantly between January and March, whereas hMPV infections occurred mostly in March and April. The proportion of children with virologically-confirmed respiratory tract infection decreased after February.

Clinical features of cases. The distribution of the age distribution by different viral infections is shown in Fig. 3. While the peak age for hMPV infection was 3-5 months, it was before 3 months for hRSV infection. For influenza A, it spread evenly during the first year of life. The peak age for mixed infection was 6-11 months and decreased thereafter. Gender was distributed evenly with each virus group but more males

(70%) had mixed viral infections. The majority (75% with hMPV, 93% with hRSV, 90% with influenza A virus infection) of the children in different etiological groups had no medical underlying conditions. Three (25%) children with hMPV infection had a cardiac disorder, one having concomitant cardiac, pulmonary, and neurological problems.

5 Signs and symptoms recorded with the different respiratory viruses were generally similar except for the vomiting which occurs more frequently with hMPV infections (p = 0.05) (Table 8). The mean and median duration of hospitalization was similar for 10 hMPV, hRSV and influenza A viruses being respectively 5.5 and 4.5, 5.8 and 5.0, and 4.9 and 4.0 days. Of note, one third of hMPV-infected children were hospitalized more than 7 days. None of the children with hMPV infection was admitted to the intensive care unit (ICU) contrasting with 15% and 16% of children with hRSV and influenza A, respectively. There was no death as part of this study. The duration of the 15 hospitalization in children with no detectable virus was shorter than that in children with single or mixed infection (Kruskal-Wallis Test, p < .0001). Two-thirds of the children were given antibiotics during their hospitalization, independently of the etiology of their respiratory disease.

20 At hospital discharge, a final diagnosis of bronchiolitis was given to 67% of children with hMPV, 84% with hRSV, and 51% with influenza A (p <0.001) (Table 9). Otitis occurred in about half of children with hMPV, hRSV, and influenza A infections. Pneumonitis was less frequently diagnosed in children with hMPV compared to those with hRSV or influenza A (17%, 25%, and 37%, p=0.22). Final diagnoses were 25 similar with single and mixed infections.

Controls. There were 51 children in the control group, 29 (56.9%) males and 22 (43.1%) females. The age distribution of the controls was similar to that of the cases (Fig. 3) as was the period of hospital admission (Fig. 4). None of the controls had a 30 virus detected by PCR.

40

hMPV in the general population. The regional virology laboratory received 1505 respiratory specimens for viral culture between January 1 and June 30, 2002. In total, 36 (including two study participants) or 2.9% were positive for hMPV: 24 (66.6%) in children < 2 years of age, 5 in those 2 to 4 years, 4 in adults 30-49 years, and 3 in 5 those 70 years or older. Most cases (81%) were isolated over a two-month period (from March 23 to May 18) (Fig. 5). When comparing the seasonal distribution of hMPV in hospitalized children (study population) and in the general population, it appears that the study in hospitalized children did not cover the entire hMPV season as it was stopped just after the peak time of hMPV transmission (April 6-20).

10

Phylogenetic analyses of hMPV strains. The 12 hMPV strains isolated in the prospective study clearly clustered into two F lineages with nine strains belonging to group 1 and three to group 2 (Fig. 6). Seven of the 9 group 1 strains had identical F gene sequences. At the nucleotide level, there was 84-85% similarity between groups 15 versus 98-100% (group 1) and 93-99% (group 2) similarity within groups. There were fewer differences at the amino acid level i.e. 94-96% similarity between groups versus 99-100% (group 1) and 98-99% (group 2) among strains within the same group. Although there was a trend for more recent strains to cluster in group 2, the correlation between genotypes and date of hospitalization was not perfect as two 20 strains detected on the same day (No. 216 and 217) belonged to two different F lineages.

Discussion

Our prospective study has revealed important clinical and epidemiological features 25 related to hMPV. First, our data indicate that hMPV is really a respiratory pathogen. Second, we found that it contributes to ARTI leading to children's hospitalization in proportion similar to adenoviruses or PIV but significantly less than hRSV and influenza viruses. Third, the symptoms and complications associated with hMPV were indistinguishable from those caused by hRSV. Finally, our results suggest that 30 the epidemiology of hMPV infection in children may differ from that of hRSV and

41

influenza viruses both in terms of the age of first acquisition and in the timing of the seasonal epidemics.

Recent studies by our group (Pelletier G, et al. *Emerg Infect Dis* 2002;8:976-8; Boivin 5 G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4) and others (van den Hoogen BG, de Jong JC, Groen J, et al *Nat Med* 2001;7:719-24.; Nissen MD et al. *Med J Aust* 2002;176:188; Stockton J, et al. *Emerg Infect Dis* 2002;8:897-901) had suggested that hMPV should be added to the list of human respiratory viral pathogens (Dowell SF, Anderson LJ, Gary HE, Jr., et al. *J Infect Dis* 1996;174:456-62; Treanor 10 JJ. *Respiratory Infections*. In: Richman DD, Whitley, R.J., Hayden, F.G., ed. *Clinical Virology*. Vol. 1. Washington: ASM Press, 2002:7-26).

The absence of hMPV in respiratory tract of our 51 control children, the absence of other respiratory viruses in 83% of the 12 hMPV-infected children and the severity of 15 their symptoms (bronchiolitis and/or pneumonitis) provide further evidence that hMPV is really a pathogenic respiratory virus. The absence of underlying medical conditions in 75% of the hMPV-infected children further demonstrates its pathogenicity. The use of PCR assays was particularly advantageous for hMPV because its growth in culture is fastidious and limited to a few permissive cell lines 20 (Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4) and because rapid antigenic detection tests are currently unavailable.

Our study provides for the first an estimate of the proportion of ARTI hospitalizations 25 attributable to hMPV in a pediatric population. During the period ranging from December 15 to April 20 2002, hMPV accounted for 5.8% of all hospitalizations for respiratory tract infections in children aged 0-3 years. This underestimates the real proportion as our hospitalization study stopped before the end of the hMPV season prevailing in the community (Fig. 5). Although we did not perform PCR testing for adenoviruses and PIV, the percentage of hospitalizations caused by hMPV seems 30 similar to that attributable to these two viruses and much smaller than that of hRSV or influenza A.

One of the most important conclusion of our study is that hMPV disease cannot be distinguished on clinical findings from that caused by hRSV and influenza A (Tables 8 and 9) but tended to be somewhat less severe with fewer pneumonia and no 5 admission in the ICU. Nevertheless, hMPV infection was associated with a significant clinical and economical burden as shown by a mean hospital stay of 5.5 days and one-third of hMPV-infected cases being hospitalized for > 7 days.

A small serological study from the Netherlands showed that all children over the age 10 of 5 years had hMPV antibodies suggesting a high level of transmission.¹ Data from our study suggest that morbidity caused by hMPV is greatest in children < 2 years of age as they represented 83% (10/12) of our hospitalized cases and two-thirds of the hMPV isolates recovered in our diagnostic virology laboratory. This suggests that similar to other paramyxoviruses such as hRSV, the morbidity of hMPV in children 15 occurs through primo-infection. In contrast to hRSV which peaked during the first three months of life, hMPV infections peaked at a slightly older age i.e. between the third and fifth month of life. Whether this difference depends on a longer persistence of maternal antibodies or a less efficient transmission mode in the case of hMPV would require additional studies.

20 During the 4-week period from mid-March to mid-April, hMPV infections clustered (11/12 detected) and accounted for 18.9% of all hospitalizations for ARTI in children. This contrasts with hRSV and influenza A which occurred mostly in January and February (Figure 4). Based on passive surveillance data from our regional virology 25 laboratory, the peak time of hMPV transmission in the community occurred between April 6-20, 2002, and continued beyond the end of our study in hospitalized children (Fig. 5). Year-long active surveillance studies will be required to better assess the seasonal patterns of hMPV transmission.

30 As described for hRSV (Mazzulli T, Peret TC, McGeer A, et al J Infect Dis 1999;180:1686-9), several strains of hMPV circulated during a very short period of

43

time (one month) in our study area. The hMPV strains segregated into two F subgroups in agreement with previous studies although one strain clearly predominated accounting for 58.3% of all isolates (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Peret TC, Boivin G, Li Y, et al. *J Infect Dis* 2002;185:1660-3; Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4).

5 Due to the small number of hMPV strains belonging to one of the F subgroup, we did not attempt to correlate hMPV genotype with clinical outcome. Such viral heterogeneity may allow multiple reinfections throughout life especially in elderly 10 subjects and immunocompromised patients (Pelletier G, Dery P, Abed Y, Boivin G *Emerg Infect Dis* 2002;8:976-8).

In conclusion, our study supports the concept of the epidemic nature of hMPV 15 infection and establishes its role as a significant pathogen in severe ARTI of children.

15 **Example 5: Determination of the hMPV Load in Clinical Samples Using Quantitative Real-time PCR**

20 An evaluation of a quantitative real-time PCR hMPV assay using a TaqMan probe was performed using naso-pharyngeal aspirate specimens collected from children and adults in Québec City during the winter seasons of 2001-02 and 2002-03. Viral RNA was first extracted from 200 µl of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN) and eluted in a volume of 40 µl. Serial concentrations 25 (5X10² to 1X10⁹ copies) of a transcribed hMPV plasmid were used to construct the standard curve of the assay. Complementary DNA was synthesized using 10 µl of eluted RNA from clinical samples or hMPV plasmid dilutions, 50 ng (0.75 µM) of random hexamer primers (Amersham Pharmacia Biotech), 0.5 mM of dNTPs, 1X Omniscript buffer and 4 units of the Omniscript reverse transcriptase (QIAGEN) in a 30 final volume of 20 µl. The reverse transcription (RT) mixture was incubated during 1.5 hr. at 37°C and inactivated at 70°C during 10 min. Complementary DNA was amplified by real-time PCR with a TaqMan probe for the hMPV L gene and the LC

44

Master Hybridization Probe Mix (Roche Diagnostics) in a LightCycler instrument (Roche Diagnostics). Each reaction had a volume of 20 μ l including 2 μ l of RT mixture, 4 mM MgCl₂, 0.3 μ M of specific hMPV L primers (sequence ID Nos. 112 and 114), 0.6 μ M of a specific hMPV L probe (SEQ. ID. No. 127), and 2 μ l of the LC 5 Master Hybridization Probe Mix (Roche Diagnostics). Cycling conditions included an initial denaturation step of 30 s at 94°C, followed by 60 cycles of 5 s at 94°C, 5 s at 56°C, and 25 s at 72°C. A fluorescence lecture was taken after each elongation step (Fig. 9A). A standard curve for the PCR reaction was constructed by plotting cycle threshold values against log concentrations of each hMPV plasmid dilution. The 10 number of hMPV copies present in clinical samples was calculated by interpolating cycle threshold values into the assay's standard curve (Fig. 9B).

Example 6: Determination of hMPV genotypes based on amplification and sequencing of the viral F and G genes.

15 Determination of hMPV genotypes was achieved by PCR amplification of the F or G genes followed by DNA sequencing of the viral amplified products. Different sets of primers were used for PCR amplification and DNA sequencing of the F (SEQ. ID. 20 Nos. 97 and 98) and G (SEQ. ID. Nos. 104 and 107 or 108 and 109) genes. Alignment of viral DNA sequences was done with the CLUSTAL W software version 1.7 for Unix and phylogenetic trees were computed by maximum parsimony, distance and maximum likelihood-based criteria analysis using PAUP version 4.0.d8. Phylogenetic trees for both the F (Fig. 10A) and G (Fig. 10B) genes from Canadian and non- 25 Canadian viral isolates revealed the existence of two hMPV groups (genotypes A and B) with two subgroups (subtypes 1 and 2) within each group.

Example 7: Comparison of viral culture and multiplex PCR assay for detection of influenza A virus.

30 A multiplex PCR assay (including PCR primers defined in SEQ. ID. Nos. 139, 140, 141, 142, 143, and 144) aimed at detecting influenza A and B viruses and the respiratory syncytial virus was used to assess the etiology of severe acute respiratory

tract infections (ARTI) necessitating hospitalization in children aged 0-3 years during the winter season 2001-02 at the CHUL, an university-based hospital, in Québec City (Canada). Nasopharyngeal (NPA) samples from all 208 children with ARTI were tested by multiplex PCR whereas a subset of 100 NPA specimens was inoculated on 5 Madin Darby Canine Kidney (MDCK) cells for influenza culture. Briefly, viral RNA was prealably extracted from 200 μ l of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). cDNA was then synthesized using 10 μ l of the RNA preparation, 0.75 μ M of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), 300 copies of an internal 10 control template, and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's instructions. The internal control template consisted of a 558-bp transcribed region of an herpes simplex virus type 2 DNA polymerase region flanked by influenza B complementary primer sequences cloned into the pDrive plasmid (QIAGEN). cDNA was amplified using a 15 real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2 μ l of complementary DNA and 18 μ l of a reaction mixture containing 4 mM MgCl₂, 2 μ l of LC Faststart DNA SYBR Green Master 1 Mix, 3% DMSO, 0.3 μ M of influenza A 20 and influenza B primers, and 0.8 μ M of human respiratory syncytial virus primers (Table 10). Cycling conditions included an initial denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. Detection of viral amplicons was characterized using the melting curve analysis feature of a 25 real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler, the reaction temperature was rapidly increased to 94°C and was then decreased to 60°C for 30 seconds followed by a slow increase to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture. Using this procedure, the amplified products of influenza A, influenza B, hRSV, and the internal control could be differentiated by virtue of their specific Tm values i.e. 85, 83, 79, and 91°C, 30 respectively (Table 13 and Fig. 11).

46

Influenza A virus was detected by multiplex PCR (specific Tm value of 85°C) in 45/208 (21.6%) of the samples tested whereas the culture was positive for this virus in 14/100 (14%) tested NPA samples from children. For the subset of 100 NPA specimens tested by both methods, 88 (88%) had concordant results (11 positive, 77 negative) whereas discordant results were obtained for 12 (12%) samples (3 culture⁺/PCR⁻, 9 culture⁻/PCR⁺). Assuming that all positive results (by either culture or PCR) were true positive, the sensitivity values of the culture and the multiplex PCR for influenza A virus were 60.9% and 87.0%, respectively. There was no positive result for influenza B virus by any detection method as part of this study.

10

Example 8: Comparison of antigen detection and multiplex PCR assay for detection of the human respiratory syncytial virus.

Same as example 1, except that the multiplex PCR assay was used to detect hRSV from NPA samples obtained from 211 children with ARTI and compared with an antigen detection test for hRSV (TestPack, Abbott Laboratories, Abbott Park, IL).

hRSV was detected by the multiplex PCR (specific Tm value of 79°C) in 109/211 (51.7%) of the tested samples whereas the hRSV antigen detection test was positive in 93/211 (44.1%) tested NPA samples from children. Concordant results were found in 183 (86.7%) samples (87 positive, 96 negative) whereas discordant results were obtained for 28 (13.3%) samples (6 antigen⁺/PCR⁻, 22 antigen⁻/PCR⁺). A second RT-PCR assay for detection of another hRSV gene (glycoprotein G) was used to resolve the discrepancies (Peret et al., 1998, J Gen Virol.79:2221-2229). After the resolution of the discrepant results, the sensitivity values of the antigen detection test and the multiplex PCR for hRSV were 80.5% and 96.5%, respectively.

Example 9: Evaluation of multiplex real time PCR assay for Influenza and human respiratory syncytial viruses.

We developed a real-time multiplex PCR assay for influenza viruses and HRSV using 5 the melting curve analysis feature of the LightCycler instrument to rapidly distinguish viral products.

Materials and methods

Study population and antigenic test. Nasopharyngeal aspirates (NPA) were 10 prospectively collected from children aged 0-3 years hospitalized for ARTI during the winter season 2001-02 at a single, university-based hospital, in Québec City (Canada) (Boivin, G., et al. 2003. Emerg. Infect. Dis. 9:634-640). The study was approved by the institutional review board of the Centre Hospitalier Universitaire de Québec. All samples were tested by the multiplex real-time PCR assay whereas antigen detection 15 tests were performed on a subset of samples upon request by the treating physician. An aliquot (750 µl) of fresh NPA was first tested for the presence of HRSV and influenza A/B antigens using respectively the RSV TestPack (Abbott Laboratories, Abbott Park, IL) and the Directigen Flu A+B test (Becton Dickinson, Sparks, MD). The rest of the specimen was frozen at -80°C for a maximum of 3 months before 20 nucleic acid extraction and PCR testing.

RNA extraction and cDNA synthesis. Viral RNA was extracted from 200 µl of NPA samples using the QIAamp Viral RNA Mini kit (QIAGEN, Missisauga, ON, Canada). Complementary DNA was then synthesized using 10 µl of the RNA preparation, 0.75 25 µM of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), and the Omniscript Reverse Transcriptase kit (QIAGEN) in presence of 300 copies of an internal control. The internal control template consisted of a 558-bp transcribed region of the herpes simplex virus type 2 DNA polymerase gene flanked by influenza B complementary primer sequences (see below) cloned into the pDrive 30 plasmid (QIAGEN).

Real-time multiplex and conventional PCR assays. The multiplex PCR respiratory assay was designed to amplify conserved regions of the influenza A (Fouchier, R. A., et al. . 2000.. J. Clin. Microbiol. 38:4096-4101) and B (Li, J., S. Chen, and D. H. Evans. 2001.. J. Clin. Microbiol. 39:696-704) matrix genes as well as the fusion gene of HRSV (Mazzulli, T., et al, 1999. J. Infect. Dis. 180:1686-1689). Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2 μ l of cDNA and 18 μ l of a reaction mixture containing 2.4 mM MgCl₂, 2 μ l of Faststart DNA SYBR Green 1 Master Mix, 3% DMSO, 0.3 mM of influenza A and B primers (SEQ. ID Nos. 139-140 and 141-142), and 0.8 mM of HRSV primers (SEQ. ID Nos. 143-144). Cycling conditions included an initial denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. At the end of each cycle, the fluorescent signal was measured at a wavelength of 530 nM using the LightCycler Fluorimeter. The melting curve analysis program of the LightCycler was used to identify specific PCR products. Briefly, following the last amplification cycle, the reaction temperature was rapidly increased to 94°C and was then decreased to 60°C for 30 s followed by a slow increase to 94°C at a rate of 0.1°C per s, with continuous fluorescence monitoring. For resolution of discrepant results between the multiplex PCR assay and antigenic tests, conventional RT-PCR assays for detection of the glycoprotein G gene of HRSV (Peret, T. C., et al. 1998. J. Gen. Virol. 79:2221-2229) and the M2 gene of influenza A viruses (Klimov, A. I., et al. . 1995. J. Infect. Dis. 172:1352-1355) were performed retrospectively.

25 Results

Assay's characteristics. The sensitivity of each individual real-time PCR assay and of the multiplex PCR respiratory assay was determined for each target by testing serial dilutions of transcribed plasmids containing specific viral sequences. The lower limit of detection for influenza A, influenza B, and HRSV was found to be 10, 50 and 30 copies, respectively, in individual PCR assays whereas it was 50 copies for each target (10 out of 10 times for influenza A and 9 out of 10 times for influenza B and

49

HRSV) in the multiplex PCR test. No amplification signal was detected in the real-time multiplex assay when testing viral DNA or RNA from adenoviruses, rhinoviruses, enteroviruses (echo 11), parainfluenza viruses 1-3, human metapneumovirus, and herpesviruses (herpes simplex virus type 1 and 2, 5 cytomegalovirus, and varicella-zoster virus). Specific melting temperature (Tm) values were first determined by testing a set of clinical isolates and vaccine strains (11 influenza A/H1, 10 influenza A/H3, 10 influenza B, and 17 HRSV) from different years (Table 14). A representative set of results is shown in Fig.11. The mean Tm values were 85.27 ± 0.22 , 83.47 ± 0.46 , and 79.51 ± 0.30 °C for influenza A, influenza 10 B, and HRSV corresponding to fragments of 245, 524, and 380 bp, respectively, after gel electrophoresis (Table 14). We found no influence of influenza A subtype (H1 and H3) and HRSV genotype (A and B) on the Tm values (Table 14). The addition of 300 copies of the internal control in the assay's master mix resulted in a specific amplification peak with a Tm value of 91°C (558 bp) in the absence of amplified viral 15 products.

Evaluation of the multiplex PCR respiratory assay in a pediatric population. The multiplex PCR assay was evaluated using extracted RNA from 208 NPA samples collected during a prospective pediatric study aimed at assessing the role of the 20 human metapneumovirus in hospitalized children (0-3 years) with ARTI (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640). The number of positive samples by multiplex PCR for influenza A, influenza B, and HRSV was found to be 45 (21.6%), 0 (0%), and 106 (51.0%), respectively. Overall, the rate of positivity for any of the 3 viruses was 66.8% (139/208) including 5.8% (12/208) of co-infections with influenza 25 A and HRSV. None of the samples was considered to contain PCR-inhibitory samples as verified by the amplification of the internal control in all PCR-negative samples. The ranges of Tm values for influenza A- and HRSV-positive samples were $85.10 \pm$ 0.39 and 79.60 ± 0.42 °C, respectively. All amplified products with one of the latter Tm values were confirmed as specific viral targets by visualizing the appropriate band 30 on agarose gel. As none of the samples contained influenza B virus sequences (which correlates with the very occasional isolation of influenza B viruses in the Québec City

50

area during the 2001-2002 season), a clinical evaluation of the multiplex PCR assay was conducted for influenza A and HRSV only.

Evaluation of the multiplex PCR respiratory assay for detecting influenza A virus. From the 208 NPA evaluated by multiplex PCR, a subset of 172 samples were also tested for the presence of influenza antigens using the Directigen Flu A+B test (Table 15). Concordant results were obtained for 145 (84.3%) samples including 17 positive and 128 negative results by the two tests. A total of 27 (15.7%) samples showed discordant results with 25 being positive by the multiplex PCR assay only and 10 two positive by the antigenic test only. In order to resolve the discrepant results, a second RT-PCR test targeting a conserved gene (M2) of influenza A viruses was performed as reported (Klimov, A. I., et al., 1995. J. Infect. Dis. 172:1352-1355). As shown in Table 15, influenza A virus M2 sequences were detected by the conventional RT-PCR assay in 22 (81.5%) of the 27 discordant samples. Using the M2 RT-PCR assay as the reference test, the sensitivity, specificity, positive predictive and negative predictive values of the multiplex real-time PCR assay and the antigenic test for influenza A virus were 100%, 97.7%, 92.8%, 100% and 43.6%, 98.5%, 89.5%, 85.6%, respectively. The multiplex PCR respiratory assay was positive for HRSV in 12 (44.4%) of the 27 discordant influenza A samples with 10 of these samples showing dual HRSV/influenza A infections by the multiplex PCR assay (Table 16). The mean cycle threshold (C_T) values, which are inversely correlated with the amounts of viral RNA, were 28.1 and 33.0 for PCR-positive/antigen-positive and PCR-positive/antigen-negative samples, respectively (Table 16). These values correspond to approximately 5000 and 50 copies, respectively, when a specific influenza A plasmid was tested in the multiplex PCR assay.

Evaluation of the multiplex PCR respiratory assay for detecting HRSV. A total of 204 NPA samples could be evaluated by both the multiplex real-time PCR assay and the presence of HRSV antigens using the RSV TestPack (Table 17). Concordant results were found in 172 (84.3%) samples including 83 positive and 89 negative results by the two tests. Thirty-two (15.7%) samples had discordant results with 21

51

being positive by the multiplex PCR assay only and 11 by the antigenic test only.

Conventional RT-PCR tests for the HRSV glycoprotein G (A and B subtypes) were performed as previously described (Peret, T. C., et al. 1998. *J. Gen. Virol.* 79:2221-2229) to resolve discrepant results. Specific sequences were detected by RT-PCR

5 assays for the HRSV glycoprotein G gene in 26 (81.2%) of the 32 discordant samples including 11 A and 15 B strains (Table 18). Using the latter test as "gold standard", the sensitivity, specificity, positive predictive and negative predictive values of the multiplex real-time PCR assay and the antigenic test for HRSV were 94.5%, 98.9%, 99.0%, 94.0% and 81.6%, 94.7%, 94.7%, 81.8%, respectively. Four (66.7%) of the 10 six false-negative HRSV results by multiplex PCR were positive for influenza A (Table 18). The mean C_T values of the PCR-positive/antigen-positive and PCR-positive/antigen-negative samples were 28.6 and 32.7, respectively (Table 18). These values correspond to approximately 1000 and 100 copies, respectively, when a specific HRSV plasmid was tested in the multiplex PCR assay.

15

Discussion

In this report, we describe a new multiplex real-time PCR assay for the most commonly detected respiratory viral pathogens, namely influenza viruses (A and B)

20 and HRSV. The key features of this novel assay include its rapidity (turnaround time of approximately 2h30 including 30 min for sample preparation, 60 min for RT and 60 min for real-time PCR including viral identification), and its sensitivity (50 copies per assay for each viral target). Our results clearly demonstrate that our multiplex real-time PCR assay is more sensitive than commercially-available antigenic detection tests for both influenza A and HRSV with the greatest difference in 25 sensitivity noted for influenza viruses.

Multiplex RT-PCR assays targeting up to nine different respiratory pathogens have been previously reported (Fan, J., K. J. Henrickson, and L. L. Savatski. 1998. *Clin.*

Infect. Dis. 26:1397-1402, Grondahl, B., et al. 1999. *J. Clin. Microbiol.* 37:1-7, Kehl,

30 S. C., et al. 2001. 39:1696-1701, Osiowy, C. 1998. *J. Clin. Microbiol.* 36:3149-3154, Stockton, J., et al. 1998. *M. J. Clin. Microbiol.* 36:2990-2995, Valassina, M., A. M.

52

Cippone, M. G. Cusi, and P. E. Valensin. 1996. *Clin. Diag. Virol.* 8:227-232). More recently, a TaqMan-based real-time PCR assay for simultaneous detection of influenza A and B viruses has also been described (van Elden, L. J., et al. 2001. *J. Clin. Microbiol.* 39:196-200). Compared to conventional multiplex PCR assays, our real-time PCR test is much more rapid because it avoids additional nested amplification and/or hybridization steps required for identification of viral products. Furthermore, the real-time amplification procedure minimizes the chances of contamination because there is no post-PCR processing of the samples. Although our multiplex real-time PCR assay based on melting curve analysis of amplicons does not permit absolute quantification of the viral targets as in the TaqMan PCR procedure (van Elden, L. J., et al. 2001. *J. Clin. Microbiol.* 39:196-200), it allows for a larger number of viral targets to be simultaneously detected since there is no limitation related to the capability of the system to detect multiple dyes linked to detection probes with distinct emission wavelengths. Eventually, more than three viral targets could be simultaneously detected in the LightCycler assay assuming the absence of interaction between PCR primers and a reproducible and discriminative Tm value for each viral amplicon.

Evaluation of our multiplex real-time PCR assay in a pediatric population with severe ARTI clearly illustrated its clinical potential. Indeed, our assay identified a viral pathogen (influenza or HRSV) in two-thirds of the hospitalized children. These numbers are similar to the ones previously reported by our group in the same population using individual real-time assays for these viral pathogens (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640). Notably, we were able to show that 6% of hospitalized children had dual viral infections, a finding that has been reported albeit at a lower frequency by other investigators (Grondahl, B., et al. 1999. *J. Clin. Microbiol.* 37:1-7, Kehl, S. C., et al. 2001. 39:1696-1701, Osiowy, C. 1998. *J. Clin. Microbiol.* 36:3149-3154). Rapid identification of these viral pathogens (influenza and HRSV) is of paramount importance for isolation purposes in the hospital setting and early institution of specific antiviral therapy (Whitley, R. J., et al. 2001.. *Pediatr. Infect. Dis. J.* 20:127-133). We are currently designing additional multiplex assays

based on the same technology to cover the whole spectrum of respiratory pathogens including parainfluenza viruses (PIV), adenoviruses, enteroviruses, and coronaviruses (Treanor, J. 2002. *Respiratory Infections*, p. 7-26, In Richard. J. Whitley, Douglas D. Richman and Frederick G. Hayden (eds.). *Clinical Virology*. 2nd ed. ASM Press. 5 Washington, D.C.). To this list, we should also add the recently described human metapneumovirus which has been reported by our group and others in up to 10% of ARTI in hospitalized children (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640, Jartti, T., B. van den Hoogen, R. P. Garofalo, A. D. Osterhaus, and O. Ruuskanen. 2002. *Lancet* 360:1393-1394, Nissen, M. D., et al 2002. *Med. J. Aust.* 176:188, van 10 den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, and A. D. Osterhaus. 2001. *Nat. Med.* 7:719-724):

A specific evaluation of the real-time multiplex PCR assay for influenza A revealed 15 that it was twice as sensitive as the rapid antigen detection test in use at our institution during the winter season of 2001-2002. None of the two PCR-negative, antigen-positive samples were confirmed by a second PCR targeting another conserved gene (M2) of influenza A whereas most (22/25, 88.0%) multiplex PCR-positive, antigen-negative were. In general, the false-negative antigenic test results could be explained by low amounts of viral RNA in those NPA samples as demonstrated by high C_T 20 values in the corresponding real-time PCR assays. Three multiplex PCR test results were not confirmed by the influenza A M2 PCR test and were thus considered false-positive results. However, as we have not formally evaluated the sensitivity of the M2 PCR test and since viral cultures were not routinely done, we cannot rule out the possibility that such discrepant results were indeed true positive. We and other 25 investigators have shown the superiority of RT-PCR tests over conventional methods (antigenic tests and viral culture) for detecting influenza viruses in clinical samples including those sent to the laboratory by mail (Boivin, G., L. Hardy, and A. Kress. 2001. *J. Clin. Microbiol.* 39:730-732, Ellis, J. S., D. M. Fleming, and M. C. Zambon. 1997. 1996. *J. Clin. Microbiol.* 35:2076-2082, Kehl, S. C., et al. 2001. 39:1696-1701, 30 Steininger, C., et al. 2002. *J. Clin. Microbiol.* 40:2051-2056, van Elden, L. J., et al. 2001. *J. Clin. Microbiol.* 39:196-200). It is now common procedure at our institution

to confirm any negative antigenic tests results for influenza A and B by either viral culture or RT-PCR considering the high specificity but relatively poor sensitivity of the former assays.

5 For HRSV, the multiplex real-time PCR assay was also found to be more sensitive (by approximately 15%) than the rapid antigenic test when a second RT-PCR assay for the HRSV gG gene was used to resolve the discrepancies. Most of the false-negative antigenic test results could be explained by low amounts of viral RNA in the NPA samples as shown by mean C_T values of 32.7 for discordant results compared to 10 28.6 for concordant positive results. The specificity of the multiplex assay was excellent with only one positive result not confirmed by the second PCR test. In contrast, the multiplex PCR assay missed six cases of HRSV which tested positive in both the antigenic test and the second PCR assay for HRSV gG. Notably, four of those six samples tested positive for influenza A in the multiplex PCR assay. Thus, 15 although our multiplex PCR test has the capability of detecting dual infections (as seen in 6% of our cases), it is possible that high amounts of one virus could inhibit amplification of other pathogens. It is noteworthy that the multiplex PCR assay had the ability to amplify both HRSV genotypes as shown by the detection of 15 B and 11 A genotypes using specific PCR assays aimed at detecting variable regions of the 20 HRSV gG gene (Mazzulli, T., et al, 1999. J. Infect. Dis. 180:1686-1689). Although the rapid antigenic test had a relatively good performance (sensitivity: 82%, specificity 95%) for detection of HRSV in young children, the real advantage of PCR probably resides in the adult population where viral titers are lower and where 25 antigenic tests are not recommended with upper respiratory tract samples (Englund, J. A., et al 1996.. 34:1649-1653).

There are some limitations to our study which are worth mentioning. First, the absence of circulation of influenza B viruses during the study period prevents adequate validation of our multiplex assay for this pathogen and in particular for its 30 ability to detect mixed (influenza B and HRSV) infections. Second, the performance of our multiplex PCR assay cannot be generalized to other types of samples (throat

swabs, sputum) and to other populations (outpatients, adults) at the present time. Also, the absence of serological testing in our study may have underestimated the rate of viral infections especially for those children who presented late after the onset of symptoms. Finally, although it was relatively easy to discriminate between the 5 different viral pathogens based on their specific Tm values only (Table 14), we sometimes had to confirm viral amplicons by gel electrophoresis, which increases the assay's turnaround time.

In conclusion, we described a rapid and sensitive multiplex real-time PCR assay for 10 detecting influenza viruses and HRSV in children's NPA samples. This new assay is as specific and much more sensitive than currently-available antigen detection tests and could complement the latter in the hospital setting when there is high clinical suspicion despite negative results. Future work is needed to expand the panel of viral pathogens detected by such rapid molecular methods in order to eventually 15 circumvent the need for viral cultures. Also, future evaluation of the multiplex PCR assay is warranted in the adult population with severe ARTI.

Example 10 : Description and Evaluation of the Multiplex Respiratory-1 PCR.

5 Same as example 9, except that hMPV primers (as defined in SEQ. ID. Nos. 95 and 96 or 112 and 114) were added to the multiplex PCR assay (already containing primers of SEQ. ID. Nos. 139+140 for influenza A, 141+142 for influenza B, and 143+144 for hRSV) at a concentration of 0.3 μ M. The cycling conditions included an amplification step of 50 cycles of 15 s at 94°C, 5 s at 58°C, and 28 s at 72°C. The T_m values determined with the LightCycler instrument were 91°C, 85°C, 83°C, 79°C, and 82°C/77°C for the internal control, influenza A, influenza B, hRSV, and hMPV N/L genes, respectively (Fig. 7A for hMPV N primers of SEQ. ID. Nos. 95 and 96 and Fig. 7B for hMPV L primers of SEQ. ID. Nos. 112 and 114). The lower limit of detection of the multiplex respiratory-1 PCR was 10, 50, 100, and 100 copies for influenza A, influenza B, hRSV, and hMPV, respectively, in the presence of 500 copies of an internal control (plasmid flanked by influenza B complementary primer sequences). The multiplex respiratory-1 assay was found to be specific with no amplification of adenoviruses, enteroviruses, rhinoviruses, parainfluenza viruses 1-3, coronaviruses, herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, HHV-6, HHV-8, and Epstein-Barr virus.

10

15

20

25 The multiplex respiratory-1 PCR was evaluated with NPA samples from 248 children \leq 3 years with acute respiratory tract infections and 108 adults \geq 50 years with exacerbation of chronic obstructive pulmonary disease or pneumonia requiring hospitalization during the 2002-03 winter/spring period in Québec City, Canada. In children, the detection rate for influenza A, influenza B, hRSV, and hMPV was 9/248 (3.6%), 4/248 (1.6%), 123/248 (49.6%), and 13/248 (5.2%), respectively. Five (2.0%) of the 248 children had a mixed viral infection. None of the NPA samples was found to contain PCR-inhibitory substances as shown by successful amplification of the internal control in all negative samples. In adults, the detection rate for influenza A, influenza B, hRSV, and hMPV was 3/108 (2.8%), 0/108 (0%), 13/108 (12.0%), and

30

2/108 (1.8%), respectively. One patient had a mixed viral infection (influenza A and hMPV). No samples contained PCR-inhibitory samples.

Example 11: Description and evaluation of the multiplex respiratory-2 PCR.

5

Same as example 9, except that the multiplex PCR assay is composed of the following PCR primers for detection of parainfluenza-1 (SEQ. ID: Nos. 147 and 148), parainfluenza-3 (SEQ. ID. Nos. 151 and 152), human adenoviruses (SEQ. ID. Nos. 10 153 and 155), and rhinoviruses/enteroviruses (SEQ. ID. Nos. 160 and 161). Primers are added in the PCR reaction mixture at a concentration of 0.2 μ M (SEQ. ID. Nos. 147 and 151), 0.3 μ M (SEQ. ID. Nos. 153 and 155), 0.4 μ M (SEQ. ID. Nos. 148 and 152), and 0.5 μ M (SEQ. ID. Nos. 160 and 161). The cycling conditions included an amplification step of 50 cycles of 15 s at 94°C, 5 s at 58°C, and 26 s at 72°C. The Tm 15 values determined with the LightCycler instrument were 91.0°C, 80.0°C, 77.5°C, 89.0°C, 82.0°C, and 85.0°C for the internal control, parainfluenza-1, parainfluenza-3, adenoviruses, rhinoviruses, and enteroviruses, respectively (Fig. 8). The lower limit of detection of the multiplex respiratory-2 PCR was 50, 100, 10, 50, and 200 copies for 20 parainfluenza-1, parainfluenza-3, adenoviruses, rhinoviruses, and enteroviruses, respectively, in the presence of 500 copies of an internal control (plasmid flanked by rhinovirus/enterovirus complementary primer sequences). The multiplex respiratory-2 assay was found to be specific with no amplification of influenza A, influenza B, hRSV, hMPV, coronavirus, herpes simplex virus type 1 and 2, varicella-zoster virus, 25 cytomegalovirus, HHV-6, HHV-8, and Epstein-Barr virus.

25

Example 12 : Description of real-time PCR assays for the SARS-coronavirus.

30 Same as example 9, except that the PCR assay is composed uniquely of primers (two different possible sets) for the SARS-coronavirus as defined in SEQ. ID. Nos. 156- 157 and 158-159. The concentration of the primers in the PCR reaction mixture is 0.5 μ M. The amplification step included 50 cycles of 15 s at 94°C, 5 s at 58°C, and 20 s at 72°C. The Tm for both PCR products is 83°C (Fig. 12).

Table 1: List of hMPV sequences revealed in the present invention

SEQ ID NO.	Isolate No.	Target gene
2	hMPV-118	Nucleoprotein
3	hMPV-174	Nucleoprotein
4	hMPV-176	Nucleoprotein
5	hMPV-193	Nucleoprotein
6	C-77807	Nucleoprotein
7	C-77748	Nucleoprotein
8	hMPV-217	Nucleoprotein
10	hMPV-163	Nucleoprotein
11	hMPV-174	Nucleoprotein
12	hMPV-184	Nucleoprotein
13	hMPV-185	Nucleoprotein
14	C-76837	Nucleoprotein
15	C-77807	Nucleoprotein
16	C-78123	Nucleoprotein
17	C-78132	Nucleoprotein
18	C-78163	Nucleoprotein
19	C-91205	Nucleoprotein
20	C-91364	Nucleoprotein
21	C-91830	Nucleoprotein
22	hMPV-Q86	Nucleoprotein
23	hMPV-Q97	Nucleoprotein
24	Can 97-83	Nucleoprotein
25	Can 98-75	Nucleoprotein
26	Can 98-75	Fusion type II
27	C-67345	Fusion type I
28	Can 97-83	Fusion type I
29	C-68661	Fusion type I
30	C-73750	Fusion type I
31	C-74549	Fusion type I
32	C-74783	Fusion type I
33	C-76837	Fusion type I
34	C-77748	Fusion type I
35	C-77807	Fusion type I
36	C-78132	Fusion type I
37	C-78163	Fusion type I
38	C-78406	Fusion type I
39	hMPV-174	Fusion type II
40	hMPV-193	Fusion type I
41	hMPV-194	Fusion type I
42	hMPV-198	Fusion type I
43	hMPV-217	Fusion type II
44	hMPV-208	Fusion type I
45	hMPV-223	Fusion type I
46	hMPV-228	Fusion type I

47	C-85885	Fusion type I
48	C-60298	Fusion type I
49	C-63778	Fusion type II
50	C-64199	Fusion type II
51	C-64200	Fusion type II
52	C-64536	Fusion type II
53	C-73769	Fusion type II
54	C-74501	Fusion type II
55	C-78429	Fusion type II
56	C-78562	Fusion type II
57	hMPV-118	Fusion type II
58	hMPV-200	Fusion type I
59	hMPV-176	Fusion type I
60	hMPV-193	Glycoprotein
61	hMPV-228	Glycoprotein
62	C-77748	Glycoprotein
63	C-78132	Glycoprotein
64	C-78406	Glycoprotein
65	C-73750	Glycoprotein
66	C-60298	Glycoprotein
67	C-74783	Glycoprotein
68	C-74549	Glycoprotein
69	C-77807	Glycoprotein
70	C-78163	Glycoprotein
71	C-68661	Glycoprotein
72	C-88448	Glycoprotein
73	C-88470	Glycoprotein
74	C-86316	Glycoprotein
76	hMPV-118	Polymerase
77	hMPV-163	Polymerase
78	hMPV-174	Polymerase
79	hMPV-184	Polymerase
80	hMPV-196	Polymerase
81	C-76837	Polymerase
82	C-77807	Polymerase
83	hMPV-185	Polymerase
84	C-78123	Polymerase
85	C-91205	Polymerase
86	C-91364	Polymerase
87	C-91749	Polymerase
88	hMPV-Q86	Polymerase
89	hMPV-Q97	Polymerase
90	Can 97-83	Polymerase

Table 2: List of hMPV PCR primers developed in the present invention

SEQ ID NO.	Target gene	Position ^a	Originating DNA SEQ ID NO.
91	Nucleoprotein (N)	25	1
92	Nucleoprotein (N)	97	1
93	Nucleoprotein (N)	146 ^b	1
94	Nucleoprotein (N)	1025 ^b	1
95	Nucleoprotein (N)	58	9
96	Nucleoprotein (N)	986 ^b	9
97	Fusion (F)	3052	1
98	Fusion (F)	3810 ^b	1
99	Fusion (F)	4671 ^b	1
100	Matrix (M)	2165	1
101	Matrix (M)	2943 ^b	1
102	Phosphoprotein (P)	1248	1
103	Phosphoprotein (P)	2124 ^b	1
104	Glycoprotein (G)	6231	1
105	Glycoprotein (G)	6247	1
106	Glycoprotein (G)	6957 ^b	1
107	Glycoprotein (G)	6981 ^b	1
108	Glycoprotein (G)	6235	1
109	Glycoprotein (G)	7227 ^b	1
110	RNA polymerase (L)	142	75
111	RNA polymerase (L)	691 ^b	75
112	RNA polymerase (L)	7308	1
113	RNA polymerase (L)	7857 ^b	1
114	RNA polymerase (L)	7616	1

^a Position refers to nucleotide position of 5' end of primer. Oligonucleotides are 17-20 bp in length.

^b Primer is reverse-complement of target sequence.

Table 3: List of hMPV probes developed in the present invention

SEQ ID NO.	Target gene	Originating DNA	
		Position ^a	SEQ ID NO.
115	Nucleoprotein (N)	786	1
116	Nucleoprotein (N)	808	1
117	Fusion (F)	3163	1
118	Fusion (F)	3187	1
119	Matrix (M)	2636	1
120	Matrix (M)	2659	1
121	Phosphoprotein (P)	1492	1
122	Phosphoprotein (P)	1518	1
123	Glycoprotein (G)	6509	1
124	Glycoprotein (G)	6530	1
125	RNA polymerase (L)	7600	1
126	RNA polymerase (L)	7627	1
127	RNA polymerase (L)	7331	1
128	Nucleoprotein (N)	824	9
129	RNA polymerase (L)	434	75

^a Position refers to nucleotide position of 5' end of probe. Oligonucleotides are 21-25 bp in length.

Table 4: Length of amplicons obtained with different hMPV primer pairs which are objects of the present invention

SEQ ID NO.	Target Gene	Length of amplicon
91 + 94	Nucleoprotein (N)	1001 bp
92 + 94	Nucleoprotein (N)	929 bp
91 + 93	Nucleoprotein (N)	122 bp
97 + 99	Fusion (F)	1620 bp
97 + 98	Fusion (F)	759 bp
100 + 101	Matrix (M)	779 bp
102 + 103	Phosphoprotein (P)	877 bp
104 + 107	Glycoprotein (G)	751 bp
105 + 106	Glycoprotein (G)	711 bp
108 + 109	Glycoprotein (G)	993 bp
112 + 113	RNA polymerase (L)	550 bp
112+114	RNA polymerase (L)	308 bp

Table 5: Comparative evaluation of different hMPV primers for detection of hMPV strains

Strains No.	Type of sample	Year	N primers		M primers		F primers		P primers		L primers	
			SEQ. Nos.	ID. 92+94	SEQ. ID. Nos.	100+101	SEQ. ID. Nos.	97+98	SEQ. ID. Nos.	102+103	SEQ. ID. Nos.	112 + 113
I or S	+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)
C-74501	I	2000	+	82.92	-		+	83.65	-		+	78.14
C-74783	I	2000	+	82.76	+	83.49	-		+	81.51	+	78.20
C-76837	I	2000	+	82.94	+	83.43	+	83.17	+	80.86	-	
C-77719	I	2001	+	83.26	+	84.64	-		-		+	77.87
C-77738	I	2001	+	82.99	-		-		-		+	77.51
C-77748	I	2001	+	83.06	+	82.96	+	83.10	+	81.27	+	77.38
C-77807	I	2001	+	82.99	+	83.26	+	83.25	+	80.65	+	78.34
C-78024	I	2001	+	82.86	+	83.95	-		-		-	
C-78028	I	2001	+	82.98	+	83.13	-		-		+	78.32
C-78123	I	2001	+	82.83	-		-		-		+	78.48
C-85984	I	2002	+	82.59	+	83.21	+	83.51	+	79.99	+	77.97
C-85448	I	2002	+	83.66	+	82.72	-		+	80.31	+	78.88
C-85983	I	2002	+	82.59	+	83.03	+	83.88	+	80.46	+	78.01
C-85988	I	2002	+	82.17	-		+	84.39	-		+	78.06
C-86316	I	2002	+	82.64	+	82.75	+	83.18	+	80.18	+	78.02
C-85126	I	2002	+	81.89	+	82.05	+	82.39	+	80.00	+	78.04
C-85473	I	2002	+	82.39	+	82.57	+	82.91	+	80.74	+	77.82
C-85332	I	2002	+	81.98	-		-		-		+	77.72
C-85596	I	2002	+	82.24	+	82.73	+	83.17	+	80.35	+	77.58
C-85542	I	2002	+	82.22	+	82.72	-		+	80.08	+	77.67
HMPV- 118	S	2002	+	82.47	-		-		-		ND	ND
HMPV- 174	S	2002	+	82.18	+	82.06	+	83.16	+	80.17	+	78.20
HMPV- 176	S	2002	+	81.41	-		+	83.97	-		+	77.81
HMPV- 193	S	2002	+	82.22	+	81.89	+	83.00	+	80.58	+	77.94
HMPV- 194	S	2002	+	82.24	+	81.32	+	82.98	-		+	77.84
HMPV- 198	S	2002	+	82.66	-		-		-		-	
HMPV- 200	S	2002	+	82.53	-		+	83.46	-		+	77.62
HMPV- 208	S	2002	+	82.11	+	81.81	+	83.33	+	80.06	+	78.40
HMPV- 217	S	2002	+	82.13	+	81.58	+	83.01	-		+	77.76

HMPV-	S	2002	+	81.89	+	82.36	+	83.04	-	+	78.10
223											
Mean				82.63 ± 0.87	82.75 ± 0.80	83.29 ± 0.45		80.48 ± 0.46	77.99 ± 0.33		

Note: I = viral isolates; S = clinical specimens; Tm = melting temperature as determined by a LightCycler instrument.

Table 6: Size of the viral fusion (F) gene fragments obtained for different hMPV isolates following enzymatic digestion with restriction endonucleases

SEQ ID NO.	Fragments obtained after digestion with the restriction endonuclease		F genotype ^a
	ApaL I	Avr II	
35	532 bp + 227 bp	759 bp	I
58	532 bp + 227 bp	759 bp	I
39	759 bp	447 bp + 312 bp	II
40	532 bp + 227 bp	759 bp	I
41	532 bp + 227 bp	759 bp	I
43	759 bp	447 bp + 312 bp	II
44	532 bp + 227 bp	759 bp	I
59	532 bp + 227 bp	759 bp	I
45	532 bp + 227 bp	759 bp	I

^aAs determined by DNA sequencing and phylogenetic studies.

Table 7. Type of laboratory confirmation by type of infection

Laboratory test	hMPV		hRSV		Influenza A		Adenovirus		PIV 2	
	Tests done	Positive	Tests done	Positive	Tests done	Positive	Tests done	Positive	Tests done	Positive
PCR	208	12 5.8%	208	106 51.0%	208	45 21.6%	NA	NA	NA	NA
Culture	100	2 2%	100	31 31%	100	14 14%	100	6 6%	100	1 1%
Antigen detection (Immunofluorescence)	NA	NA	NA	NA	NA	NA	81	1 1%	76	1 1.3%
Antigen detection (ELISA)	NA	NA	204	94 46.1%	100	14 14%	NA	NA	NA	NA
Total (+) in at least one test	12 (5.8%)		118 (56.7%)		49 (23.6%)		6 (6%)		2 (2%)	

Delay between onset of symptoms and NPA, days	Mean/median	5.2/4.0	8.7/5.0	6.0/6.5	3.0/3.0
---	-------------	---------	---------	---------	---------

Note: HMPV, human metapneumovirus; hRSV, human respiratory syncytial virus; PIV, parainfluenza virus; NPA, nasopharyngeal aspirate; NA, not available.

Table 8. Signs and symptoms by type of viral infection

Signs and symptoms	HMPV	hRSV	Influenza A	Single virus	Multiple viruses	No virus detected	Total	
							N=12	N=208
Fever	8 67%	67 57%	38 78%	85 60%	17 74%	25 57%	127 61%	
Cough	12 100%	117 99%	47 96%	138 98%	23 100%	40 90%	201 97%	
Rhinorrhea	11 92%	107 91%	41 84%	123 87%	22 96%	42 96%	187 90%	
Retractions	11 92%	112 95%	40 82%	125 89%	22 96%	22 89%	186 89%	
Wheezing	10 83%	77 65%	28 57%	83 59%	19 83%	31 71%	133 64%	
Laryngation	3 25%	37 31%	15 31%	46 33%	6 26%	11 23%	63 30%	
Diarrhea	1 25%	19 31%	13 13%	24 24%	5 5%	10 10%	39 39%	

	8%	17%	27%	17%	22%	21%	19%
Vomiting	3	9	5	10	4	1	15
	25%	8%	10%	7%	17%	2%	7%
Other	0	31	9	33	4	9	46
	26%	18%	23%	17%	21%	22%	

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.

Table 9. Final diagnoses (complications) by type of viral infection

Complications	hMPV	HRSV	Influenza A	Single virus	Multiple viruses	No virus detected	Total	
							N=12	N=208
Bronchiolitis	8 66.7%	99 83.9%	25 51.0%	98 69.5%	19 82.6%	25 56.8%	25 68.3%	142
Otitis	6 50.0%	70 59.3%	27 55.1%	78 55.3%	15 65.2%	24 54.6%	117 56.3%	117
Pneumonia	2 16.7%	30 25.4%	18 36.7%	39 27.7%	7 30.4%	12 27.3%	58 27.9%	58
Laryngotracheobronchitis	0 8.5%	10 12.2%	6 6.4%	9 17.4%	4 2.3%	1 2.3%	14 6.7%	14
Sinusitis	0 2.5%	3 6.1%	3 1.4%	2 8.7%	2 2.3%	1 2.3%	5 2.4%	5
Pharyngitis	0 0.9%	1 0.9%	0 1.4%	2 1.4%	0 0.0%	2 4.6%	4 1.9%	4
Flu syndrome	0 1.7%	2 0	0 1.4%	2 1.4%	0 0.0%	4 9.1%	6 2.9%	6

Group	0	2	0	2	0	1	3
Other	1	4	3	9	0	5	14
	8.3%	3.4%	6.1%	6.4%		11.4%	6.7%

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.

Table 10: List of PCR primers used for amplification of respiratory viruses

Primer SEQ ID NO.	Virus	Target Gene	Originating DNA Position ^a	SEQ ID NO.
139	Influenza A	Matrix	32 / 7	130-131
140	Influenza A	Matrix	276 ^b / 251 ^b	130-131
141	Influenza B	Matrix	82	132
142	Influenza B	Matrix	605 ^b	132
143	RSV	Fusion	1111	133
144	RSV	Fusion	1490 ^b	133
95	hMPV	Nucleocapsid	58	9
96	hMPV	Nucleocapsid	986 ^b	9
110	hMPV	Polymerase	142	75
111	hMPV	Polymerase	691 ^b	75
145	PIV-1	Nucleocapsid	64	134
146	PIV-1	Nucleocapsid	147 ^b	134
149	PIV-3	Nucleocapsid	416	135
150	PIV-3	Nucleocapsid	649 ^b	135
154	Adenovirus	Hexon	154	136
155	Adenovirus	Hexon	368 ^b	136
160	Enter/Rhinovirus	5'-non coding region	94 / 71	137/138
161	Enter/Rhinovirus	5'-non coding region / VP2	746 ^b / 603 ^b	137/138
141	IC ^c multiplex 1	DNA polymerase HSV-2	1	170
142	IC ^c multiplex 1	DNA polymerase HSV-2	558 ^b	170
160	IC ^c multiplex 2	DNA polymerase HSV-2	1	171
161	IC ^c multiplex 2	DNA polymerase HSV-2	554 ^b	171
112	hMPV	Polymerase	7308	1
114	hMPV	Polymerase	7616	1
147	PIV-1	Nucleocapsid	822	134
148	PIV-1	Nucleocapsid	1029	134
151	PIV-3	Nucleocapsid	792	135
152	PIV-3	Nucleocapsid	902	135
153	Adenovirus	Hexon	7	136
156	Sars-CoV	nsp9		
157	Sars-CoV	nsp9		
158	Sars-CoV	nsp11		
159	Sars-CoV	nsp11		

^aPosition refers to nucleotide position of 5'-end of primer. Oligonucleotides are 16-26 bp in length.

^bPrimer is reverse-complement of target sequence.

^cIC refers to the internal control used to monitor the efficiency of the PCR amplification

Table 11: List of viral probes developed in the present invention

Probe SEQ ID NO.	Target	Position ^a	Originating DNA SEQ ID NO.
162	Influenza A	114 ^b / 89 ^b	130/131
163	Influenza B	383	132
164	hRSV	1391 ^b	133
128	hMPV	824	9
129	hMPV	434	75
165	PIV-1	96	134
166	PIV- 3	616 ^b	135
167	Adenovirus	228	136
168	Rhinovirus	467 ^b	138
169	Enterovirus	644 ^b	137
172	Internal Control ^c	321 ^b / 325 ^b	170/171

^aPosition refers to nucleotide position of 5'-end of primer. Oligonucleotides are 20-23 bp in length.

^bProbe is reverse-complement of target sequence.

^cA modified DNA polymerase gene sequence of herpes simplex virus (HSV) type 2 serves as the internal control template.

Table 12: Length of amplicons obtained with the different viral primer pairs

Primer SEQ ID NO.	Virus	Target gene	Length of amplicons
139 + 140	Influenza A	Matrix	245 bp
141 + 142	Influenza B	Matrix	524 bp
143 + 144	hRSV	Fusion	380 bp
95 + 96	hMPV	Nucleocapsid	929 bp
110 + 111	hMPV	Polymerase	550 bp
145 + 146	PIV-1	Nucleocapsid	84 bp
149 + 150	PIV-3	Nucleocapsid	234 bp
154 + 155	Adenoviruses	Hexon	215 bp
160 + 161	Rhinoviruses	5'-non coding region - VP2	533 bp
160 + 161	Enteroviruses	5'-non coding region	653 bp
141 + 142	IC multiplex 1	DNA polymerase HSV-2	558 bp
160 + 161	IC multiplex 2	DNA polymerase HSV-2	554 bp
112 + 114	hMPV	Polymerase	308 bp
147 + 148	PIV-1	Nucleocapsid	208 bp
151 + 152	PIV-3	Nucleocapsid	111 bp
153 + 155	Adenovirus	Hexon	362 bp
156 + 157	Sars-CoV	nsp9	198 bp
158 + 159	Sars-CoV	nsp11	368 bp

- 75 -

Table 13: Selection of primer sets with resulting melting temperature (Tm) values of the corresponding amplicons for each multiplex assay

Primer SEQ ID NO.	Target	Multiplex NO.	Tm (°C)
139 + 140	Influenza A	1	85
141 + 142	Influenza B	1	83
143 + 144	hRSV	1	79
95 + 96 or 112 + 114	hMPV	1	82 or 77
141 + 142	Internal Control	1	91
147 + 148	Parainfluenza 1	2	80.0
151 + 152	Parainfluenza 3	2	77.5
153 + 155	Adenovirus	2	89.0
160 + 161	Rhinovirus	2	82.0
160 + 161	Enterovirus	2	85.0
160 + 161	Internal Control	2	91

Table 14. Evaluation of the multiplex PCR respiratory assay with temporally-different strains of influenza (Flu) and human respiratory syncytial (HRSV) viruses.

Virus	Subtype / Genotype ^a	Year	Type	Strain	Tm (°C)
Flu A	H1	99-00	clinical	-	85.10
Flu A	H1	99-00	clinical	-	85.39
Flu A	H1	00-01	clinical	-	85.12
Flu A	H1	00-01	clinical	-	85.20
Flu A	H1	00-01	clinical	-	85.04
Flu A	H1	01-02	clinical	-	84.62
Flu A	H1	01-02	clinical	-	85.07
Flu A	H1	02-03	clinical	-	85.50
Flu A	H1	02-03	clinical	-	85.29
Flu A	H1	95	vaccine	A/Beijing/262/95	85.06
Flu A	H1	33	vaccine	A/WSN/33	85.25
Mean AH1					85.15±0.22
Flu A	H3	98-99	clinical	-	85.58
Flu A	H3	98-99	clinical	-	85.18
Flu A	H3	98-99	clinical	-	85.35
Flu A	H3	98-99	clinical	-	85.57
Flu A	H3	98-99	clinical	-	85.37
Flu A	H3	01-02	clinical	-	85.07
Flu A	H3	01-02	clinical	-	85.65
Flu A	H3	02-03	clinical	-	84.92
Flu A	H3	99	vaccine	A/Panama/2007/99	85.18
Flu A	H3	97	vaccine	A/Sydney/5/97	85.06
Mean AH3					85.31±0.25
Mean FluA					85.27±0.22
Flu B	-	98-99	clinical	-	83.87
Flu B	-	98-99	clinical	-	83.12
Flu B	-	00-01	clinical	-	83.01
Flu B	-	00-01	clinical	-	83.03
Flu B	-	00-01	clinical	-	82.88
Flu B	-	00-01	clinical	-	83.75
Flu B	-	00-01	clinical	-	83.17
Flu B	-	02-03	clinical	-	83.89
Flu B	-	02-03	clinical	-	83.84
Flu B	-	97	vaccine	B/Harbin/7/97	84.12
Mean FluB					83.47±0.46

Table 14. Evaluation of the multiplex PCR respiratory assay with temporally-different strains of influenza (Flu) and human respiratory syncytial (HRSV) viruses. (Continued).

HRSV	B	99-00	clinical	-	79.32
HRSV	A	99-00	clinical	-	79.83
HRSV	A	00-01	clinical	-	79.06
HRSV	A	00-01	clinical	-	78.85
HRSV	B	01-02	clinical	-	79.34
HRSV	B	01-02	clinical	-	79.52
HRSV	B	01-02	clinical	-	79.98
HRSV	B	01-02	clinical	-	79.52
HRSV	A	01-02	clinical	-	79.84
HRSV	B	01-02	clinical	-	79.42
HRSV	B	01-02	clinical	-	79.49
HRSV	B	01-02	clinical	-	79.48
HRSV	B	01-02	clinical	-	79.55
HRSV	B	01-02	clinical	-	79.32
HRSV	A	01-02	clinical	-	79.77
HRSV	A	01-02	clinical	-	79.92
HRSV	A	01-02	clinical	-	79.40
Mean HRSV-A					79.52±0.43
Mean HRSV-B					79.49±0.19
Mean HRSV					79.51±0.30

5

^a Subtyping was performed by multiplex PCR for the influenza hemagglutinin gene (2) whereas genotyping was done by conventional PCR for the HRSV G gene (22)

- 78 -

Table 15. Evaluation of the multiplex PCR respiratory assay for detection of influenza A (Flu A) virus.

	Antigenic test (Directigen Flu A+B) (n = 172)		Flu A M2 PCR assay ^a (n = 27)		
	+	-	+	-	
Multiplex PCR	+	17	25	22	3
	-	2	128	0	2

5 Sensitivity: 39/39 = 100%
Specificity: 130/133 = 97.7%
Positive predictive value: 39/42 = 92.8%
Negative predictive value: 130/130 = 100%

Only performed for samples showing discordant results with the multiplex PCR assay and the antigenic test.

- 79 -

Table 16: Evaluation of discordant test results for influenza A (Flu A) virus.

Sample No.	Multiplex PCR Flu A results (C _T) ^a	Antigenic test Flu A results	M2 PCR Flu A results	Other PCR- amplified viruses ^b
16	-	+	-	HRSV
23	+(27)	-	+	
24	-	+	-	HRSV
27	+(28)	-	+	HRSV
35	+(28)	-	+	HRSV
36	+(32)	-	+	
40	+(34)	-	+	
43	+(36)	-	+	HRSV
44	+(35)	-	+	
50	+(34)	-	+	
51	+(33)	-	+	HRSV
103	+(35)	-	+	
107	+(35)	-	+	
114	+(37)	-	-	
118	+(38)	-	+	HRSV
120	+(36)	-	+	HRSV
125	+(38)	-	+	
130	+(35)	-	+	HRSV
131	+(36)	-	-	
132	+(24)	-	+	HRSV
134	+(36)	-	-	
141	+(28)	-	+	
152	+(34)	-	+	
158	+(32)	-	+	
160	+(33)	-	+	HRSV
161	+(28)	-	+	HRSV
163	+(32)	-	+	

^a Cycle threshold value as determined by LightCycler.^b Viruses amplified by the multiplex PCR assay i. e. influenza (Flu) A and B as well as the human respiratory syncytial virus (HRSV).

- 80 -

Table 17: Evaluation of the multiplex PCR respiratory assay for detection of human respiratory syncytial virus (HRSV).

	Antigenic test (RSV TestPack) (n = 204)		HRSV gG PCR assays ^a (n = 32)		
	+	-	+	-	
Multiplex PCR	+	83	21	20	1
	-	11	89	6	5

Sensitivity: $103/109 = 94.5\%$
Specificity: $94/95 = 98.9\%$
Positive predictive value: $103/104 = 99.0\%$
Negative predictive value: $94/100 = 94.0\%$

10 " Only performed for samples showing discordant results with the multiplex PCR assay and the antigenic test.

- 81 -

Table 18: Evaluation of discordant test results for human respiratory syncytial virus (HRSV).

Sample No.	Multiplex PCR HRSV results (C_T) ^a	Antigenic test HRSV results	Glycoprotein G PCR HRSV	Other PCR- amplified viruses ^b results (genotype)
16	+(32)	-	+(B)	
17	+(27)	-	+(B)	
26	+(36)	-	+(B)	
34	-	+		
35	+(33)	-	+(B)	Flu A
43	+(36)	-	+(A)	Flu A
46	+(34)	-	+(B)	
55	+(34)	-	+(B)	
58	+(33)	-	+(B)	
62	-	+	+(A)	Flu A
70	+(37)	-	+(B)	
71	+(35)	-	+(B)	
72	+(34)	-	+(B)	
73	+(26)	-	+(A)	
79	+(33)	-	+(B)	
80	-	+	-	
91	+(35)	-	+(A)	
95	+(29)	-	+(B)	
100	+(30)	-	+(A)	
112	-	+	-	
129	+(34)	-	+(B)	
130	+(35)	-	+(B)	Flu A
134	-	+	+(A)	Flu A
139	-	+	+(A)	
142	-	+	+(A)	Flu A
144	-	+	+(B)	Flu A
150	+(34)	-	-	
187	+(31)	-	+(A)	
191	+(29)	-	+(A)	

- 82 -

Table 18: Evaluation of discordant test results for human respiratory syncytial virus (HRSV). (Continued).

193	-	+	+ (A)
211	-	+	-
212	-	+	-

5

^a Cycle threshold value as determined by Lightcycler.

^b Viruses amplified by the multiplex PCR assay i. e. influenza (Flu) A and B as well as the human respiratory syncytial virus (HRSV).

CLAIMS:

1- A method for detecting and/or quantifying human metapneumovirus (hMPV) in a sample said method comprising:
5 -providing at least one probe or primer specific for a nucleic acid sequence of said hMPV;
-contacting said at least one probe and/or primer with said sample to allow annealing of said probe and/or primer with said nucleic acid sequence; and
-detecting and/or quantifying said nucleic acid sequence using said annealed probe and/or primer.

10 2- The method as claimed in claim 1 wherein said nucleic acid sequence is comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

15 3- The method as claimed in claim 2 wherein said nucleic acid sequence is selected from any one of SEQ ID NO 2-8, 10-74, 76-90 or fragments thereof.

20 4- The method as claimed in claim 3 wherein said probe or primer is at least 10 nucleotides in length.

5- A method for detecting and/or quantifying human metapneumovirus (hMPV) in a sample said method comprising:
25 -performing reverse transcription using a template RNA derived from said sample to obtain a nucleic acid product;
-amplifying said nucleic acid product using a pair of oligonucleotide primers wherein said primers are specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion

- 84 -

(F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes to produce an amplification product; and
-detecting and/or quantifying said amplification product.

5 6- The method as claimed in claim 5 wherein said oligonucleotide primers are at least 10 nucleotides in length and capable of hybridizing with any one of SEQ ID 2-8, 10-74, 76-90.

10 7- The method as claimed in claim 5 or 6 wherein said step of performing reverse transcription comprises contacting said template RNA with a primer selected from SEQ ID Nos 91-114 and wherein said oligonucleotide primers for PCR are selected from SEQ ID Nos 91-114.

15 8- The method as claimed in any one of claim 5-7 wherein said oligonucleotide primers are pairs of primers selected from SEQ ID Nos 91 and 94, 92 and 94, 91 and 93, 97 and 99, 97 and 98, 100 and 101, 102 and 103, 104 and 107, 105 and 106, 108 and 109, 112 and 113 and 112 and 114.

20 9- The method as claimed in claim 5 wherein said template RNA is contacted with primer selected from SEQ ID NO 91-94 and 112-114 and wherein said oligonucleotide primers are selected from SEQ ID NO 91-94 and 112-114.

10- The method as claimed in any one of claim 5-9 wherein said step of amplifying is performed using PCR.

25

11- The method as claimed in claim 10 wherein said PCR is RT-PCR.

12- The method as claimed in claim 11 wherein said RT-PCR is real time RT-PCR.

30

13- The method as claimed in claim 11 or 12 wherein said RT-PCR comprises detecting said amplification products by characteristic melting temperature of said amplification products.

5 14- The method as claimed in claim 11 or 12 wherein said RT-PCR comprises detecting and/or quantifying said amplification products with probes specific for said products.

10 15- The method as claimed in claim 14 wherein said probes are selected from SEQ ID no 115-129.

16- A composition for detecting a hMPV said composition comprising a combination of oligonucleotides for performing reverse transcription of a template RNA from said hMPV virus and for an amplification reaction of a product obtained 15 from said reverse transcription wherein said oligonucleotides for said amplification reaction are specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

20 17- The composition of claim 16 wherein said oligonucleotides for said amplification reaction are primers selected from the group comprising SEQ ID Nos 91-114 and combination thereof.

25 18- A kit comprising a combination of oligonucleotides wherein the oligonucleotides are selected from:
SEQ ID NOs: 91-114 and the pairs of SEQ ID Nos 91 and 94, 92 and 94, 91 and 93, 97 and 99, 97 and 98, 100 and 101, 102 and 103, 104 and 107, 105 and 106, 108 and 109, 112 and 113 and 112 and 114.

30 19- A method for typing an hMPV strain which comprises the steps of:

- amplifying an hMPV nucleic acid fragment and detecting specific viral sequences;
- digesting said fragment with one or more restriction endonuclease; and
- analysing the restriction fragment length polymorphisms.

5

20- The method as claimed in claim 19 wherein said nucleotide sequences are found in fusion(F) or glycoprotein (G) gene.

21- The method as claimed in claim 20 wherein said sequences are selected from
10 SEQ ID NO 26-74.

22- A method for detecting and/or quantifying two or more respiratory viruses in a sample said method comprising:

- providing at least two probes and/or primers specific for a nucleic acid
15 sequences in said two or more respiratory viruses;
- contacting said at least two probes and/or primers with said sample to allow annealing of said probes and/or primers with said nucleic acid sequences; and
- detecting and/or quantifying said nucleic acid sequences using said annealed probes and/or primers.

20

23- The method as claimed in claim 22 wherein at least one of said nucleic acid sequences is comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

25

24- The method as claimed in claim 23 wherein said nucleic acid sequence is selected from any one of SEQ ID NO 2-8, 10-74, 76-90 or fragments thereof.

25- The method as claimed in claim 24 wherein said probes and/or primers are at
30 least 10 nucleotides in length.

26- A method for detecting and/or quantifying two or more respiratory viruses in a sample said method comprising:

5 -performing reverse transcription using a template RNA derived from said sample to obtain nucleic acid products for each of said viruses;
-amplifying said nucleic acid products using two or more pairs of oligonucleotide primers to produce an amplification product; and
-detecting and/or quantifying said amplification products.

10 27- The method as claimed in claim 26 wherein at least one of said primers is specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

15 28- The method as claimed in claim 27 wherein said oligonucleotide primers specific for a sequence comprised in a hMPV gene are capable of hybridizing with any one of SEQ ID 2-8, 10-74, 76-90.

20 29- The method as claimed in claim 28 wherein said oligonucleotide primers are at least 10 nucleotides in length.

25 30- The method as claimed in claim 29 wherein said oligonucleotide primer specific for a sequence comprised in a hMPV gene are selected from SEQ ID Nos 91-114.

31- The method as claimed in any one of claim 26-30 wherein said at least two respiratory viruses comprise influenza A and B, human respiratory syncytial viruses A and B, parainfluenza viruses (PIV) types 1-4, adenoviruses, rhinoviruses,

- 88 -

enteroviruses and coronaviruses or any combination thereof and wherein said primers and said two or more viruses are selected such that the detection and or quantification is specific for each of said viruses.

5 32- The method as claimed in claim 31 wherein said oligonucleotide primers are at least 10 nucleotides in length and capable of hybridizing with any one of SEQ ID NO 130-138 and 170-171.

10 33- The method as claimed in claim 31 or 32 wherein said at least two viruses are influenza A, human Respiratory syncytial virus, human metapneumovirus and influenza B.

15 34- The method as claimed in claim 31 or 32 wherein said at least two viruses are Parainfluenza 1, Rhinovirus, Adenovirus, Parainfluenza 3, Enterovirus, and coronavirus.

35- The method as claimed in claim 31 wherein said pairs of oligonucleotide primers are selected from SEQ ID Nos 139 and 140, 141 and 142, 143 and 144, 92 and 94, 112 and 113, 112 and 114, 145 and 146, 147 and 148, 149 and 150, 151 and 20 152, 154 and 155, 153 and 155, 156 and 157, 158 and 159, 160 and 161.

25 36- The method as claimed in any one of claim 26-35 wherein said step of amplifying is performed using PCR and said primer are selected such that the products of the amplifications can be distinguished.

37-

The method as claimed in claim 36 wherein said PCR is RT-PCR.

38- The method as claimed in claim 37 wherein said RT-PCR is real time RT-PCR.

30

- 89 -

39- The method as claimed in claim 37 or 38 wherein said RT-PCR comprises detecting said amplification products by characteristic melting temperature of said amplification products.

5 40- The method as claimed in claim 37 or 38 wherein said RT-PCR comprises detecting and/or quantifying said amplification products with probes specific for said products.

41- The method as claimed in claim 40 wherein said probes are selected from SEQ
10 ID no 162-169 and 172.

42- A composition for detecting at least two respiratory viruses said viruses comprising at least hMPV said composition comprising a combination of oligonucleotides for performing reverse transcription of a template RNA from said at least two respiratory viruses and for an amplification reaction of a product obtained from said reverse transcription wherein said oligonucleotides for said amplification reaction comprise oligonucleotides specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

15
20
25

43- The composition of claim 42 wherein said oligonucleotides for said amplification reaction are primers selected from the group comprising SEQ ID Nos 91-114 and combination thereof.

44- A method for simultaneously detecting two or more respiratory tract viruses in a sample, said method comprising:

- 90 -

Selecting primers specific for a nucleic acid sequence in each of said two or more viruses, said primers to be used in an amplification reaction for detection of said nucleic acid sequences;

5 distributing said primers in one or more assay mixture comprising said sample and at least two pairs of primers; and

10 wherein said selecting and said distributing is based on said detection of said nucleic acid sequence of said two or more viruses being substantially free of overlap and enabling to distinguish between said two or more viruses.

45- The method as claimed in claim 44 wherein said amplification reaction is
PCR

15

46- The method as claimed in claim 45 wherein said PCR is RT-PCR.

47-

20

48- The method as claimed in claim 24 wherein said detection is melting temperature.

49- An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a hybridization probe the nucleotide sequence of which consists of any

50- A kit comprising a nucleic acid probe that is at least 10 nucleotides in length and
is selected from a group consisting sequences hybridizable to SEQ ID Nos 2-8, 10-74,
30 76-90 or fragments thereof.

- 91 -

51- A human metapneumovirus (hMPV) deposited with the International Depository Authority of Canada under Accession number IDAC 111203-01 (CAN97-83).

5 52- A human metapneumovirus (hMPV) deposited with the International Depository Authority of Canada under Accession number IDAC 111203-02 (CAN98-75).

1/13





FIGURE 1

2/13

**FIGURE 2**

3/13




FIGURE 3

4/13




FIGURE 4

5/13




FIGURE 5

6/13




FIGURE 6

7/13




FIGURE 7

8/13




FIGURE 8

9/13




FIGURE 9




FIGURE 10 A

11/13




FIGURE 10 B

12/13




FIGURE 11

13/13




FIGURE 12

SEQUENCE LISTING

<110> Boivin, Guy

<120> METHOD FOR DETECTING RESPIRATORY VIRUSES

<130> 6013-148PCT

<150> CA 2,411,264

<151> 2002-12-19

<150> CA 2,418,004

<151> 2003-01-24

<160> 172

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 13350

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(13450)

<223> human metapneumovirus, strain 00-1

Accession number af371337

<400> 1

gtataaaatta	gattccaaaaaa	aaatatggga	caagtggaaaa	tgtctcttca	agggattcac	60
ctgagtatt	tatcatacaa	gcatgtata	ttaaaagagt	ctcagtacac	aataaaaaga	120
gatgtggta	caacaactgc	agtgcacacc	tcatcatgtc	aacaagaaaat	acactgttgt	180
tgtggggaaa	ttctgtatgc	taaacatgtc	gactacaaaat	atgcgtgcaga	aataggaaata	240
caatataatt	gcacacgttt	aggatcagac	agagtgcagc	agattctgtg	gaactcaggc	300
agtgaagtcc	aatgggtctt	aaccgaacg	tactctctgg	ggaaaattaa	aaacaataaa	360
ggagaagatt	tacagatgtt	agacatcacac	ggggtagaga	agagctgggt	agaagagata	420
yacaaagaag	caaggaaaaac	aatggczaacc	ttgttttaagg	aatcatcagg	taatataccca	480
caaaaatcaga	ggccctcagc	accagacaca	cccataaatt	tattatgtgt	aggtgcctta	540
atattcaacta	aactatgcac	accatagaa	gtggggactag	agacacacat	cagaaggggct	600
aaccgtgtac	taatgtatgc	actcaagaga	tacccttagaa	tggacatacc	aaagattgc	660
agatccctct	atgacattt	tgaacaaaaa	gtgtatcaca	gaagttttgtt	cattgagtat	720
ggcaaaagcat	taggtctcatc	atctacaggc	agcazaacg	zaagttctt	tgttaatata	780
ttcatgcraag	ttatggggc	cggtcaaaaca	atgtcaagg	gggggggtcat	tgcceaggta	840
tccaaacata	taatgtttag	acatgtatcc	gtccaaagctg	agttaaaaaca	ggtcacagaa	900
gtctatgact	tgggtcgaga	aatggggccct	gaatctggac	ttctacattt	aaggcaaaagc	960
ccaaaagctg	gactgttata	actagccaa	tgtcccaact	ttgcaagtgt	tgttctcgga	1020
aatgcctcag	gctttaggc	aatcggat	tatcgaggga	gatggaaaa	cacagaattt	1080
ttttcagcag	ctggaaaggta	tgccaaaat	ttgaaagaaa	gcaataaaaat	aaatttctct	1140
tcatttaggac	ttacagatga	agagaaaaag	gtgcagaac	atttctttaaa	tgtgagtgtac	1200
gacagtcataa	atgattatgt	gtatattaaa	aatggggaca	agtcaaaatg	tcattttccctg	1260
aaggaaaga	tattttttt	atgggtat	aagcagcaaa	atttgcagaa	cttttcccaga	1320
aatcattaag	aaaaccagg	cataaaaaat	ttcaatctat	tataggagaa	aaagtgaata	1380
ctgtatcaga	aacatggaa	ttacacta	tcagtagacc	tgcaaaaacca	accataccgt	1440
cagaacaaa	gttagcatgg	acagataaa	gtggggcaac	caaaactggaa	ataaaagcaag	1500
caatcaaaat	catggatccc	atggaaag	aaaggttac	cgagaagaag	gtgttaccc	1560
ccagtgtatgg	gaaaacccct	gtggggaaa	aactggaaacc	atcaactaac	acccaaaaaga	1620
aggtttcatt	tacaccaa	gaaccaggga	aatataaaaa	gttgaaaaaa	gtgtctctag	1680
atttgccttc	agataatggaa	gaagaagatg	cagaatcttc	aatctttaacc	tttgaagaaa	1740
gagataatcc	atcattaagc	attgggc	gatggaaatc	aatatgggg	aaatthaagca	1800
tgatatttag	gtctattaaga	acactcaaca	ttgtctacagc	aaatgggg	gcagcaagag	1860
atggggatcg	agatgcata	atggcgtaa	gagggaaatt	aatagcagac	ataataaaagg	1920
aagcttaagg	gaaagcagca	gaaatgtat	gagggaaaat	gatcaacga	tcaaaaatag	1980
gaaatggtag	tgtaaaaatt	acagaaaaa	caaaagagct	caaaaaatt	gttgaagatg	2040
aaagcacaag	tggagaatcc	gaagaagaa	agaaccaaa	agacacacaa	gacaatagt	2100
aagaagatga	catttaccag	ttaattatgt	agtttataaa	aaataaaacaa	tgggacaagt	2160
aaaaatggag	tcctacctag	tagacacca	tcaaggcatt	ccttacacag	cagctgttca	2220
agtgtatcta	atagaaaaagg	acctgttacc	tgcaagccia	acaatatgg	tccctttgtt	2280
tcaggccac	acaccaccc	cagtgtctgt	cgatcagta	aaaaccctga	caataaccac	2340
tctgtatgt	gcatcacaaa	atggtccaa	actcaaaat	aatgtcatcg	cccaagggtc	2400

2/52

gtacttccca aaaaatrrga agtcaatgcg actgtacac tcgatgata
gaatttgaca aactcacagi ctgtgaagta aaaacagttt acttaacaac 2520
tacgggatgc tataaaattt tggactctca gccaaatcg ttgcaaaaa 2580
tatgttattt tttggatcta aaaaaggaca caccgttac 2640
caaagggatg aacacaggcc aaaatttgac ctatgcggg 2700
tttggatcta ttcaaaaaggc ttcaaaaaggc ttggagctgg 2760
tttggatcta gaaagcataa gcaaaatatcg 2820
tttggatcta tttggatcta gaaagcataa aaccacgac 2880
tttggatcta agatcataaa gtcacccattc tagttatata 2940
tttggatcta tcaagaacgg gacaaataaa aatgtctgg 3000
tttggatcta acacccatc acggctttaa agagactac 3060
tttggatcta gggatctca ttggatctca ttggatctgg 3120
tttggatcta gatgttagaga acctttatcg tgcctatgg 3180
tttggatcta accaaaatgt cactaagaga gctcagaaca 3240
tttggatcta caaaaatgtt atcccaagaca atctatgtt 3300
tttggatcta atggatctca ttggatctca ttggatctgg 3360
tttggatcta atggatctca ttggatctca ttggatctgg 3420
tttggatcta gtaacagcaaa tttaaaatgtc cctcaaaaag 3480
tttggatcta ggagttctg ttttggcaac tgcgtgaga 3540
tttggatcta acacccatc ttcaaaaatggc caatgtcgac 3600
tttggatcta agtcaatc ttcaaaaatggc cttaaatgtt 3660
tttggatcta acacccatc ttcaaaaatggc cttaaatgtt 3720
tttggatcta atggatctca ttggatctca ttggatctgg 3780
tttggatcta ttggatctca ttggatctca ttggatctgg 3840
tttggatcta ccaatcttgc gggatctata cacccttgc 3900
tttggatcta gggaaaatggc gaaactatgc ttggcttctt 3960
tttggatcta ttggatctca ttggatctca ttggatctgg 4020
tttggatcta ttggatctca ttggatctca ttggatctgg 4080
tttggatcta ttggatctca ttggatctca ttggatctgg 4140
tttggatcta ttggatctca ttggatctca ttggatctgg 4200
tttggatcta agcaacagag tagggatcat caagcaactg 4260
tttggatcta gacgcagaca ctttggatctca ttggatctgg 4320
tttggatcta ctttggatctca ttggatctca ttggatctgg 4380
tttggatcta ttggatctca ttggatctca ttggatctgg 4440
tttggatcta ttggatctca ttggatctca ttggatctgg 4500
tttggatcta ttggatctca ttggatctca ttggatctgg 4560
tttggatcta ttggatctca ttggatctca ttggatctgg 4620
tttggatcta ttggatctca ttggatctca ttggatctgg 4680
tttggatcta ttggatctca ttggatctca ttggatctgg 4740
tttggatcta ttggatctca ttggatctca ttggatctgg 4800
tttggatcta ttggatctca ttggatctca ttggatctgg 4860
tttggatcta ttggatctca ttggatctca ttggatctgg 4920
tttggatcta ttggatctca ttggatctca ttggatctgg 4980
tttggatcta ttggatctca ttggatctca ttggatctgg 5040
tttggatcta ttggatctca ttggatctca ttggatctgg 5100
tttggatcta ttggatctca ttggatctca ttggatctgg 5160
tttggatcta ttggatctca ttggatctca ttggatctgg 5220
tttggatcta ttggatctca ttggatctca ttggatctgg 5280
tttggatcta ttggatctca ttggatctca ttggatctgg 5340
tttggatcta ttggatctca ttggatctca ttggatctgg 5400
tttggatcta ttggatctca ttggatctca ttggatctgg 5460
tttggatcta ttggatctca ttggatctca ttggatctgg 5520
tttggatcta ttggatctca ttggatctca ttggatctgg 5580
tttggatcta ttggatctca ttggatctca ttggatctgg 5640
tttggatcta ttggatctca ttggatctca ttggatctgg 5700
tttggatcta ttggatctca ttggatctca ttggatctgg 5760
tttggatcta ttggatctca ttggatctca ttggatctgg 5820
tttggatcta ttggatctca ttggatctca ttggatctgg 5880
tttggatcta ttggatctca ttggatctca ttggatctgg 5940
tttggatcta ttggatctca ttggatctca ttggatctgg 6000
tttggatcta ttggatctca ttggatctca ttggatctgg 6060
tttggatcta ttggatctca ttggatctca ttggatctgg 6120
tttggatcta ttggatctca ttggatctca ttggatctgg 6180
tttggatcta ttggatctca ttggatctca ttggatctgg 6240
tttggatcta ttggatctca ttggatctca ttggatctgg 6300
tttggatcta ttggatctca ttggatctca ttggatctgg 6360
tttggatcta ttggatctca ttggatctca ttggatctgg 6420
tttggatcta ttggatctca ttggatctca ttggatctgg 6480
tttggatcta ttggatctca ttggatctca ttggatctgg 6540
tttggatcta ttggatctca ttggatctca ttggatctgg 6600
tttggatcta ttggatctca ttggatctca ttggatctgg 6660
tttggatcta ttggatctca ttggatctca ttggatctgg 6720

4/52

ctattaatca	agcactaagt	gagagatttg	ggaatgaaga	tattaatttg	gtcttccaaa	11100
atgcaatcg	ctgrrgaaatt	agcataatga	gtgttagtaga	acaattaact	ggtaggagtc	11160
caaaacaggct	agttttaaata	cctcaatttg	aagaaataga	cattatgcct	ccaccagtgt	11220
ttcaagggaa	attcaattat	aagcttagtag	ataagataaac	ttctgtatcaa	cataatcttca	11280
gtccagacaa	aatagatatg	ttaacactgg	ggaaaatgtct	catgcccact	ataaaagggtc	11340
agaaaaacaga	tcagttcctg	aacaagagag	agaattatgg	ccatgggaaat	aatcttatttg	11400
agtctttgtc	agcagcgta	gcatgtcatt	ggtgtgggat	atthaacagag	caatgtatag	11460
aaaataacat	tttcaagaaata	gactggggat	acgggttcat	atcggtatcat	gcctttatgg	11520
acttcaaaat	attccctatgt	gtctttaaaaa	cttaaacttgc	ttctgtatgg	gggtcccaag	11580
ggaaaaaacat	taaagatgaa	gatatagttag	atgaatcaat	agataaaactg	ttaaggatttg	11640
ataatacttt	ttggagaatg	ttcagcagg	ttatgtttga	atcaaagggtt	aagaazagga	11700
taatgttata	tgatgttaaaa	tttctatcat	tagtaggtt	tatagggttt	aagaatttgt	11760
ttatagaaca	ttttagatca	gctgagttgc	ataggatacc	ttggattgtc	aatgcccag	11820
gtgatctgg	tttagatcaag	tcaattaaaa	tcttttgca	actgtatagag	caaaggttat	11880
ttttttaagaat	aactgttttg	aactatacag	atatggcaca	tgctctcaca	agattaatca	11940
gaaagaaggt	gatgtgtat	aatgtactat	taatcccgat	tccatcccca	atggtttaat	12000
taactcaatgt	tatgtatct	acagaaacat	tagttttat	ccctaaagata	acatttggaa	12060
ggctaaaaaa	ttatgacact	agttcaattt	atgtttaaagg	aaagcttaaca	aggaattaca	12120
tgatactgtt	gcccattggca	catgttaata	gatataactt	tgtctttatgt	tctactggat	12180
gtttagttag	tcttttttttt	tgcatgttgc	aactttagaa	agatcttaaac	cctaaagtgc	12240
tgtactttat	tggagaaggg	gcaggaaat	ggatggccag	aacagcatgt	gaatatcttg	12300
acatcaaaatt	tgttatacaga	agttttttaaag	atgacatttgc	tcatcattat	ccittggaaat	12360
accagagagt	tataggagaa	ttaagcagg	taatagatag	cggtgaagg	ctttcaatgg	12420
aaacaacaga	tgcaactcaa	aaaacttattt	gggattttgtat	acacagatgt	agcaaaatgt	12480
ctttttaat	aactttttatgt	gatgcgatgt	ttaaggacag	agatgtttt	tttaagatgg	12540
taattctatg	gaggaaacat	gttattatcat	gcagaatttttgc	cacttattat	gggacagacc	12600
tcttattttt	cgcaaaatgt	catgttaaaag	actgtcaatgt	aaaatttact	ttttttttgt	12660
gatcgtatgc	cacccatttt	atgcgaaggta	gttaactgtc	aggctcagaa	tgctacat	12720
tcttaaact	aggccaccac	aacaattttac	ccrccatgg	agaaatataaa	aattcttaaga	12780
tgaaaatatac	atgtgtat	gatttttatgt	ctgaaaaaaa	atctgacaat	aaatcttattt	12840
aaagccaaatgt	taaatttactt	ttatcagggt	taagaataacc	gataaaataag	aaagaattaa	12900
atagacagag	aagggtttat	acactacaaa	gcaaccatcc	ttctgtatgc	acagtggag	12960
gttagcaagg	catagagttt	aaatgtttaaa	caaaacaaaggc	aaacacataata	attgtatttgt	13020
tagaatacat	ttttttttttt	ccaaaagggt	aattttttttt	ttgttttttt	gaagcattag	13080
aaaataactta	ccctaaatatg	attttttttt	tagataatct	agggaaatgc	gagataaaaa	13140
aactgtatca	agtaacttgc	tatattttttt	taatgtttttt	atgaaaaatgt	ataaaaatgt	13200
taaaataggt	gacaacttca	tacttttttca	aagttatcat	tttgattatgc	aattatgtttaa	13260
tagtttaat	aaaaactttttt	atccaaatgtt	agaaatcttac	aactgttattt	aagtttattttt	13320
aaatataagaa	attataatttgc	gatgtatcat	tttttttttttt			13350<210> 2

<211> 782

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(782)

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-118

<400> 2

atgttaggcac	cacaactgca	gtgacacctt	catcartgca	gcaagagata	acacttttgt	60
gtggagagat	tcttttacact	aaacatactg	attacaaaata	tgctgcagag	ataggatata	120
aatatatttg	cacggctctta	ggatcagaaaa	gagttacaata	gattttttaaga	aatttcaggca	180
gtgaaggatca	gtgtgttctta	accaagacat	actcttttagg	gaaaggtaaa	aatagtaaaag	240
ggaaaggtt	gcaaaatgtta	gatatacatg	gagtggaaaa	gagttgggtt	gaagaaatgt	300
acaaaaggggc	aaagaaaaacaa	atggtgactt	tgttaaaagg	atcatcagg	aacatcccac	360
aaaaccaggag	gccttcagca	ccagacacac	caataatttt	attatgttgc	ggtgctttaa	420
tatttactaa	acttagcatca	acaatagaag	tttggacttaga	gacttacagg	agaagagacta	480
acagagtgtt	aagtgtatgc	actcaaaagat	acccttaggg	agatatacc	aagattgtca	540
gtatctttctt	tgtacttattt	gagcagaaaa	ttttttttttt	gagtcttattt	atttgatgt	600
ggaaaggctt	aggctcatct	tgcacaggaa	gcaaaaggcaga	ttttttttttt	gtaaaatata	660
ttatgtccatc	ttatggatcc	ggtcaaaacaa	tgttaagggt	gggtgttcat	gccagatcat	720
ctaataatac	attgttaggg	catgtatctg	tgcacacccat	attttttttttt	agtccacagag	780
gt						782

<210> 3

<211> 878

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

5/52

<222> (1)...(878)

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-174

<400> 3

atgtgggtac	caccactgca	gtgacacccct	catcattgca	acaagaaaata	acgctgttgt	60
gtggagaaat	tctgtatgt	aaacatgtcg	attacaaaata	tgctgcagaa	ataggaatac	120
aatatatttg	cacagcttta	ggatcagaga	gagtgcagca	gattctgagg	aactcaggca	180
gtgaagtcca	agtgttca	accagaacgt	actctctggg	gaaagttaaa	aacaataaaag	240
gagaagattt	acagatgtta	gacatacacg	gggttagagaa	gagctgggtt	gaagagatag	300
acaaaagaac	aaggaaaaaca	atggcaaccc	tgcttaagga	atcatcagg	aatatccgc	360
aaaatccagg	gcccctcagca	ccagacacac	ccataatctt	attatgtgt	gtgccttaa	420
tatttactaa	actagcatca	accatagaag	ttggactaga	gaccacagt	agaaggccta	480
accgtgtact	aagtgtatgc	ctcaagagat	accctagaat	ggacatcccc	aaaatttgcca	540
gatcccttcta	tgacttattt	gaacaaaaag	tgtatcacag	aagtttgtt	attgagttatg	600
gcaaaagcatt	aggctcatca	tctacaggca	gcaaaaggaga	aagtcttattt	gttaatataat	660
tcatgcaagc	ttatggagcc	ggtcaaaacaa	tgctaaagg	gggggttatt	gccaggcat	720
ccaacaatata	aatgttatga	catgtatccg	tccaaagctga	gttaaacaca	gttcacagaa	780
gtctatgact	tggtgcgaga	aatgggtcct	gaatctggac	ttctacattt	aaggcaaaagc	840
ccaaaagctg	gactgtatca	ctagccaaact	tcccaact			878

<210> 4

<211> 876

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(876)

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-176

<400> 4

atgtaggccc	cacaactqca	gtgacacccct	catcattgca	gcaagagata	acacttttgt	60
gtggagagat	tctttacact	aaacatactg	attacaaaata	tgctgcagag	atagggatac	120
aatatatttg	cacggctcta	ggatcagaaa	gagtacaaca	gattttaaa	atttcaggta	180
gtgaagtcca	gggtggttcta	accaagacat	actctttagg	gaaaggtaaa	aatagtaaaag	240
ggggagagtt	gcaaaatgtta	gatatacatg	gagtggggaa	gatgtgggt	gaagaaaatag	300
acaaaagaggc	aagaaaagaca	atggtgactt	tgctaaagga	atcatcagg	acatccccac	360
aaaaccagag	gcccctcagca	ccagacacac	caataatgg	attatgtgt	gtgtgcgtttaa	420
tatttactaa	actagcatca	aaacatagaag	ttggactaga	gactacagt	agaagagcta	480
acagagtgt	aagtgtatgc	ctcaaaagat	acccttaggt	agatatacca	agattgtcta	540
gatcttttta	tgaacttattt	gagcagaaag	tgtattacag	gagtcttattc	attgagttatg	600
ggaaaagctt	aggctcatca	tcaacaggaa	gcaaaaggaga	aagtttgtt	gtaaatataat	660
ttatgcgac	ttatggagcc	ggtcaaaacaa	tgctaaagg	gggggttatt	gccagatcat	720
ctaacaacat	aatgttaggg	catgtatctg	tgcaagctga	attgaaacaa	gttacagagg	780
ttttagtattt	ggtgagagaa	atgggtcctg	aatctgggc	tttactctta	agaacaagtc	840
caaaggcagg	actgttatcg	tggctaatgc	ccccaaat			876

<210> 5

<211> 869

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(869)

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-193

<400> 5

atgtgggtac	aacaactgca	gtgacacccct	catcattgca	acaagaaaata	acgctgttgt	60
gtggagaaat	tctgtatgt	aaacatgtcg	attacaaaata	tgctgcagaa	ataggaatac	120
aatatatttg	cacagcttta	ggatcagaga	gagtgcagca	gattctgagg	aactcaggta	180
gtgaagtcca	agtggcttta	accagaacgt	actctctggg	gaaaggtaaa	aacaataaaag	240
gagaagattt	acagatgtta	gacatacacg	gggttagagaa	gagctgggt	gaagagatag	300
acaaaagaac	aaggaaaaaca	atggcaaccc	tgcttaagga	atcatcagg	aatatccac	360
aaaatccagg	gcccctcagca	ccagacacac	ccataatctt	attatgtgt	gtgccttaa	420
tatrttactaa	gctagcatca	accaatagaag	ttggactaga	gaccacagtc	agaagggtca	480
accgtgtact	aagtgtatgc	ctcaacagat	acccttagaa	ggacatcccc	aaaatttgcca	540
gatcccttcta	tgaacttattt	gaacaaaaag	tgtatcacag	aaatgggtt	attgagttatg	600
gtaaaggcatt	aggatcatca	tctacaggca	gcaaaaggaga	aagtcttattt	gttaatataat	660

6/52

tcatgc	ttatggagcc	ggtcaaaacaa	tgctaaagg	gggggtcatt	gccagg	tcatt	720
ccaa	acaat	aat	gtttag	catgtatcc	tccaa	ggct	780
gtctat	gact	ttg	tg	ggag	aaaaca	tcac	840
ccaa	aaag	act	gt	gaga	act	tttt	869
aaag	ctg	gtt	ttat	aat	tttt	tttt	

<210> 6
 <211> 848
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(848)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77B07

<400> 6
 atgtaggcac cacaactgca gtgacacaccc ttcatcattgca acaagaaaata acaacttttgc
 gtggggaaat tcttttacact aaacacactg attacaaaata tgctgtcgag ataggatgc
 aatataatttgc cacagctcta ggatcagaaaa gatgtacaaa aacttcaggta
 gtgaagttca ggtgggtttt accaaaacat actccctttagg gaaaggccaa aacagttaaag
 gggaaagagct gcatatcatg gatgtggaaaa gatgtgggtt gaaagaaaatag
 acaaaagaggc aagaaaagaca atggtaactt tgcttaagga gtcatcaggta aacatcccac
 aaaaccagag accttcagca ccagacacac caataattttt attatgtgtt ggtgccttaa
 tattactcaa actagcatc acaatagaag ttggattaga gactacaggta acaagagctt
 atagatgtctt aagtgtatgc ctcaaaaatg acccttaggtt agatataccca aagattgtcta
 gatcttttta tgaactatrtt gaacaaaaag tgtactacag aagttttttt atttgatgtac
 gaaaagctttt aggttcatc tcaacacggaa gcaaaagcaga aagttttttt gtaaaatata
 ttatgcagc ttatggatg ggtcaaaacac tgctaaaggty ggggtgtt ggcagatcat
 ccaacaacat aatgtctaggg catgtatctg tcaatctga attgtaaagca ttccacagagg
 tttatgactt ggtgagagaa atgggtccctg aatctgggtt ttatcatctt agacaaaagtc
 caaaggca 848

<210> 7
 <211> 894
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(894)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77748

<400> 7
 atgtgggtac aacaactgca gtgacacaccc ttcatcattgca acaagaaaata acgttgttgc
 gtggagaaat tctgtatgtt aaacatgtcg attacaaaata tgctgcagaa ataggatata
 aatataatttgc cacagcttta ggatcagaga gatgtcgacca gatgtctggg aacttcaggca
 gtgaagttca agtgggtcttta accggaaacgt actctctggg gaaaggtaaa aacaataaag
 gagaagatit acagatgtta gacatcacacg ggttagagaa gagctgggtt gaaagagata
 acaaagaagc aaggaaaaaca atggcaacaccc tgcttaagga atcatcaggta aatatacccac
 aaaatccatgg gcccttcagca ccagacacac ccataatctt attatgtgtt ggtgccttaa
 tattactcaa gctagcatc accatagaag tggactaga gaccacatggc acaagaggctt
 accgtgtact aagtgtatgc ctcaaaagat acccttagaaat ggacatccca aaaaatgtca
 gatcccttctt tgacttattt gaacaaaaag tttatcacaat aagttttttt atttgatgtat
 gcaaaaggattt aggttcatc tctacaggca gcaaaaggaa aagtcttatattt gcttatata
 tcattgcagc ttatggagcc ggtccaaacaa tgctaaaggty ggggtgtt ggcagatcat
 ccaacaat aatgtttaga catgtatctg tcaaaatgtt aatgtaaacaa gacacagaag
 tccatgactt ggtgtagaa atggggctgt aatctggact ttctacttttta aggcaaaagcc
 caaaagctgg actgttttaca ctatccaactt gtcccaactt tgcaagtgtt gttc 894

<210> 8
 <211> 850
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(850)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-217

7/52.

<400> 8

atgtgggtac	aacaactgca	gtgacaccct	catcattgca	acaagaaaata	acgctgttg	60
gtggagaat	tctgtatgt	aaacatgtg	attacaata	tgctgcagaa	ataggaatac	120
aataatattag	cacagctta	ggatcagaga	gagtgcagca	gattctgagg	aactcaggta	180
gtgaagtcca	agtgttctta	accagaacgt	actctctgg	gaaagttaaa	acaataaaag	240
gagaagat	acagatgtt	gacatcacacg	ggtagagaa	gagctgggt	gaagagatag	300
acaagaagc	aaggaaaaaca	atggcaacct	tgcttaagga	atcatcagg	aatatcccac	360
aaaatcagag	gccctcagca	ccagacacac	ccataatctt	attatgtgt	gtgccttaa	420
tatTTactaa	gctagcatca	accatagaag	tggactaga	gaccacagtc	agaaggcata	480
accgtgtact	aagtgtatgc	Ctcaagagat	accctagaat	ggacatccc	aaaattgcca	540
gateccttcta	tgacttattt	gaacaaaaaa	tgtatcacag	aagtgttgc	attgagatag	600
gtaaaggatt	aggatcatca	tctacaggca	gcaaaagcaga	aagtcttattt	gttaatata	660
tcatgcagc	ttatggagcc	ggtcaaaca	tgctaaagg	gggggtcatt	gccaagtcat	720
ccaaacaatat	aatgttagga	catgtatccg	tccaaagctga	attaaaaaca	gttcccagaa	780
tcctcatgt	tggtgcgaga	aatggggct	gaatctggac	ttctactttt	aaggcaaaagc	840
ccaaaagctg						850

<210> 9

<211> 1185

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(1185)

<223> human metapneumovirus, strain 00-1, accession

number af371337

<400> 9

atgtctcttc	aagggattca	cctgagtgt	ttatcataca	agcatgttat	attaaaaagag	60
tctcgtacaa	taaaaaaa	agatgtgggt	acaacaatcg	cagtgcacacc	ctcatcattt	120
caacaagaaa	taacactgtt	gtgtggagaa	attctgtatg	ctaaacatgc	tgactacaaa	180
tatgtctcag	aaataggaat	acaatataatt	agcacagctt	taggatcaga	gagagtgcag	240
cagattctga	ggaactctagg	cagtgaatgc	caagtgtt	taaccaggca	gtactctctg	300
ggggaaatatt	aaaacataaa	aggagaatgt	ttacagatgt	tagacataac	ggggtagag	360
aagagctggg	ttagaaagagat	agacaaaaaa	gcaaggaaaa	caatggcaac	cttgcattaa	420
gaatcatcag	gtatataccc	acaaaaatcg	aggccctcag	caccagacac	accataatc	480
ttattatgtt	taggtgcctt	aatatctact	aaacttagcat	caaccataga	agtgggacta	540
gagaccacac	tcaagaaggc	taaccgtgt	ctaagtgtt	cactcaagag	atacccttaga	600
atggacatcata	caaaagatgc	cagatcttc	tatgacttat	ttgaaacaaaa	agtgtatc	660
agaaggttgt	tcatttgcgt	tggcaaaagca	ttaggctcat	cattctacagg	cagcaagca	720
gaaagtctat	ttgttaat	attcatgca	gtttatgggg	ccggtaaaac	aatgtctaa	780
tggggggctca	tttccagggtc	atccaaata	ataatgttag	gacatgtatc	cgtccaaagct	840
gagttttaaaac	aggtcacaga	tttgcgttgc	tttgcgttgc	aaatggggcc	tgtatcttga	900
tttctacatt	taaggcaaa	cccaaaaatgt	ggactgttat	cactagccaa	ctgrcccaac	960
tttgcgttgc	tttttcttcgg	aaatgtctca	ggctttaggc	taatcggtat	gtatcgagg	1020
agagtaccaa	acacagaat	attttcagca	gcttgcgttgc	atgcacaaa	tttgcgttgc	1080
agcaataaaa	taattttctc	tttccatgg	cttacagatg	aaagaaaaga	ggctgcgaaa	1140
cattttttaa	atgtgatgt	cgacagtca	aatgattatg	agtaa		1185

<210> 10

<211> 700

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(700)

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-163

<400> 10

tgcagaaaata	ggaataacaat	atattagcac	agcttttagga	tcagagagag	tgcagcagat	60
tctgaggaaac	tcaggcagt	aagtccaaat	ggtcttaacc	agaacgtact	ctctggggaa	120
agttaaaaac	aataaaggag	aaatattaca	gatgttagac	atacacgggg	tagagaagag	180
ctgggttagaa	gagatagaca	aagaagcaag	gaaaacaaatg	gcaacccttgc	ttaaggaatc	240
atcaggtat	atcccccaaa	atcaggtat	ctcagcccca	gacacacccca	taatcttatt	300
atgtgttaggt	gtcttaat	ttacttaaaat	agcatacacc	atagaatgtt	gacttagagac	360
cacagtca	aggccaaacc	gtgtactaag	tgatgcactc	aagagatacc	ctagaatgtt	420
catcccaaaa	atggccat	ctttctatga	cttatttgaa	caaaaaatgtt	atcacagaa	480
tttgcgttgc	ggtatgttgc	aaggcatttt	ctcattatct	acaggtagca	aaggcagaaag	540
tctatatttt	aatatata	tgcagatgt	tggagccgt	caaacaatgc	taagggttggg	600

8/52

ggtaattgcc aggtcatcca acaatataat gttaggacat **gtatccgtcc** aagctgagtt 660
 aaaaacaggta acagaagtct atgacttggt gcgagaaaatg 700

<210> 11
 <211> 705
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(705)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-174

<400> 11
 tatttagcaca gcttttaggat cagagagagt gcagcagatt ctgaggaact caggcagtga 60
 agtccaaagtg gtcttaacca gaacgtactc tctggggaaa gttaaaaaca ataaaggaga 120
 agatttacag atgtagaca tacacggggt agagaaggac tgggtagaag agatagacaa 180
 aagaagcaagg aaaaacaaatgg caaccttgct taaggaaatca tcaggtataa tccccaaaaa 240
 tcagaggccc tcagcaccag acacacccat aatcttattta tgtgttagtg ccttaatatt 300
 tactaaacta gcatcaacca tagaagtggg actagagacc acagtcaagaa gggctaaaccg 360
 tggtaactgt gatgcactca agagataccc tagaatggac atccccaaaaa ttgcagatc 420
 ctttctatgac ttatggtaac aaaaagtgtt aacacaaatgg tttttttttt agtatggca 480
 agcatttaggc tcacatcatca caggcagcaa agcagaaatgt gtatttgtt atatattcat 540
 gcaagcttat ggagccgtc aaacaatgtt gagggtgggg gtcattgca ggtcatccaa 600
 caatataatg ttaggacatg tttttttttt agctgagctt aaaccgggtca cagaatgttca 660
 tgacttggtg cgagaaatgtt ttcctgtatc tttttttttt catta 705

<210> 12
 <211> 700
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-184

<400> 12
 aaatatgtctt cagaaatagg aatacaatat attagcacag cttaggatc agagagagt 60
 cagcagatcc tgaggaactc aggcaatggaa gtccaaatgg tttttttttt aacgtactct 120
 ctggggaaaat ttaaaaacaa taaaaggagaa gatttacaga tttttttttt acacgggtt 180
 gagaagagct gggtagaaat gatagacaaa gaagcaagga aaacaatggc aacccatgtt 240
 aaggaatcat cagttatattt cccacaaatgg tttttttttt cttttttttt cttttttttt 300
 atcttattttt gtgttagtgc ttatattttt actaaacttag catcaacccat agaagtggga 360
 cttagagacca cttttttttt ggcacccgtt ttatattttt tttttttttt gggatccct 420
 agaattggaca tcccaaaaat ttatattttt tttttttttt tttttttttt tttttttttt 480
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600
 gcaagaaatggc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 700

<210> 13
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-185

<400> 13
 taggaataca atatatttgc acagctctag gatcaagagag agtacacgcg attttaagaa 60
 actcaggcag tgaagttccaa gtgtttttaa ccagaacgtt cttttttttt aaatggggaaa 120
 acaacaaaagg agaagatttta cttttttttt acatacacgg agttagagaaaa agtgggtgg 180
 aagagataga caaagaagca agaaaaacaa tggcaactttt gttttttttt tcacggca 240
 atattccaca aaatcaggg cttttttttt cttttttttt cttttttttt tttttttttt 300
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420

9/52

aaatcgctag	atctttctat	gacttatttg	aacaaaaagt	gtattacaga	agcttgtca	480
ttgagtatgg	caaaggcatta	ggctcatctt	ctacaggcag	caaaggcagaa	agttttatcg	540
ttaatatat	catgcaagct	tacggtgctg	gtcaaaacaaat	gctgaggtgg	ggagtcattg	600
ccaggctcatc	taacaatata	atgtttaggac	atgratctgt	ccaaagctgag		650
<210> 14						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Quebec Isolate No C-76837						
<400> 14						
acaaatatgc	atcataaata	ggaataacaat	atattagcac	agcttttagag	atcagagaga	60
gtgcagcaga	ttctaaaggaa	ctcaggcagt	gaagtccaaag	tggctttaac	cagaacgtac	120
tctctggat	agttaaaaaa	caataaaggaa	gaagattac	agatgtttaga	catacacggg	180
gtagagaaga	gctgggtaga	agagatagac	aaagaagcaa	ggaaaacaat	ggcaaccttg	240
cttaaggaat	catcaggtaa	tatcccacaa	aatcagaggc	cctcagcacc	agacacacccc	300
ataatcttat	tatgtgttag	tgccttataa	tttactaaac	tagcatcaac	catagaagtg	360
ggactagaga	ccacagtca	aaaggcttaac	cgtgtactaa	gtgatgact	caagagatac	420
cctagaatgg	acatcccaa	aattgcaga	tcctttatgt	acttatttg	acaaaaagtg	480
tatcacagaa	gtttgttcat	tgagtatggc	aaagcattag	gctcatcatc	tacaggcagc	540
aaagcagaaa	gtcttatttg	taatataat	atgcaagctt	atggagccgg	tcaaacaatg	600
ctaagggtgg	gggtcattgc	caggtcatcc	aacaatataa	tgtttaggata		650
<210> 15						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Quebec Isolate No C-77807						
<400> 15						
gtatgctaaa	catgctgatt	acaaatatgc	tgcagaaaata	ggaataacaat	atattagcac	60
agcttttag	tcagagagag	tgcagcagat	tctggggac	tcaggcagt	aagtccaaat	120
ggctttaacc	agaacgtact	ctctggggaa	agttaaaaac	aataaaaaggaa	gaagatttac	180
agatgtttaga	catacacggg	gtagagaaga	gctgggtaga	agagatagac	aaagaagcaa	240
ggaaaacaat	ggcaaccttg	cttaaggaat	catcaggtaa	tatcccacaa	aatcagaggc	300
cctcagcacc	agacacaccc	ataatcttat	tatgtgttag	tgccttataa	tttactaagc	360
tagcatcaac	catagaaatg	ggactagaga	ccacagtca	aaaggcttaac	cgtgtactaa	420
gtgatgact	caagagataa	ccttagatgg	acatcccaa	aatggccaga	tcctttatgt	480
acttatttg	acaaaaagtg	tatcacagaa	gtttgttcat	tgagtatggc	aaagcattag	540
gctcatcatc	tacaggcagc	aaagcagaaa	gtcttatttg	taatataat	atgcaagctt	600
atggagccgg	tcaaaacaaatg	ctaagggtggg	gggtcattgc	caggtcatcc		650
<210> 16						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Quebec Isolate No HMPV-C-78123						
<400> 16						
ttaggatcag	agagagtgc	gcagattcta	aggaactcag	gcagtgaagt	ccaaagtggc	60
ttaaccagaa	cgtactct	ggggaaaagt	aaaaacaata	aaggagaaga	tttacagatg	120
ttagacatac	acggggtaga	gaagagctgg	gttagaaggaga	tagacaaaaga	agcaaggaaa	180
acaatggcaa	ccttgctttaa	ggaatcatca	gttaatatacc	cacaaaatca	gaggccctca	240
gcaccagaca	caccataat	cttattatgt	gttaggtgcct	taatatttac	aaaactagca	300
tcaaccatag	aagtgggact	agagaccaca	gtcagaaggg	ctaaccgtgt	actaagtgt	360
gcactcaaga	gataccctag	aatggacatc	ccaaaaattg	ccagatccct	ctatgactta	420

10/52

tttgaacaaa	aagtgtatca	cagaagtttg	ttcattgagt	atggcaaggc	attaggctca	480
tcatctacag	gcagcaaagc	agaaagtcta	tttgttaata	tattcatgca	agtttatgga	540
gccccgtcaaa	caatgctaag	gtggggggtc	attgcaggt	catccaaacaa	tataatgtta	600
ggacatgtat	ccgtccaaagc	tgagttaaaa	caggtcacag	zaagtctatg	650	
<210> 17						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(700)						
<223> human metapneumovirus, strain Quebec Isolate No C-78132						
<400> 17						
cagaagaggt	acaaacagatt	ttgagaaaact	caggtatgt	agttcagggt	gttttaacca	60
aaacataactc	cttagggaaa	ggcaaaaaca	gtttttggga	agagctgcag	atgttttagata	120
tacatggagt	ggaaaagagt	tgggttagaag	aaatagacaa	agaggcaaga	aagacaatgg	180
taatgttgc	taaggagtca	tcaggtaaca	tcccaaaaa	ccagagacct	tcageaccag	240
acacaccat	aattttata	tgtgttagtg	cccttaattt	cactaaacta	gcatctacaa	300
tagaagttgg	attagagact	acagtttagaa	gagctaatag	agtgcataagt	gatgcactca	360
aaagataccc	tagggtagat	ataccaaaaga	ttgttagat	ttttttatgaa	ctatttgaac	420
aaaaagtgt	ctacacaaagt	ttatttcattt	agtacggaaa	agcttttaggc	tcatcticca	480
caggaagcaa	agcagaaaagt	ttgtttgtaa	atattttat	gcaagcttat	ggagctggc	540
aaacactgt	aaagggtgggt	gtcattgcca	gatcatccaa	caacataatg	ctagggcatg	600
tatctgtca	atctgaattt	aagcaagttt	cagagggtttt	tgactttgggt		650
<210> 18						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Quebec Isolate No C-78163						
<400> 18						
ggatccagaaa	gagtacaaca	gattttggaa	aactcaggta	gtgaagttca	gggggtttta	60
accaaaacat	actcctttagg	gaaaggcaaa	aacagtaaaag	ggggagagct	gcagatgtta	120
gatatacatgt	gagtggaaaa	gagttgggtt	gaagaaatag	acaaagaggc	aagaaagaca	180
atggtaactt	tgcttaaggg	gtcatcagg	aaacatccac	aaacccacag	acccatcagca	240
ccagacacac	caataaattt	attatgtgt	ggtgccttaa	tattcaacta	actagcatca	300
acaatagaag	ttggatttga	gactacagt	agaagagcta	atagagtgt	aaatgtatgtca	360
ctcaaaagat	acccttaggt	agatataccaa	aaatgtgt	gtatgtttttt	tgaactattt	420
gaacaaaaaaag	tgtactacag	aaattttttc	atggatgt	gaaaagcttt	aggctcatct	480
tcaacaggaa	gcaaaaggcga	aaatttttttt	gtatgtatat	ttatgtcaac	ttatggact	540
ggtcaaacac	tgcttaagggt	gggtgttatt	gccagatcat	ccaacaacat	aatgttaggg	600
catgtatctg	tgcaatctga	attgttagca	gttacagagg	ttttatgactt		650
<210> 19						
<211> 600						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(600)						
<223> human metapneumovirus, strain Quebec Isolate No C-91205						
<400> 19						
atatttgcac	agctcttaggg	atcagagaga	gtacagcaga	ttcttaagaaa	ctcaggcagt	60
gaagtccaaag	ttgttttaac	cagaacgtac	tttttggga	aaatttaaaaaa	caacaaagga	120
gaagatttac	agatgtttaga	catacacgg	gttagagaaaa	gtgggttgg	agagatagac	180
aaagaagcaa	gaaaaacaaat	ggcaactttt	ctttaaagaaat	catcaggcaca	tattccacaa	240
aatccagaggc	tttcagcacc	agacacaccc	ataatcttat	tatgtgttag	tgccttaata	300
tttacccaaac	tagcatcaac	tatagaagtg	ggatttagaga	ccacagtcag	aaagagctaac	360
cgtgtactaa	gtgtatgcact	caaaagatac	cctaggatgg	acataccaa	aatcgctaga	420

11/52

tctttctatg	acttatttga	acaaaaagtg	tattacagaa	gcttgttcat	tgagtatggc	480
aaagcattag	gctcatcctc	tacaggcagc	aaagcagaaa	gtttattcgt	taatataatc	540
atgcaagctt	acgggtctgg	tcaaacaatg	ctgaggtggg	gagtcatgtc	caggtcatct	600
<210> 20						
<211> 700						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(700)						
<223> human metapneumovirus, strain Quebec Isolate No						
C-91364						
<400> 20						
gattacaaat	atgctgtcga	gataggaatg	caatatattt	gcacagctct	aggatcagaa	60
agagtacaac	agattttgag	aaactcaggt	agtgaagttc	aggtgttct	aaacaaaaca	120
tactccttag	ggaaaggcaa	aaacagtaaa	ggggaaagagc	tgcagatgtt	agatatacat	180
ggagtggaaa	agatgtgggt	agaagaaaata	gacaaaaggg	caagaaagac	aatgttaact	240
ttgtctttaagg	agtcatcagg	taacatccc	aaaaaccaga	gaccttcagc	accagacaca	300
ccaaataattt	tattatgtgt	agggtcccta	atatttcacta	aacttagcatc	aacaatagaa	360
gttggattag	agactacagt	tagaagagct	aatagagtgc	taagtgtatgc	actcaaaaaga	420
tacccttaggg	tagatatacc	aaagattgtc	agatctttttt	atgaactatt	tgaacaaaaaa	480
gtgtactaca	aaagtttatt	cattgatgc	gaaaaagctt	taggtctatc	ticaacagga	540
agcaaagcag	aaagtttgcgtt	tgttaatata	ttttagcag	tttatggagc	tggtcaaaca	600
ctgctaaggt	gggggtgtcat	tgccagatca	tccaaacaaca	taatgctagg	gcatgtatct	660
gtgcaatctg	aaatttgcgtt	agttacagag	gttttatgc			700
<210> 21						
<211> 600						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(600)						
<223> human metapneumovirus, strain quebec isolate No						
C-91830						
<400> 21						
cagctctagg	atcagaaga	gtacaacaga	ttttgagaaa	ctcaggtagt	gaagttcagg	60
ttgttctaac	aaaaacatac	tccttaggga	aaggcaaaaa	cgttaaagg	gaagagctgc	120
agatgttaga	tatacatgga	gtggaaaaa	gttgggttaga	agaaatagac	aaagaggcaa	180
gaaagacaat	ggtaactttt	cttaaggagt	catcaggtaa	catccccaa	aaccagagac	240
tttcagcacc	agacacaccc	ataattttt	tatgtgtagg	tgccttaata	tttcactaaac	300
tagcatcaac	aatagaagtt	ggtagagaa	ctacagttag	aagagctaat	agagtgcata	360
gtgtatgcact	aaaaagatac	ccttaggttag	atataccaaa	gattgttaga	tctttttatg	420
aactatgtt	aaaaaaagt	tactacagaa	gcttattcat	tgatgtatgc	aaagcttttag	480
gctcatcttc	aacaggaagc	aaagcagaga	gtttgtttgt	aaatataattt	atgcacatctt	540
atggagctgg	tcaaaacactg	ctaaagggtgg	gtgtcatgtc	cagatcatcc	aacaacataaa	600
<210> 22						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Quebec isolate No						
hMPV-Q86						
<400> 22						
atgctgatta	caaataatgct	gcagaaaatag	gaatacataa	tattagcaca	gctctagggt	60
cagagaaaagt	acagcagatt	ctaaagaaact	caggcagtga	agtccaaagcg	gttttaacca	120
gaacgtactc	tttggggaaa	gttaaaaaaca	ataaaggaga	agatttacag	atgttagaca	180
tacacggatg	agaaaaaaagc	tgggtggaaag	agatagacaaa	agaagcaaga	aaaacaatgg	240
caactttact	taaaagaatca	tcaggtata	ttccaaaaaa	ttagaggtcct	tcagcacccag	300
acacacccat	aatcttatta	tgttaggtg	ccttaatatt	caccaaaacta	gcataacta	360
tagaagtggg	attagagacc	acagtcagaa	gagctaaccg	tgtactaagt	gatgcactca	420
aaagatacc	tagaatggac	ataccaaaaa	ttgctagatc	tttctatgac	ttatgttgaac	480

12/52

aaaaagtgtt	tcacagaagt	ttgttcattt	agtatggca	aagcatttagg	cttcattttttt	540
acaggcagca	aaggcagaaag	tttatttcgtt	aatatatttttca	tgcaagctt	tggtgctgg	600
caaacaatgc	tgagggtgggg	gggttatcgc	caggtcattt	aacaatataa		650
<210> 23						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Quebec Isolate No hMPV-Q97						
<400> 23						
tagcacagct	ctaggatcag	agagagtaca	gcagattcta	agaaacttag	gcagtgaagt	60
ccaaagtggtt	tttaaccaggaa	cgtacttcctt	ggggaaagtt	aaaaacaaca	aaggagaaga	120
tttacagatg	tttagacatc	acggagtaga	gaaaagctgg	gtggaaagaga	tagacaaga	180
agcaagaaaa	aaatggccaa	cttgcatttaa	agaatcatca	ggcaatattt	cacaaaatca	240
gaggccttca	gcaccagaca	cacctataat	cttattatgt	gttaggtgcct	taatattttac	300
caaactagca	tcaactatag	aagtgggatt	agagaccaca	gtcagaagag	ctaaccgtgt	360
actaagtgtat	gcactcaaaa	gatacccttag	gttgcacata	ccaaaaatcg	ctagatcttt	420
ctatgacttt	tttgcacaaa	aagtgttata	cagaagcttg	tttcatttggt	atggcaagc	480
attaggctca	tcctctacag	gcagcaaagc	agaaagtttt	attcgtaat	atattcatgc	540
aagcttacgg	tgctggtcaa	acaatgtca	ggtggggagt	cattgccagg	tcatctaaca	600
atataatgtt	aggacatgtt	tctgttcaag	ctgagttaaa	acaagtacgc		650
<210> 24						
<211> 741						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(741)						
<223> human metapneumovirus, strain Can 97-83						
<400> 24						
agtgcacacc	tcatcatgtt	aacaagaaat	aacactattt	tgtggagaaa	ttcttatatgc	60
taagcatgtt	gattacaat	atgctgcaga	aataggaata	caatataattt	gcacagctct	120
aggatccagag	agagtagcag	agattttaag	aaactcaggc	agtgaagtcc	aagtgttttt	180
aaccagaacac	tactccttgg	ggaaagttaa	aaacaacaaa	ggagaagagat	catagatgtt	240
agacatacac	ggagtagaga	aaagctgggt	ggaaagagata	gacaaaagag	caagaaaaac	300
aatggcaact	tttgcattaaag	aatcatcagg	caatatttcca	caaaaatcaga	ggccttcagc	360
accagacatc	cctataatct	tattatgtt	aggtgcctta	atattttacca	aacttagcatc	420
aactatagaa	gtgggatttt	agaccacat	cagaagagct	aaccgtgtac	taagtgtatgc	480
actcaaaaag	tacccttagga	tggacatacc	aaaaatcgct	agatctttt	atgatttttt	540
tgaacaaaaaa	gtgtattaca	gaaggttttt	cattgagttat	ggcaaagcat	taggttcate	600
cctctacaggc	agcaaaagcg	aaaggtttt	cgtaatata	ttcatgcag	tttacgggtgc	660
tgtcaaaaca	atgtcgagg	ggggaggcat	tgccagggtca	tctaaacaata	taatgtttagg	720
acatgttatct	gtccaaatgt	a				741
<210> 25						
<211> 650						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(650)						
<223> human metapneumovirus, strain Can 98-75						
<400> 25						
caatataatttt	gcacggctct	aggatcagaa	agagtacaac	agattttaag	aaattcaggc	60
agtgaagttt	agggtggtttct	aaaccagaca	tacitcttttag	ggaaaggttt	aaatagtaaa	120
ggggaaaggt	tgcattatgtt	agatatacat	ggagtggaaa	agagtgggt	agaagaaata	180
gacaaaagg	caagaaaaac	aatgggtact	ttgtctttaagg	aatcatcagg	taacatcccc	240
caaaaacagg	ggccttcagc	accagacaca	ccaataattt	tattatgtt	aggtgttttt	300
atatttcacta	aaactagcatc	aacaatagaa	gttggacttag	agactacatgt	tagaagagct	360
aacagatgtt	taagtgtatgc	gctcaaaaaga	tacccttaggg	tagatatacc	gaagattgtt	420
agatcttttct	atgtaaatattt	tgagcagaaa	gtgtattaca	ggagtctttt	cattgagttat	480

		13/52	540
ggggaaagctt	taggctcatc	ttcaacagga	aaagttgtt
tttatgcaga	ctttagggagc	cggtcaaaaca	atgctaagg
tctaaacaaca	taatgtcttag	acatgtgtct	gtgcaagctg
		aatttgaagca	
<210>	26		
<211>	759		
<212>	DNA		
<213>	human metapneumovirus		
<220>			
<221>	gene		
<222>	(1)...(759)		
<223>	human metapneumovirus, strain Can 98-75		
<400>	26		
atgtcttgg	aagtgggtat	tatcattrg	ttactcataa
aaaaggtaatt	tagaagaatc	atgttagtact	ataactgaaag
acagggttgtt	acacaaatgt	ctttacatta	gaagttggtg
actgtatggac	ctagcttaat	caaaacagaa	atgtgaaaaa
ctcaaaacag	tttctgtga	ttagtttagcg	ccaaaggatgc
tcaagggttg	tccttaggtgc	ataatgtctt	tcttacatgt
ggcattggca	tagccaaaac	cataaggctt	gagatgttgg
ctcaaaacaa	ccaaacgaggc	agtatccaca	cttagaaaaat
gcagtaagag	agctgaaaaga	attttgtgac	aaaacttgc
aaatgtgaca	tttgcgactt	gaagatggct	cttagtgcata
ctaaatgttg	tgccggcagg	gtcagcttca	gtcaatttcaa
ctaaatgtctg	ttcagacaat	gcagggtata	caccagcaat
ataaaaactaa	tgttagagaa	gtatcataca	tgccaaatc
	ccgtgcaatg	tgccaggacag	tgccaggacag
			759
<210>	27		
<211>	759		
<212>	DNA		
<213>	human metapneumovirus		
<220>			
<221>	gene		
<222>	(1)...(759)		
<223>	human metapneumovirus, strain Quebec Isolate No C-67345		
<400>	27		
atgtcttgg	aagtgggtat	catttttttc	ttgtcaataaa
gagagctacc	tagaagaatc	atgtatcact	ataactgagg
acagggttgtt	ataccaacgt	ttttacatta	gaggtgggtg
tctgtatggac	ctagcttaat	aaaaacagaa	atgtgaaaaa
ctcaaaacag	tctctgtga	ccaaatggca	tttagatctg
tctaggtttg	ttctgggagc	aatagcactc	ccaaatggca
ggtgttgc	ttgcacaaac	catccggctt	agagatgtgc
ctcaaaacaa	ccaaatggac	atgtatctca	ttggggaaatg
gcagtgcag	agctgaaaga	ttttgtgagc	gagttcgagt
aagtgcgaca	ttgtatgac	aaaaatggcc	tttgcgactt
ctaaatgttg	tgccggcaatt	ttcagacaat	gtcacttcaa
ttaatgacag	atgtgtact	agccaggccc	gctggaataa
		gtttccaaaca	caccagcaat
		tgccgacatc	atctttggac
			720
	tgttggagaa	ccgtgctgt	tgccaggacaa
		gtaagaaga	759
<210>	28		
<211>	759		
<212>	DNA		
<213>	human metapneumovirus		
<220>			
<221>	gene		
<222>	(1)...(759)		
<223>	human metapneumovirus, strain Can 97-83		
<400>	28		
ataaaaatgt	cttggaaagt	ggtgatcatt	ttttcattgc
cttaaagaga	gtcacctaga	agaatcatgt	taataacacc
ctgaggacag	gttggatatac	acacgtttt	tcaacacgg
acatgttctt	atggacacct	caataaaaa	tttttagtgtt
agagagatca	aaacatgtctc	acagaatttg	ttgggtgatgt
agacaatcta	ggttggatct	atgtgaccaa	agaaaacctt
		ttggcaagag	aatgtgcacta
		agaacaat	tgagaatccc
		qactctgggt	agctqcaqtc
		tttgcacaaqc	300

14/52

acagcagggt	trgcaattgc	caaaaccatc	cggcttgaga	gtgaagtcac	agcaattaag	420
aatgcctca	aaacgaccaa	tgaagcagta	tctacattgg	ggaatggagt	tcgagtgttg	480
gcaactgcag	tgagagagct	gaaagacttt	gtgagcaaga	attttaactcg	tgcaatcaac	540
aaaaacaactg	gcaacatgg	tgacccaaaa	atggccgtta	gcttcagtc	attcaacaga	600
aggtttctaa	atgttgtcg	gcaatrttca	gaaatgtctg	gataaacacc	agcaatatct	660
ttgacttaa	tgacagatgc	tgaacttagcc	aggccgttt	ctaaccatgcc	gacatctgca	720
ggacaaataa	aattgtatgtt	ggagaaccgt	ggatgggt			759

<210> 29

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain quebec Isolate No C-68661

<400> 29

atgtcttgg	aagtgggtat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acagggttgtt	ataccaacgt	tttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacttga	ccaaaagtgc	actaagagag	240
ctcagaacag	ttttctgtga	tcaacttggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagatttt	ttcttagggc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
ggtgttgc	ttgccaazac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	tttggggatg	gagttcgagt	gttggcaact	480
gcagtgggg	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	tttgcgaccc	gaaaatggcc	gttagcttca	gtcaaitcaa	cagaagggtt	600
cttaatgttg	tgccggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaactga	tgttggagaa	ccgtgcaatg	gttggagaa			759

<210> 30

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-73750

<400> 30

atgtcttgg	aagtgggtat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acagggttgtt	ataccaacgt	tttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacttga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgtga	tcaacttggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagatttt	ttcttagggc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
ggtgttgc	ttgccaazac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	tttggggatg	gagttcgagt	gttggcaact	480
gcagtgggg	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	tttgcgaccc	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
cttaatgttg	tgccggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaactga	tgttggagaa	ccgtgcaatg	gttggagaa			759

<210> 31

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-74549

<400> 31

15/52

atgtcttgg	aagtggtgat	catttttca	ttgctaataa	cacctcaaca	cggtcttaaa	60
gagagctacc	tagaagaatc	atgttagact	ataactgagg	gatatcttag	tgttctgagg	120
acagggttgt	ataccaaacgt	ttttacatta	gagggtgggt	atgttagaaaa	ccttacatgt	180
tctgatggac	ctagcttaat	aaaaacagaa	tttagatctga	ccaaaagtgc	actaagagag	240
tctcaaaacag	tctctgtca	ccaattggca	agagaggaac	aaattgagaa	tcccagacaa	300
tcttaggttt	ttcttaggagc	aatagcactc	ggtgttgc	cagcagctgc	agtacacagca	360
ggtgttgc	ttgccaaac	catccggctt	gagagigaag	tcacagcaat	taagaatgcc	420
ctcaaaacga	ccaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtgtgg	agctgaaga	tttggtgagc	aagaattttaa	ctctgtcaat	caacaaaaac	540
aagtgcgaca	ttgatgac	aaaaatggcc	tttagcttca	gtcaattcaa	cagaaggttt	600
ctaaatgtt	tgccggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atctttggac	660
ttaatgacag	atgtgaact	agccaggggcc	ttttctaa	tgccgacatc	tgcaggacaa	720
ataaaaattga	tggtggagaa	ccgcgcgtat	gttggagaa			759

<210> 32

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-74783

<400> 32

atgtcttgg	aagtggtgat	catttttca	ttgctaataa	cacctcaaca	cggtcttaaa	60
gagagctacc	tagaagaatc	atgttagact	ataactgagg	gatatcttag	tgttctgagg	120
acagggttgt	ataccaaacgt	ttttacatta	gagggtgggt	atgttagaaaa	ccttacatgt	180
tctgatggac	ctagcttaat	aaaaacagaa	tttagatctga	ccaaaagtgc	actaagagag	240
tctcaaaacag	tctctgtca	ccaattggca	agagaggaac	aaattgagaa	tcccagacaa	300
tcttaggttt	ttcttaggagc	aatagcactc	ggtgttgc	cagcagctgc	agtacacagca	360
ggtgttgc	ttgccaaac	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
ctcaaaacga	ccaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtgtgg	agctgaaga	tttggtgagc	aagaattttaa	ctctgtcaat	caacaaaaac	540
aagtgcgaca	ttgatgac	aaaaatggcc	tttagcttca	gtcaattcaa	cagaaggttt	600
ctaaatgtt	tgccggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atctttggac	660
ttaatgacag	atgtgaact	agccaggggcc	ttttctaa	tgccgacatc	tgcaggacaa	720
ataaaaattga	tggtggagaa	ccgcgcgtat	gttggagaa			759

<210> 33

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-76837

<400> 33

atgtcttgg	aagtggtgat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctat	tagaagatc	atgttagact	ataactgaa	gatatctcg	tgttctgagg	120
acagggttgt	ataccaaacgt	ttttacactg	gaggtagtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagatctga	ccaaaagtgc	actaagagag	240
ttcttagat	tttctgtca	tcaactggca	agagagggagc	aaattgagaa	tcccagacaa	300
tcttaggttt	ttcttaggagc	aatagcactc	ggtgttgc	cagcagctgc	agtacacagca	360
ggtgttgc	ttgccaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtgtgg	aactgaaga	tttggtgagc	aagaattttaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgac	aaaaatggcc	tttagcttca	gtcaattcaa	cagaaggttt	600
ctaaatgtt	tgccggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atctttggac	660
ttaatgacag	atgtgaact	agccaggagct	ttttccaa	tgccacatc	tgcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaat	gttggagaa			759

<210> 34

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

16/52

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
C-77748

<400> 34

atgtcttggaa	aagtggtgat	catttttca	ttgttaataa	cacttcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acaggttgg	ataccaacgt	ttttacactg	aaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagactcg	ccaaaagtgc	actaagagaa	240
ctcagaacag	tttctgtcg	tcaactggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagatttg	ttcttagggc	aatagcactc	ggtgttgca	cagcagctgc	agttacagca	360
ggtgttgca	ttggccaaaat	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggatg	gagttcgcgt	gttggcaact	480
gcagtgggg	actgtgaaaga	ttttgtgac	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	aaaaatggcc	gttagcttca	gtcaattca	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaaact	agccagagct	gtttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 35

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
C-77807

<400> 35

atgtcttggaa	aagtggtgat	catttttca	ttgttaataa	cacttcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acaggttgg	ataccaacgt	ttttacactg	aaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagactcg	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgtcg	tcaactggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagatttg	ttcttagggc	aatagcactc	ggtgttgca	cagcagctgc	agttacagca	360
ggtgttgca	ttggccaaaat	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggatg	gagttcgcgt	gttggcaact	480
gcagtgggg	actgtgaaaga	ttttgtgac	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	aaaaatggcc	gttagcttca	gtcaattca	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaaact	agccagagct	gtttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 36

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
C-78132

<400> 36

atgtcttggaa	aagtggtgat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acaggttgg	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagactcg	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgtcg	tcaactggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagatttg	ttcttagggc	aatagcactc	ggtgttgca	cagcagctgc	agttacagca	360
ggtgttgca	ttggccaaaat	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggatg	gagttcgcgt	gttggcaact	480
gcagtgggg	actgtgaaaga	ttttgtgac	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	aaaaatggcc	gttagcttca	gtcaattca	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaaact	agccagagct	gtttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

17/52

<210> 37

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 37

atgtcttgg aagrggtgat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	120
acagggttgg	ataccaacgt	ttttacactg	gaggttaggtg	atgttagagaa	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagatctga	ccaaaaagtgc	240
ctcagaacag	tttctgtcga	tcaactggca	agagaggagc	aaatttgagaa	300
tctagatgg	ttcttaggagc	aatagcactc	ggtgttgc当地	cagcagctgc	360
ggtgttgc当地	ttgc当地aaac	catccggctt	gaaagtgaag	taacagcaat	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gatgtcgag	480
gcagtgggg	aactgaaaga	ttttgtgagc	aagaatctaa	cacgtgc当地	540
aagtgc当地	ttgctgacct	gaaaatggcc	gttagcttca	gtcaatttca	600
cttaatgtt	tgccggcaatt	ttcagacaat	gctgaaataa	caccagcaat	660
ttaatgacag	atgtctgact	agccagagct	gtttccaaca	tgccaacatc	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga		759

<210> 38

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-78406

<400> 38

atgtcttgg aagtgggtgat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	120
acagggttgg	ataccaacgt	ttttacactg	gaggttaggtg	atgttagagaa	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagatctga	ccaaaaagtgc	240
ctcagaacag	tttctgtcga	tcaactggca	agagaggagc	aaatttgagaa	300
tctagatgg	ttcttaggagc	aatagcactc	ggtgttgc当地	cagcagctgc	360
ggtgttgc当地	ttgc当地aaac	catccggctt	gaaagtgaag	taacagcaat	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gatgtcgag	480
gcagtgggg	aactgaaaga	ttttgtgagc	aagaatctaa	cacgtgc当地	540
aagtgc当地	ttgctgacct	gaaaatggcc	gttagcttca	gtcaatttca	600
cttaatgtt	tgccggcaatt	ttcagacaat	gtrggaaataa	caccagcaat	660
ttaatgacag	atgtctgact	agccagagct	gtttccaaca	tgccaacatc	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga		759

<210> 39

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No hMPV-174

<400> 39

atgtcttgg aagtgggtgat	catttttca	ttgttaataa	cacctcaaca	cggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	120
acagggttgg	ataccaacgt	ttttacactg	gaggttaggtg	atgttagagaa	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagatctga	ccaaaaagtgc	240
ctcagaacag	tttctgtcga	tcaactggca	agagaggagc	aaatttgagaa	300
tctagatgg	ttcttaggagc	aatagcactc	ggtgttgc当地	cagcagctgc	360
ggtgttgc当地	ttgc当地aaac	catccggctt	gaaagtgaag	taacagcaat	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaaatg	gatgtcgag	480

18/52

gcagtgagag	agctgaaaaga	ttttgtgagc	aagaatctaa	cacgtcaat	caacaaaaac	540
aagtgcgaca	ttgtgtacat	aaaaatggcc	tttagcttca	gtcaatttca	cagaaggttt	600
ctaaatgtt	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccctggac	660
ttaatgacag	atgtgtacat	agccagagct	ttttccaaca	tgccaacatc	tgaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759
<210>	40					
<211>	759					
<212>	DNA					
<213>	human metapneumovirus					
<220>						
<221>	gene					
<222>	(1)...(759)					
<223>	human metapneumovirus, strain Quebec Isolate No					
hMPV-193						
<400>	40					
atgtcttgg	aagtgggtat	cattttttca	ttgttaataaa	cacctcaaca	cggtcttaaa	60
gagagcttatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	tgttctgagg	120
acagggttgg	ataccaacgt	tttacactg	gaggtaggtt	atgttagagaa	ccttacatgt	180
gctgtatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaagagag	240
cttcagaacac	tttctgtca	tcaactggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagattt	ttcttagggc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
gggttgtc	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaaga	ccaaatgaagc	agtatctaca	ttggggatgt	gagttcgagt	gttggcaact	480
gcagtggag	agctgaaaaga	ttttgtgagc	aagaatctaa	cacgtcaat	caacaaaaac	540
aagtgcgaca	ttgtgtacat	gaaaatggcc	tttagcttca	gtcaatttca	cagaaggttt	600
ctaaatgtt	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccctggac	660
ttaatgacag	atgtgtacat	agccagagct	ttttccaaca	tgccaacatc	tgaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759
<210>	41					
<211>	759					
<212>	DNA					
<213>	human metapneumovirus					
<220>						
<221>	gene					
<222>	(1)...(759)					
<223>	human metapneumovirus, strain Quebec Isolate No					
hMPV-194						
<400>	41					
atgtcttgg	aagtgggtat	cattttttca	ttgttaataaa	cacctcaaca	cggttttaaa	60
gagagcttatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	tgttctgagg	120
acagggttgg	ataccaacgt	tttacactg	gaggtaggtt	atgttagagaa	ccttacatgt	180
gctgtatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaagagag	240
cttcagaacac	tttctgtca	tcaactggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctagattt	ttcttagggc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
gggttgtc	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaaga	ccaaatgaagc	agtatctaca	ttggggatgt	gagttcgagt	gttggcaact	480
gcagtggag	agctgaaaaga	ttttgtgagc	aagaatctaa	cacgtcaat	caacaaaaac	540
aagtgcgaca	ttgtgtacat	gaaaatggcc	tttagcttca	gtcaatttca	cagaaggttt	600
ctaaatgtt	tgccggcaatt	ttcagacaat	gctggataaa	caccagcaat	atccctggac	660
ttaatgacag	atgtgtacat	agccagagct	ttttccaaca	tgccaacatc	tgaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759
<210>	42					
<211>	759					
<212>	DNA					
<213>	human metapneumovirus					
<220>						
<221>	gene					
<222>	(1)...(759)					
<223>	human metapneumovirus, strain Quebec Isolate No					
hMPV-198						
<400>	42					
atgtcttgg	aagtgggtat	cattttttca	ttgttaataaa	cacctcaaca	cggtcttaaa	60
gagagcttatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	tgttctgagg	120

19/52

acagggttggat	ataccaaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaatttggaaa	tcccagacaa	300
tctagatttg	ttcttaggagc	aatagcaactc	ggtgttgc当地	cagcagctgc	agttacagca	360
ggtgttgc当地	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaaatgaagc	agtatctaca	ttggggatg	gagttcgag	gttggcaact	480
gcagtggag	agctgaaaga	ttttgtggagc	aaagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgc当地	ttgctgaccc	aaaaatggcc	gttagcttca	gtcaattcaa	cagaaggaaa	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaaat	caccagcaat	atccctggac	660
ttaatgacag	atgctgaaact	agccagagct	gttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 43

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No hMPV-217

<400> 43

atgtcttggaa	aagggttggat	cattttttca	ttgttaataaa	cacctcaaca	cggctttaaa	60
gagagcttatt	tagaagagtc	atgttagcaact	ataaactgaag	gatatctcg	tgttctgagg	120
acagggttggat	ataccaaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaatttggaaa	tcccagacaa	300
tctagatttg	ttcttaggagc	aatagcaactc	ggtgttgc当地	cagcagctgc	agttacagca	360
ggtgttgc当地	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaaatgaagc	agtatctaca	ttggggatg	gagttcgag	gttggcaact	480
gcagtggag	agctgaaaga	ttttgtggagc	aaagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgc当地	ttgctgaccc	aaaaatggcc	gttagcttca	gtcaattcaa	cagaaggaaa	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaaat	caccagcaat	atccctggac	660
ttaatgacag	atgctgaaact	agccagagct	gttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 44

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No hMPV-208

<400> 44

atgtcttggaa	aagggttggat	cattttttca	ttgttaataaa	cacctcaaca	cggctttaaa	60
gagagcttatt	tagaagagtc	atgttagcaact	ataaactgaag	gatatctcg	tgttctgagg	120
acagggttggat	ataccaaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaatttggaaa	tcccagacaa	300
tctagatttg	ttcttaggagc	aatagcaactc	ggtgttgc当地	cagcagctgc	agttacagca	360
ggtgttgc当地	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaaatgaagc	agtatctaca	ttggggatg	gagttcgag	gttggcaact	480
gcagtggagg	agctgaaaga	ttttgtggagc	aaagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgc当地	ttgctgaccc	aaaaatggcc	gttagcttca	gtcaattcaa	cagaaggaaa	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaaat	caccagcaat	atccctggac	660
ttaatgacag	atgctgaaatt	agccagagct	gttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 45

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

20/52

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-223

<400> 45

atgtcttggaa	aagtgggtat	catttttca	ttgttaataaa	cacctcaaca	cgggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acagggttgtt	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaaagagag	240
ctcagaacag	tttctgtcgt	tcaactggca	agagaggagc	aaattgagaa	tcccgaccaa	300
tctagatttt	ttcttagggagc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
ggtgttgc	ttgccaaaac	catcggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgc	caacaaaaac	540
aagtgcgaca	ttgctgaccc	gaaaatggcc	gttagcttca	gtcaatttca	cagaagg	600
ctaaatgtt	tgcggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atccttgac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaactga	tggtggagaa	ccgtgcatt	gttggagaa			759

<210> 46

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
hMPV-223

<400> 46

atgtcttggaa	aagtgggtat	catttttca	ttgttaataaa	cacctcaaca	cgggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acagggttgtt	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaaagagag	240
ctcagaacag	tttctgtcgt	tcaactggca	agagaggagc	aaattgagaa	tcccgaccaa	300
tctagatttt	ttcttagggagc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
ggtgttgc	ttgccaaaac	catcggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgc	caacaaaaac	540
aagtgcgaca	ttgctgaccc	gaaaatggcc	gttagcttca	gtcaatttca	cagaagg	600
ctaaatgtt	tgcggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atccttgac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaactga	tggtggagaa	ccgtgcatt	gttggagaa			759

<210> 47

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
C-85885

<400> 47

atgtcttggaa	aagtgggtat	catttttca	ttgttaataaa	cacctcaaca	cgggtcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcg	tgttctgagg	120
acagggttgtt	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	tttagacctga	ccaaaagtgc	actaaagagag	240
ctcagaacag	tttctgtcgt	tcaactggca	agagaggagc	aaattgagaa	tcccgaccaa	300
tctagatttt	ttcttagggagc	aatagcactc	ggtgttgc	cagcagctgc	agttacagca	360
ggtgttgc	ttgccaaaac	catcggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaaatgaagc	agtatctaca	ttggggaaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgc	caacaaaaac	540
aagtgcgaca	ttgctgaccc	gaaaatggcc	gttagcttca	gtcaatttca	cagaagg	600
ctaaatgtt	tgcggcaatt	ttcagacaat	gttggaaataa	caccagcaat	atccttgac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaactga	tggtggagaa	ccgtgcatt	gttggagaa			759

<210> 48

<211> 759

21/52

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-60298

<400> 48

atgtcttgg	aagtgggtat	catttttca	ttgttaataa	caccccaaca	cggtcttaaa	60
gagagtttt	tagaagagtc	atgttagact	ataactgaag	gatatctcg	tgttctgagg	120
acagggttgt	ataccaacgt	ttttacactg	gaggtaggt	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagatctg	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgtcg	taactggca	agagaggagc	aaatttgagaa	tcccagacaa	300
tctatgttt	ttcttaggac	aatagactc	ggtgttgc	cagcagctgc	agttacagca	360
ggtgttgc	ttggaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaac	agtatctaca	ttgggaaatg	gagttcgagt	gttggcaact	480
gcagtggagg	aactgaaga	tttttgtgac	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcaca	ttgctgaccc	gaaaatggcc	gttagctca	gtcaattcaa	cagaaggttt	600
ctaaatgtt	tgcggcaatt	ttcagacaat	gtcggaaat	caccagcaat	atccctggac	660
ttaatgacag	atgctgaaact	agccagagct	gtttccaaca	tgccaaacatc	tgcaggacaa	720
ataaaactg	tgttggaga	ccgtgcaatg	gttggaga			759

<210> 49

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-63778

<400> 49

atgtcttgg	aagtgggtat	tatcatttcg	ttactcataa	cacccagca	cggaactaaag	60
gaaaggattt	tagaagaatc	atgttagact	ataactgaag	gatatctcg	tgttttaaga	120
acagggttgt	acaccaatgt	ttttacattt	gaaggtaggt	atgttggaaa	tcttacatgt	180
actgtatggac	ctagcttaat	aaaaacagaa	tttgacactaa	ccaaaagtgc	tcttaagagaa	240
ctcaaaaacag	tttctgtcg	tcaggtagcg	agagaagaac	aaatttgaaa	tcccagacaa	300
tcaagggttt	tccttaggtgc	aatagctctt	ggtgttgc	cagcagcagc	agtcacagca	360
ggcaatggca	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcatt	caaagggtct	420
ctcaaaaacaa	ccaaacgaggc	agtatccaca	ttggaaaatg	gagtcgcagt	cctagccacc	480
gcagtaaag	agctgaaga	atttgtgac	aaaaacctga	ctagtgcatt	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagctca	gtcaattcaa	cagaagattc	600
ctaaatgtt	tgcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaatgact	atgctgagct	ggccagaact	gtatcataca	tgccaaacatt	tgcaggacag	720
ataaaactaa	tgtagagaa	ccgtgcaatg	gttggaga			759

<210> 50

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-64199

<400> 50

atgtcttgg	aagtgggtat	tatcatttcg	ttactcataa	cacccagca	cggaactaaaa	60
gaaaggattt	tagaagaatc	atgttagact	ataactgaag	gatatctcg	tgttttaaga	120
acagggttgt	acaccaatgt	ttttacattt	gaaggtaggt	atgttggaaa	tcttacatgt	180
actgtatggac	ctagcttaat	aaaaacagaa	tttgacactaa	ccaaaagtgc	tcttaagagaa	240
ctcaaaaacag	tttctgtcg	tcaggtagcg	agagaagaac	aaatttgaaa	tcccagacaa	300
tcaagggttt	tccttaggtgc	aatagctctt	ggtgttgc	cagcagcagc	agrccacagca	360
ggcattgtcg	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcatt	caaaggatgt	420
ctcaaaaacaa	ccaaacgaggc	agtatccaca	ttggaaaatg	gagtcgcagt	cctagccacc	480
gcagtaaag	agctgaaga	atttgtgac	aaaaacctga	ctagtgcatt	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagctca	gtcaattcaa	cagaagattc	600

22/52

ctaaaatgttg	tgcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaatgactg	atgctgagct	ggccagagct	gtatcataca	tgccaaacatc	tgcaggacag	720
ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 51
 <211> 759
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-64200

<400> 51	atgtcttgg	aagtggtgat	tatcatttcg	ttactcataa	cacccatcgca	cggaactaaaa	60
	gaaaggttatt	tagaagaatc	atgttagtact	ataactgaag	gatatctcg	tgttttaaga	120
	acagggttgtt	acaccaatgt	cttacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
	actgtatggac	ctagcttaat	caaaacagaa	cttgaccta	ccaaaatgtgc	tctaagagaa	240
	ctcaaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgtaaaa	tcccagacaa	300
	tcaagggtttg	tccttaggtgc	aatagcttctt	ggtgttgc	cagcagcagc	agtccacagca	360
	ggcatttgcga	tagccaaaac	cataaggctt	gaggttgaag	tgaatgtcaat	caaagggtct	420
	ctcaaaaacaa	ccaacgcaggc	agtatccaca	cttaggaaatg	gagtgcgagt	cctagccacc	480
	gcagtaagag	agctgaaaga	atttgtgac	aaaaacctga	ctagtgc	taacaagaac	540
	aatatgtgaca	ttgctgtatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
	ctaaaatgttg	tgcggcagtt	ttagacaaat	gcagggataa	caccagcaat	atcattggac	660
	ctaatgactg	atgctgagct	ggccagagct	gtatcataca	tgccaaacatc	tgccaggacag	720
	ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 52
 <211> 759
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gené
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-64536

<400> 52	atgtcttgg	aagtggtgat	tatcatttcg	ttactcataa	cacccatcgca	cggaactaaaa	60
	gaaaggttatt	tagaagaatc	atgttagtact	ataactgaag	gatatctcg	tgttttaaga	120
	acagggttgtt	acaccaatgt	cttacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
	actgtatggac	ctagcttaat	caaaacagaa	cttgaccta	ccaaaatgtgc	tctaagagaa	240
	ctcaaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgtaaaa	tcccagacaa	300
	tcaagggtttg	tccttaggtgc	aatagcttctt	ggtgttgc	cagcagcagc	agtccacagca	360
	ggcatttgcga	tagccaaaac	cataaggctt	gaggttgaag	tgaatgtcaat	caaagggtct	420
	ctcaaaaacaa	ccaacgcaggc	agtatccaca	cttaggaaatg	gagtgcgagt	cctagccacc	480
	gcagtaagag	agctgaaaga	atttgtgac	aaaaacctga	ctagtgc	taacaagaac	540
	aatatgtgaca	ttgctgtatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
	ctaaaatgttg	tgcggcagtt	ttagacaaat	gcagggataa	caccagcaat	atcattggac	660
	ctaatgactg	atgctgagct	ggccagagct	gtatcataca	tgccaaacatc	tgccaggacag	720
	ataaaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 53
 <211> 759
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-73769

<400> 53	atgtcttgg	aagtggtgat	tatcatttcg	ttactcatac	cacccatcgca	cggaactaaaa	60
	gaaaggttatt	tagaagaatc	atgttagtact	ataactgaag	gatatctcg	tgttttaaga	120
	ccagggttgtt	acaccaatgt	cttacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
	actgtatggac	ctagcttaat	caaaacagaa	cttgaccta	ccaaaatgtgc	tctaagagaa	240

23/52

ctaaaaacag	tttctgtga	tcagttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaagggttg	tccttaggtgc	aatagctctt	ggtgttgcctt	cagcagcagc	agtcatagca	360
ggattgcga	tagccaaac	cataaggctt	gagagtggag	tgaatgcatt	caaagggtgt	420
ctaaaaacaa	ccaaacgaggc	agtatccaca	ctaggaaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agttgaaaga	atttgtgac	aaaaacctga	ctagtgcatt	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattagac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaaacatc	tgcaggacag	720
ataaaactaa	tgttagagaa	ccgtgcatt	gttaagaaga			759

<210> 54

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-74501

<400> 54

atgtcttgg	aagtgggtat	tatcatttcg	ttactctataa	cacttcagca	cggactaaaa	60
gaaggatttt	tagaagaatc	atgttagtact	ataactgaag	gatatcttag	tgttttaaga	120
acagggttgt	acaccaatgt	ctttacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
actgtatggac	ctagcttaat	aaaaacagaa	cttgcaccaa	ccaaaagtgc	tctaagagaa	240
ctaaaaacac	tttctgtgc	tcagttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaagggttg	tcttaggtgc	aatagctctt	ggtgttgcctt	cagcagcagc	agtcatagca	360
ggattgcga	tagccaaac	cataaggctt	gagagtggag	tgaatgcatt	caaagggtgt	420
ctaaaaacaa	ccaaacgaggc	agtatccaca	ctaggaaatg	gagtgcgagt	cctagccact	480
gcagtaagag	agctgaaaga	atttgtgac	aaaaacctga	ctagtgcatt	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattagac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaaacatc	tgcaggacag	720
ataaaactaa	tgttagagaa	ccgtgcatt	gttaagaaga			759

<210> 55

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-78429

<400> 55

atgtcttgg	aagtgggttt	catcatttcg	ttactctataa	caccccaagca	cgggctaaag	60
gagaggattt	tggagaagaatc	atgcagact	ataactgagg	gatacctcag	tgttttaaga	120
acaggcttgt	acattaaatgt	cttcacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
actgtatggac	ctagcttaat	aaaaacagaa	cttgcaccaa	ccaaaagtgc	ttaaaggaa	240
ctaaaaacag	tctctgtgc	tcagttagcg	agagaggagc	aaattgaaaa	tcccagacaa	300
tcagatgttg	tcttaggtgc	aatagctctt	ggagttgtctt	CAGCAGCAGC	agtcatagca	360
ggcattgc	tagccaaac	cataaggctt	gagagtggagg	tgaatgcatt	taaagggtgt	420
ctaaaaacaa	ctaatgaaac	agtatccaca	ttttagaaatg	gtgtgcgggt	cctagccact	480
gcagtggag	agctaaaaaga	atttgtgac	aaaaatctga	ctagtgcatt	caacaggaa	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattt	600
ctaaatgttg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgaaat	ggccagagct	gtatcataca	tgccaaacatc	tgcaggacag	720
ataaaactga	tgttggagaa	ccgtgcatt	gttaagaaga			759

<210> 56

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No C-78652

24/52

<400> 56
 atgtcttgg aagtgggtgat catcatttcg ttactcataa caccccagca cgggctaaag 60
 gagagttatt tggagaatac atgcgtact ataaactgagg gataacctcg tgttttaaga 120
 acgggctggt acaccaatgt ctgcacatta gaagttggtg atgttggaaa tcttacatgt 180
 actgtatggac ctgcattaaat caaaacagaa ctgcacccaa caaaaaggcgtc tttaaggaa 240
 ctcaaaacag tttctgtcga tcagttacg agagaggagc aaattgaaaaa tcccagacaa 300
 tcaagatttgc tccatggc aatagctcgc ggaggcgtc cagcagcagc agtcacagca 360
 ggcatttgcg tagccaaaac cataaggctt gagagtggg tgaatgcata taaaagggtct 420
 ctcaaaacaaa ctaatgaaac agtattccaca tttagggaaatg gtgtgcgggt cctagccact 480
 gcagtggag agctaaaaga atttgtggc aaaaatctga ctatgtcata caacaggaaac 540
 aatatgtgaca ttgtgtatctt gaagatggcgt gtcagcttc gtcatttca cagaagattt 600
 cttaatgttgc tgccggcgtt ttcagacaat gcagggataa caccagcaat atcatggac 660
 ctaatgactg atgtgtgaaat ggccagagct gtatcataca tgccaaacatc tgcaggacag 720
 ataaaactgta tggggagaa ccgtgcataatg gtaagaaga 759

<210> 57

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No

hMPV-118

<400> 57
 atgtcttgg aagggggtgat tttttttcg ttactcataa caccccagca cggactaaaa 60
 gaaagttatt tagaagaatac atgtgtact ataaactgagg gataacctcg tgttttaaga 120
 acagggtggt acaccaatgt ctgcacatta gaagttggtg atgttggaaa tcttacatgt 180
 actgtatggac ctgcattaaat caaaacagaa ctgcacccaa caaaaaggcgtc tttaaggaa 240
 ctcaaaacag tttctgtcga tcagttacg agagaagaaac aaattgaaaaa tcccagacaa 300
 tcaaggttttgc ttcttaggtgc aatagctcgtt ggtgttgcga cagcagcagc agtcacagca 360
 ggcatttgcg tagccaaaac cataaggctt gagagtggg tgaatgcata taaaagggtct 420
 ctcaaaacaaa ccaacggc agtattccaca cttagggaaatg ggtgtgcgtt cctagccact 480
 gcaigtggag agctgaaaga atttgtggc aaaaacctga ccagtgcata taacaaggaaac 540
 aatatgtgaca ttgtgtatctt gaagatggcgt gtcagcttc gtcatttca cagaagatttc 600
 cttaatgttgc tgccggcgtt ttcagacaat gcagggataa caccagcaat atcatttagac 660
 ctaatgactg atgtgtgagct ggccagagct gtatcataca tgccaaacatc tgcaggcag 720
 ataaaactgta tggtagagaa ccgtgcataatg gtaagaaga 759

<210> 58

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No

hMPV-200

<400> 58

atgtcttgg aagtgggtgat cttttttcg ttactcataa caccccagca cggactaaaa 60
 gaaagttatt tagaagaatac atgtgtact ataaactgagg gataacctcg tgttttaaga 120
 acagggtggt acaccaatgt ctgcacatta gaagttggtg atgttggaaa tcttacatgt 180
 actgtatggac ctgcattaaat caaaacagaa ctgcacccaa caaaaaggcgtc tttaaggaa 240
 ctcaaaacag tttctgtcga tcagttacg agagaagaaac aaattgaaaaa tcccagacaa 300
 tcaaggttttgc ttcttaggtgc aatagctcgtt ggtgttgcga cagcagcagc agtcacagca 360
 ggcatttgcg tagccaaaac cataaggctt gagagtggg tgaatgcata taaaagggtct 420
 ctcaaaacaaa ccaacggc agtattccaca cttagggaaatg ggtgtgcgtt cctagccact 480
 gcaigtggag agctgaaaga atttgtggc aaaaacctga ccagtgcata taacaaggaaac 540
 aatatgtgaca ttgtgtatctt gaagatggcgt gtcagcttc gtcatttca cagaagatttc 600
 cttaatgttgc tgccggcgtt ttcagacaat gcagggataa caccagcaat atcatttagac 660
 ctaatgactg atgtgtgagct ggccagagct gtatcataca tgccaaacatc tgcaggcag 720
 ataaaactgta tggtagagaa ccgtgcataatg gtaagaaga 759

<210> 59

<211> 759

<212> DNA

<213> human metapneumovirus

26/52

<210> 62
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77748

<400> 62
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtggaaaaat
 cgtgtggcac gcagcaaatg cttaaaaat gcctcttga tcctaataagg aataactaca 60
 ttgagttatag ccctcaaatat ctatctatc ataaaactata caatgcaaga aaacacatcc 120
 gaatcagaac atcacaccag ctcatcacc 540
 cctatggaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 180
 ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 240
 ccagacacaca caagccgccc gccttcgtc gacacacaca caacacacc 300
 agaacaaggaa caagtccggc agtccacaca aaaaacaatc caaggacaag ccccagaaca 360
 cattcccccac catggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaaggc 420
 agcacaagaa aaagacccgc tacagcatca gtccaaacctg acagcagcgc aacaacccac 480
 aaacacgaa aagcaagccc agtggagcccg caaacatctg cgagcacaggc aagaccacaa 540
 aggaaggggca tggaggccag ccatcaaca acatacaacc aacttagtt a 600
 660
 711

<210> 63
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78132

<400> 63
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtggaaaaat
 cgtgtggcac gcagcaaatg cttaaaaat gcctcttga tcctaataagg aataactaca 60
 ttgagttatag ccctcaacat ctatctgatc ataaaactata caatgcaaga aaacacatcc 120
 gaatcagaac atcacaccag ctcatcacc 540
 cctatagaca actcagacac. caatccaggc tcacagtatc caactcaaca gtccacagaa 180
 ggctccacac tccactttgc agcctcagca agtccaccag agacagaacc aacatcaaca 240
 ccagacacaca caagccgccc gccttcgtc gacacacaca caacacacc 300
 agaacaaggaa caagtccggc agtccacaca aaaaacaatc taaagataag ccccagaata 360
 cattcccccac catggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaaggc 420
 agcacaagaa aaagacccgc tacagcatca gtccaaacctg acagcagcgc aacaactcac 480
 aaacacgaa aagcaagccc agtggagccca caaacatctg caagcacage aagaccacaa 540
 aggaaggggca tggaggccag ccatcaaca acatacaacc aacttagtt a 600
 660
 711

<210> 64
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78406

<400> 64
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtggaaaaat
 cgtgtggcac gcagcaaatg cttaaaaat gcctcttga tcctaataagg aataactaca 60
 ttgagttatag ccctcaacat ctatctgatc ataaaactata caatgcaaga aaacacatcc 120
 gaatcagaac atcacaccag ctcatcacc 540
 cctatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 180
 ggctccacac tccactttgc agcctcagca agtccaccag agacagaacc aacatcaaca 240
 ccagacacaca caagccgccc gccttcgtc gacacacaca caacacacc 300
 agaacaaggaa caagtccggc agtccacaca aaaaacaatc taaagataag ccccagaata 360
 cattcccccac catggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaaggc 420
 agcacaagaa aaagacccgc tacagcatca gtccaaacctg acagcagcgc aacaactcac 480
 540
 600
 aggaaggggca tggaggccag ccatcaaca acatacaacc aacttagtt a 600

27/52

aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa
 aggaaggcga tggaggccag cacatcaaca acatacaacc aaactagtta a. 660
 711

<210> 65
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-73750

<400> 65
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtggaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaat gcttctttga tcctaatagg aataactaca 120
 ttgagtagat cctcaacat ctatctgatc ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcaccc atggaatcca gcaggggaaac tccaaacggtc 240
 ccttagaca actcagaccc caatcgaggc tcacagtatc caactcaaca gtccacagaa 300
 ggttccacac tccatcttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa caagccgccc gcccctcggtc gacacacaca caacaccacc aagtgcagc 420
 agaacaagga caagtccggc agtccacaca aaaaacaatc taaagataag ccccgagaaca 480
 cattcccccac catgggcaat gacaaggacg gtccgtggaa ccaccatctt ccgcacaaggc 540
 agcatagaa aagagccgc tccatcgatca gtccaaacctg acagcagcac aacaacccac 600
 aaacatcaaga aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
 aggaaggcga tggaggccag cacatcaaca acacacaacc aaactagtta a 711

<210> 66
 <211> 660
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(660)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-60298

<400> 66
 atggagggtga aagtggagaa cattcggca atagacatgc tcaaagcaag agtggaaaaat 60
 cgtgtggcac gtggcaaatg ctttaaaaat gcttctttaa tcctcatagg aataactaca 120
 ctgagtagat ctctcaaatat ctatctgatc ataaactaca caatacaaaaa aacccatct 180
 gaatcagaac accacaccag ctcaccaccc acagaatcca acaaggaaagc ttcaacaatc 240
 tccacacaca accccacacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 aacccacac tcaaccccgat agcatcagtg agcccatcag aaacagaacc agcatcaaca 360
 ccagacacaa caaaaccgcct gtccctccgt aacagggtcca cagcacaacc aagtgaagc 420
 agaacaaga aaaaaccgc tccatcgatca agaaacaatc caagcagcagc ttcccgatc 480
 caatcccccac cacgggcaac aacgaaggca atcccgagag ccaccatctt ccgcgtgagc 540
 agcacaggaa aaagaccaatc cacaacatca gtccagtccg acagcagcac cacaacccaa 600
 aatcatgaag aaacagggttc agcgaaccca caggcatctg taagcaaat gcaaaactag 660

<210> 67
 <211> 654
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(654)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-74783

<400> 67
 atggagggtga aagtggagaa cattcggca atagacatgc tcaaagcaag agtggaaaaat 60
 cgtgtggcat gtggcaaatg ctttaaaaat gttttttaa tcctcatagg aataactaca 120
 ctgagtagat ctctcaaatat ctatctgatc ataaaccacca caatacaaaaa aaccacatct 180
 gaatcagaac accacaccag ctcaccaccc acagaatctt acaaggaaagc ttcaacaatc 240
 tccacacaca acccagacat caatccaaac tcacagcatc caactcaaca gtccatcgaa 300
 aacccacac tcaaccccgat agtatacaca agcccatcag aaacagaacc aacatcaaca 360
 ccagacacaa caaaaccgcct gtccctccgt aacagggtcca cagcacaacc aagtgaagc 420
 agaacaaga aaaaatcgac agtccacacca agaaacaacc caagcagcagc ttcccgacca 480

28/52

taatccccac cacgggcaac aacgaaggca atccgcagag ccaccactt ccgcattgagc	540
agcacagaaa aaagaccaac cacaacacta gtccagtacg acagcagcac cacaacccaa	600
aatcatgaag aaacaggttc agcgaaccca caggcatctg caagcacaat gtaa	654

<210> 68

<211> 660

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(660)

<223> human metapneumovirus, strain Quebec Isolate No C-74549

<400> 68

atggagggtga aagtggagaa cattcgagca atagacatgc tcaaaggcaag agtggaaaaat	60
cgtgtggcac gtagcaatg cttaaaaat gcttcccaaa tcctcaagg aataaccaca	120
ctgagcatag ctctcaatat ccacctgatc ataaaactata caatacaaaa accacatct	180
gaatcagaac accacaccag ctacccaccc acagaatcta acaaggaagc ttcaacaatc	240
tccacagacaa acccagacat caatccaaac tcacagcatc caactcaaca gtctacagaa	300
aacccacac tcaaccccgc agtataaca agccccatcg aatcagaacc aacatcaaca	360
ccagacacaa caaaacccct gtctccgtt gacaggtcca cagcacaacc aagtggaaagc	420
agaacaaaga caaaaatcgac agtccacaca agaaaacaacc caagcacagc ttccagtcaca	480
caatccccac cacgggcaac aacgaaggca atccgcagag ccaccactt ccgcattgagc	540
agcacagaaa aaagaccaac cacaacatta gtccagtacg acagcagcac cacaacccaa	600
aatcatgaag aaacaggttc agcgaaccca caggcatctg taaggcacaat gtaaaacttag	660

<210> 69

<211> 711

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(711)

<223> human metapneumovirus, strain Quebec Isolate No C-77807

<400> 69

atggagggtga aagtggagaa cattcgaaaca atagatatgc tcaaaggcaag agtggaaaaat	60
cgtgtggcac gcagcaatg cttaaaaat gcctctttga tccttaatagg aataacgaca	120
tttagtatacg ccctcaacat ctatctgatc ataaaactata caatgcaga aacacatctc	180
gaatcagaac atcacaccag ctcatcaccct atggaatcca gcagggaaaac tccaaacggtc	240
cctatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa	300
ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca	360
ccagacacaa caagccggccc gccccttcgtc gacacacaca caacaccacc aagtgcagc	420
agaacaaggaa caagtccggc agtccacaca aaaaacatc taaagataag ccccagaata	480
cattccccac catgggcaat gacaggagc gtccgtggaa ccaccactct ccgcacaagc	540
agcacaaggaa aaagacccgtc tacagcatc gtccaaacctg acagcagcac aacaactcac	600
aaacacgaaag aacgacccctc agtgaggccc caacacatcg caagcacaacc aagaccacaa	660
aggaaggcgtc tggaggccgt cacaatcaaca acatacaacc aactagttt a	711

<210> 70

<211> 711

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(711)

<223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 70

atggagggtga aagtggagaa cattcgaaaca atagatatgc tcaaaggcaag agtggaaaaat	60
cgtgtggcac gcagcaatg cttaaaaat gcctctttga tccttaatagg aataactaca	120
tttagtatacg ccctcaacat ctatctgatc ataaaactata caatgcaga aacacatctc	180
gaatcagaac atcacaccag ctcatcaccct atggaatcca gcagggaaaac tccaaacggtc	240
cctatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa	300
ggctccacac tccactttgc agcctcagca agctcaccag agacagaacc aacatcaaca	360
ccagacacaa caagccggccc gccccttcgtc gacacacaca caacaccacc aagtgcagc	420

29/52

agaacaagga	caagtccggc	agtccacaca	aaaaacaatc	taaagataag	ccccagaata	480
cattcccccac	catgggcaat	gacaaggacg	gtccgtggaa	ccaccactct	ccgracaagc	540
aggacaagaa	aaagaccgtc	tacagcatca	gtccaaacctg	acagcagcac	aacaactcac	600
aaacacgaag	aagcaagccc	agtgagccc	caaacatctg	caagcacagc	aagaccacaa	660
aggaaggcga	tggagggccag	cacatcaaca	acatacaacc	aaactagttt	a	711

<210> 71
<211> 711
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No C-68661

<400> 71
atggagggtga aagtggagaa cattcgaaca atagatacgc tcaaagcaag agtggaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagttatag ccctcaatat ctatctgatc ataaaactata caatgcaga 180
aaatcagaac atccacaccag ctcatcacc 240
cctatagaca actcagacatc 240
ggctcacac 300
tccactttgc agcctcagca agctcaccag agatcagaacc 360
ccagacacaa caagccggcc 420
agaacaagga caagtccggc 480
cattcccccac catgggcaat 540
agcacaagaa aaagaccgtc 600
aaacacgaag aagcaagccc 660
aggaaggcga tggagggccag 711
cacatcaaca acatacaacc aaactagttt a

<210> 72
<211> 711
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No C-88448

<400> 72
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtggaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagttatag ccctcaatat ctatcta 180
gaatcagaac atccacaccag ctcatcacc 240
cctatggaca actcagacac 240
ggcttcacac tctactttgc 300
ccagacacaa caagccggcc 360
agaacaagga caagtccggc 420
cattcccccac catgggcaat 480
agcacaagaa aaagaccgtc 540
aaacacgaag aagcaagccc 600
aggaaggcga tggagggccag 660
cacatcaaca acatacaacc 711
aaactagttt a

<210> 73
<211> 711
<212> DNA
<213> human metapneumovirus

<220>
<221> gene
<222> (1)...(711)
<223> human metapneumovirus, strain Quebec Isolate No C-88470

<400> 73
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtggaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagttatag ccctcaatat ctatctgatc ataaaactata caatgcaga 180
gaatcagaac atccacaccag ctcatcacc 240

30/52						
ccatggact	acccagacac	caatccaggc	tcacagcatc	caactcaaca	gtccacagaa	300
ggctccacac	tctactttgc	agecctcagca	agctcaccag	agacagaacc	aacatcaaca	360
ccaaacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacacacc	aagtgcagc	420
agaacacaaga	caagtccgge	agttccacaca	aaaaacaaatc	caaggataag	cctcagaaca	480
cattccccac	catggccat	gacaaggacg	gtcccgaa	ccaccactct	ccgcacaagc	540
agcacaaga	aaagatccgtc	tacagcatca	gtccaaacctg	acagcagcgc	aacaacccac	600
aaacacgaag	aagcaagccc	agtggagcccg	caaacatctg	cgagcacagc	aagaccacaa	660
aggaaggcca	tggaggccag	cacatcaaca	acatacaacc	aaactagtt	a	711
<210> 74						
<211> 711						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(711)						
<223> human metapneumovirus, strain Quebec Isolate No						
C-86316						
<400> 74						
atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtggaaaaat	60
cgtgtggcac	gcagcaaattg	ctttaaaaat	gccttcttga	tccttaatagg	aataactaca	120
tttagttatag	ccctcaat	ctatctaattc	ataaaactata	caatgcaga	aaacacatcc	180
gaatcagaac	atcacacag	ctcatcacc	atggaatc	gcaaggaaac	tccaaacagtc	240
cctatggaca	actcagacac	caatccaggc	tcacagttatc	caactcaaca	gtccacagaa	300
ggctccacac	tctactttgc	agecctcagca	agctcaccag	agacagaacc	aacatcaaca	360
ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacacacc	aagtgcagc	420
agaacacaaga	caagtccgge	agttccacaca	aaaaacaaatc	caaggacaag	cctcagaaca	480
cattccccac	catggccat	gacaaggacg	gtccgtggaa	ccaccactt	ccgcacaagc	540
agcacaaga	aaagatccgtc	tacagcatca	gtccaaacctg	acagcagcgc	aacaacccac	600
aaacacgaag	aagcaagccc	agtggagcccg	caaacatctg	cgagcacagc	aagaccacaa	660
aggaaggcca	tggaggccag	cacatcaaca	acatacaacc	aaactagtt	a	711
<210> 75						
<211> 6017						
<212> DNA						
<213> human metapneumovirus						
<220>						
<221> gene						
<222> (1)...(6017)						
<223> human metapneumovirus, strain 00-1						
accession number af371337						
<400> 75						
atggatcc	tcaatgaatc	cactgttaat	gtcttatcttc	ctgactcata	tcttaaagga	60
gtgatttcc	ttagtgagac	taatgcaatt	gtttcatgtc	tctttaaaag	accttaccta	120
aaaaatgaca	acactgcaaa	agttggccata	gagaatccgt	ttatcgagca	tgttagactc	180
aaaaatgcag	tcaattctaa	gatggaaaata	tcagattaca	agatagatga	gcctgtaaaac	240
atgcaacatg	aaatttatgaa	gaatgtacac	agtgtgtgagc	tcacattatt	aaaacagttt	300
ttaacaagga	gtaaaaatata	tagctcttc	aaatattaa	tgatatgtga	ttggctgcag	360
ttaaagtcta	catcagatg	tacctcaatc	ctaagtttt	tagatgttga	atttataacct	420
agctggtaa	gcaatgtgtt	tagtaattgg	tacaatctca	acaagggtat	tctggaaattc	480
agggaaaag	aagtaataag	aactgtgtca	atcttgcgt	ggtcattgg	taaatttagtt	540
tttgttgtt	catcatatgc	atgtatgtc	aaaggtcaaa	aaagccaaaag	agtggagcttc	600
ttcacatata	atcaactgtt	aaatgtggaa	gtatgtatgt	taagtagatt	caatgcaaat	660
ttttgtatata	gggttaagcaa	cagtctgtat	aaaaatccag	aagggtcttag	gttgagaagt	720
aatctgcaag	gcataatataac	taataagcta	tatgtaaactg	tagattatata	gccttagttt	780
tgttgcattg	aagggtttctc	acttgtgaaa	gagttcgtaa	gcttttattat	gagtggaaaatt	840
tttaggttata	ctgaacatgc	tcaatttcgt	actagattta	gaaatatttt	attnaaatgg	900
ttaactgtat	aattaaacaa	ataaaaaaat	aaaaacagac	tcagagttca	tgttaccgtg	960
tttagaaaaata	atgattatcc	aatgtacgaa	gtttgtactt	agtattttagg	agatacttgc	1020
agatgtatata	aatttataat	caataaaaaaac	ttagagaatg	ctgctgtat	atactatata	1080
ttttagataat	tcggttcaccc	aatgtgtat	gaaagagatg	caatggatgc	tgtcaatata	1140
aacaatgaaa	tcacaaaaat	cctttaggtgg	gagagcttga	cagaactaag	agggggcatc	1200
atattaagga	ttatcaaagg	atttgtat	aaaaacaaaa	gatggcccaa	aattaaaaac	1260
ttaaaatgtc	ttagttaagag	atggactatg	tactttcaaa	aaaaaaatgtt	ccccagtcaa	1320
tttgaattaa	gcgaacaaga	tttttttagag	cttgcgtca	tacatgttga	acaagagttt	1380
tctgtccctg	aaaaaaaccaa	cctttagatg	gtatataatg	attnaaatgtat	atcaccttct	1440
aaaagattaa	tatgttgtgt	gtatccaaaa	aattatcac	ctgagaaaaat	aaaaaaatcg	1500
tatctagaag	agactttcaa	tgcagatgtat	agtctcaaaa	caagaagagt	actagagtac	1560

31/52

32/52

gtgaaattaaa ttatgatttt ttgtgaagcat tagaaaatac ttacccataat atgattaaac
 taatagataa tctaggaaat gcagagataa aaaaactgat caaagttaact ggatatatgc
 ttgtaaatggaaaatgta
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-118

<400> 76

taaaatgaaa	atatacgatt	acaaggtagt	agaaccagta	aacatgcac	atgaaataat	60
gaagaatgt	cacagctgt	agcacacact	attgaaaacag	tttttaacaa	gggtaaaaaa	120
cattagact	ctcaaaat	atatgatatg	tgattggctg	caataaaaat	ctacatcaga	180
ttgtacccat	atccaaatgtt	ttatagatgt	agaatttata	cctagttggg	taagcaactg	240
gttttagtaat	tggtacaatc	tcaataagtt	aatttttagaa	ttcaggagag	aagaagtaat	300
aagaacccgt	tcaatcttgc	gcagggtcatt	aggtaaaat	gttttttattt	tatcatcata	360
ttggatgtatc	gtcaagagca	acaaaagcaa	aagagtggc	ttctttacat	acaatcaact	420
gttaacatgg	aaagatgtga	tgttaagtcg				450

<210> 77
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-163

<400> 77

ttgaaatatac	agattacagg	atagtagagc	cagtaaacat	gcaacatgaa	attatgaaga	60
atgtacacag	tttgtgagctc	acattttttaa	aacagtttt	aacaaggagt	aaaaatattt	120
gcactctaa	attaaatatg	atatgtgatt	ggctgcgtt	aaaatctaca	tcagatgata	180
cctcaatctt	aagttttata	gatgttagat	ttatacttag	ctgggttaagc	aattggttt	240
gtaattggta	caatctcaac	aagttgattc	tggatttcag	gaaaagaagaa	gtaataagaa	300
ctggttcaat	tttgtgttag	tcatttagta	aatttagttt	tgttgtatca	tcatatggat	360
gtatagtc	gagcaacaaa	agcaaaagag	tgagcttctt	cacatacaat	caactgtttaa	420
catggaaaga	tgtgtgtta	agtagattca				450

<210> 78
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-174

<400> 78

gagaatcctg	ttatcgagca	tttttagactc	aaaaatgcaa	tcaatctaaa	gtgaaaata	60
tcagattaca	ggatgtaga	ggccataaaac	atgcacatcg	aaattatgaa	aatgtacac	120
agttgtgac	tcacatttt	aaaacagttt	ttaacaagga	gtaaaaat	tagcactctc	180
aaattaaata	tgatgtgt	ttggctgcag	ttaaaagtcta	catcagatga	tacctcaatc	240
ttaaagtttt	tagatgtaga	atttatacc	agctggtaa	gcaatgttt	tagtaattgg	300
tacaatctca	acaatgtat	tctggattt	aggaaaagaag	aatgtataag	aactggttca	360
atcttggat	ggtcattgg	taaatttagt	tttggttat	catcatatgg	atgtatagtc	420
aaagacaca	aaagcaaaaag	agtgagctt	ttcacataca	atcaactgtt	aacatggaaa	480
gtatgtgt	taatgttagt					500

<210> 79
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>

33/52

<221> gene
 <222> (1)...(450)
 <223> Human metapneumovirus, strain Quebec Isolate No
 hMPV-184

<400> 79
 attggaaatat cagattacag gatagtagag ccagtaaaca tgcaacatga aattatgaag 60
 aatgtacaca gtgtgagct cacattatta aaacagtttt taacaaggag taaaaatatt 120
 agcactctca aattaaatat gatatgtat tggctgagt taaagtctac atcagatgat 180
 acctcaatct taagttttat agatgttagaa ttatatactt gctggtaag caattggtt 240
 agtaatttgtt acaatctcaa caagttgatt ctggaaatca ggaagaaga agtaataaga 300
 actggttcaa tcttgtgtat gtcatttaggt aaatttagttt ttgttgtatc atcataatgga 360
 tgtatagtca agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta 420
 acatggaaag atgtatgtt aagtagattc 450

<210> 80
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-196

<400> 80
 ttggcccatag agaatccrqt tattgagcat gtgagactca aaaaatgcgt caattctaaa 60
 atgaaaatat cagattacaa ggttagtagag ccagtaaaca tgcaacatga aataatgaag 120
 aatgtacaca gtgtgagct cacacttattt aaacagtttt taacaaggag taaaaacatt 180
 agcactctca aattaaatat gatatgtat tggctgcaat taaagtctac atcagatgat 240
 acctcaatcc taagtttcat agatgttagaa ttatatactt gttggtaag caactggtt 300
 agtaatttgtt acaatctcaa taagtttattt ttggaaatca gaagagaaga agtaataaga 360
 accgggtcaa tcttatgtcag gtcattgggtt aaatttagttt ttattgtatc atcataatgga 420
 tgtatgtca agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta 480
 acatggaaag atgtatgtt 500

<210> 81
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-76837

<400> 81
 agatgaaaat atcagattac aggatagtag agccagtaaa catgcaacat gaaaattatga 60
 agaatgtaca cagttgttag ctcacattat taaaacagtt tttacaagg agtaaaaata 120
 ttagcactct caaattaaat atgatatgtt attggctgca gttaaaagtct acatcagatg 180
 atacctcaat cttaaatgttt atagatgtt aatttatacc tagtggta agcaatttgt 240
 ttgtatattg gtacaatctc aacaaggttt ttctggaaat cagaaagaa gaagtaataaa 300
 gaactggttc aatcttgtc aggtctttggttaaaatgtt ttgttgtatc tcatcatatg 360
 gatgtatagt caagagcaac aaaagcaaaa gagtgagctt cttcacatac aatcaactgt 420
 taacatggaa agatgtatgtt 450

<210> 82
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77807

<400> 82
 taagatgaaa atatcgatt acaggatgtt agagccagta aacatgcaac atgaaaattat 60
 gaagaatgtt cacagttgtt agtcacattt attaaaacag ttttttaacaa ggagtaaaaa 120

34/52

tattagca	ctcaaattaa	atatgatatg	tgattggctg	cagttaaagt	ctacatcaga	180
tgataccctca	atcttaagtt	ttatagatgt	agaafftata	cctagctgg	taagcaatig	240
gttttagtaat	tggtacaatc	tcaacaagtt	gattctggaa	ttcaggaaag	aagaagtaat	300
aagaactgg	tcaatcttgc	gttagtcatt	gggtaaattt	gtttttgttg	tatcatcata	360
cgatgtata	gtcaagagca	acaaaagcaa	aagagtgac	ttcttcacat	acaatcaact	420
gtttaacatgg	aaagatgtga	tgttaagtag				450

<210> 83
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-185

<400> 83						
taaaattgaa	atatcagatt	acaaggtagt	agagccagta	aacatgcac	atgaaataat	60
gaagaatgt	cacagtgt	agctcacact	attgaaacag	tttttaacaa	ggagtaaaaa	120
cattagca	ctcaaattaa	atatgatatg	tgattggctg	caatcaaagt	ctacatcaga	180
tgataccctca	atccataat	ttatagatgt	agaafftata	cctagctgg	taagcaactg	240
gttttagtaat	tggtacaatc	tcaataat	gattttggaa	ttcaggaaag	aagaagtaat	300
aagaaccgg	tcaatcttgc	gttagtcatt	gggtaaattt	gtttttgttg	tatcatcata	360
tggatgtatc	gtcaagagca	acaaaagcaa	aagagtgac	ttcttcacat	acaatcaact	420
gtttaacatgg	aaagatgtga	tgttaagtag				450

<210> 84
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78123

<400> 84						
atccctgttat	cgagcatgtt	agactcaaaa	atgcaatcaa	ttctaaagatg	aaaatatacag	60
attacaggat	agttagagcca	gtaaacatgc	aacatgaaat	tatgaagaat	gtacacagtt	120
gttagctcac	attattaaaa	cagttttaa	caaggagtaa	aaatattatgc	actctcaat	180
taaaatgtat	atgttgg	ctacagttaa	agtctacatc	agatgatacc	tcaatctttaa	240
ttttttataga	tgttagattt	ataccatgt	gggttaagca	ttggtttagt	attggtaca	300
atctcaacaa	gtttagtctg	gaattcagga	aagaagaagt	aataagaact	gttcaatct	360
tgtgcagg	ttttggtaaa	tttagttttt	ttgtatcata	atatggatgt	atagtcaaga	420
gcaacaaaag	aaaagatgt	agcttctca	catacataatca	actgttaaca	tggaaagatg	480
tgatgttaag	tagatccaat					500

<210> 85
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-91205

<400> 85						
caattctaaa	atgaaaatat	cagattacaa	ggtagtagag	ccagtaaaca	tgcaacatga	60
aataatgtaa	aatgtacaca	gttgtgagct	cacacttatt	aaacagttt	taacaaggag	120
taaaaacatt	agcactctca	attttatata	gatatgtat	tggctgcaat	taaagtctac	180
atcagatgtat	acctcaatcc	taagtttcat	agatgttagaa	tttataccct	gttgggttaag	240
caactgg	atgtatgtt	acaatctcaa	taagtttatt	ttgaaattca	aaagagaaga	300
atgtatataa	accggttcaa	tcttatgcag	gttattgggt	aaatttagttt	ttattgtatc	360
atcatatgg	tgtattgtca	agagcaacaa	aaggaaaga	gtgagcttct	tcacataacaa	420
tcaactgtta	acatggaaag	atgtgtatgtt				450

<210> 86

35/52

<211> 400
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gene
 <222> (1)...(400)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-91364

<400> 86
 ttgcatacgag aatctgtta ttgacatgt cagactcaa aatggcgta attctaaaat 60
 gaaaatatca gattacaagg tagtagaacc agtaaacatg caacatgaaa taatgaagaa 120
 ttttacacgc ttttggcgca cactattgaa acagttttta acaaggagta aaaacattag 180
 cactctcaa taaaatatga tatgtgattt gctgcaatta aaatctacat cagatggtag 240
 ctcataatccta agttttatag atgtagaattt tatacctagt tgggtaagca actggtttag 300
 taattggcac aatctcaata agttaatttt agaatttcagg agagaagaag taataagaac 360
 cgttcaatc ttgtcgaggc cattagttaa attagttttt 400

<210> 87
 <211> 500
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-91749

<400> 87
 atagagaatc ctgttatttga gcatgtgaga ctcaaaaatg cagtcaattc taaaatgaaa 60
 atatcagatt acaaggtagt agagcccgta aacatgcaac atgaaataat gaagaatgtt 120
 cacagttgtg agctcacat attgaaacag ttttttaacta ggagttaaaaa cattagcaat 180
 ctcaaaattaa atatgatatg tgattggctg caattttaaatgt ctacatcaga tgatacctca 240
 atctctaagtt tcatacgatgt agaattttata cctagttggg taagcaactg gtttagtaat 300
 tggtacataatc tcaataatgt aattttggaa ttccaaagag aagaagtaat aagaaccgg 360
 tcaatctttt gcaggcttattt ggttaatttta gttttttttt tatcatcata tggatgtatc 420
 gtciaagagca acaaaagcaa aagagtggc ttcttcacat acaatcaact gttaaatcg 480
 aaagatgtga tggtaatgtt 500

<210> 88
 <211> 450
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-Q86

<400> 88
 aattctaaaa tggaaatatac agattacaag gtagtagaaac caataaaacat gcaacatgaa 60
 ataatgaaga atgtacacag ttgtggcgca acactattgtt aacagttttt aacaaggagt 120
 aaaaacatttta gcaactctca attaaatatg atatgtgattt ggctgcaattt aaaatctaca 180
 tcagatgata ctcaatctt asgttttata gatgttagaaat ttatcacctg ttgggttaagc 240
 aactggttta gtaattgtt caacatcaat aagttttttt tagaatttcag gagagaggaa 300
 gtaataagaa ccggttcaat ttgtggcagg tcatttagtta aattttttt tattttatca 360
 tcataatgtt gatgtcgatca gagcaacaaa agcaaaagag tgagcttctt cacatcaat 420
 caactgtttaa catggaaaga tttttttttt 450

<210> 89
 <211> 450
 <212> DNA
 <213> human metapneumovirus

 <220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-Q97

<400> 89
 aaaaatgaaaa tatcagattt caaggttagta gagccagtaa acatycaca a tgaataatg 60
 aagaatgtac acagtgtga gctcacacta ttgaaaacagt ttttaactag gagaaaaac 120
 atttagcactc tcaaattaaa tatgatatgt gatggctgc aattaaagt c tacatcagat 180
 gataccctcaa tcctaagttt catagatgt a gaatttatac ctagttggg aagcaactgg 240
 ttttagtaatg ggtacaatct caataagttt a ttttggaaat tcagaagaga agaagtaata 300
 agaaccgggtt Caatctttag caggcattt ggtttttttt aatcataat 360
 ggatgtatcg tcaagagcaa caaaagcaaa agagttagt ttttcacata caatcaactg 420
 ttaacatgga aagatgtatg gttaagttaga 450

<210> 90
 <211> 537
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(537)
 <223> human metapneumovirus, strain Can 97-83

<400> 90
 agaattccgtt tattggcat gtgagactca aaaaatggcgg tcattctaaa atgaaaatat 60
 cagattttttt ggttagtagg ccagccaaaca tgcaacatgt aataatgtt aatgtacaca 120
 gtttgtggctt cacactattt aacacgtttt taacaaggag taaaacatcattt agcactctca 180
 aattgtatat gatatgtgtat tggctgcaat taaagtctac atcagatgtat acctcaatcc 240
 taagtttcatt agatgttagaa ttatataccta gttgggttaag caactgggtt agtattgg 300
 acaatctcaa taatgttattt ttggaaatttca gaagagaggaa agtataaga accgggttcaa 360
 tctttatgcag gtcattttttt aatattgtttt ttattgttattt atcataatgg tttatcgatca 420
 agagcaacaa aagcaaaaaga gtgagcttct tcacatacaaa tcaactgtt aatggaaag 480
 atgtgtatgtt aatgcgattt ttgtatgtt ggttaagcaac agtctgt 537

<210> 91
 <211> 20
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 55

<400> 91
 atgggacaag tgaaaatgtc 20

<210> 92
 <211> 19
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 56

<400> 92
 gagtctcagt acacaataa 19

<210> 93
 <211> 18
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 57

<400> 93
 gtcactgcag ttgttgta 18

<210> 94
 <211> 19
 <212> DNA
 <213> human metapneumovirus

<220>
 <223> primer no 58

37/52

<400> 94
gcatttccga gaacaacac 19
<210> 95
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 18 multiplex assay

<400> 95
gagtctcagt acacaataa 19
<210> 96
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 19 multiplex assay

<400> 96
gcatttccga gaacaacac 19
<210> 97
<211> 18
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 59

<400> 97
atgtcttggaa aagtggtg 18
<210> 98
<211> 17
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 60

<400> 98
tcttcttacc attgcac 17
<210> 99
<211> 20
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 61

<400> 99
ctaattatgt ggtatgaagc 20
<210> 100
<211> 18
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 62

<400> 100
atggagtcct acctagta 18
<210> 101
<211> 19

38/52

<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 63

<400> 101
aagggtgcttg gttgttatac 19

<210> 102
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 64

<400> 102
atgtcattcc ctgaaggaa 19

<210> 103
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 65

<400> 103
ttaactggta aatctcatc 19

<210> 104
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 66

<400> 104
catggggacaa gtagttatg 19

<210> 105
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 67

<400> 105
atggaggtga aagtggaga 19

<210> 106
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 68

<400> 106
ttaacttagtt tggttgtat 19

<210> 107
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 69

39/52

<400> 107
tttagagttt ttttgtatt 19
<210> 108
<211> 24
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 70

<400> 108
ggacaagtag ttatggaggt gaaa 24
<210> 109
<211> 28
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 71

<400> 109
ctcctttaag atatgagtca ggmagrrta 28
<210> 110
<211> 22
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 20 multiplex assay

<400> 110
gttgcctatag agaattccgtt ta 22
<210> 111
<211> 22
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 21 multiplex assay

<400> 111
cattcagact gttgcttacc ca 22
<210> 112
<211> 22
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 72

<400> 112
gttgcctatag agaattccgtt ta 22
<210> 113
<211> 22
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 73

<400> 113
cattcagact gttgcttacc ca 22
<210> 114
<211> 27
<212> DNA

40/52

<213> human Metapneumovirus
<220>
<223> human Metapneumovirus
primer A1

<400> 114
ccaattacta aaccaattgc ttaccca 27

<210> 115
<211> 21
<212> DNA
<213> human metapneumovirus

<220>
<223> probe no 74

<400> 115
gcaagcttat ggggcccggtc a 21

<210> 116
<211> 25
<212> DNA
<213> human metapneumovirus

<220>
<223> probe no 75

<400> 116
acaatgctaa ggtgggggggt cattg 25

<210> 117
<211> 23
<212> DNA
<213> human metapneumovirus

<220>
<223> probe no 76

<400> 117
gttctgagga caggttggta cac 23

<210> 118
<211> 23
<212> DNA
<213> human metapneumovirus

<220>
<223> probe no 77

<400> 118
aatgttttta cactggaggt agg 23

<210> 119
<211> 22
<212> DNA
<213> human metapneumovirus

<220>
<223> probe no 78

<400> 119
gttacaatac cagcattcat ca 22

<210> 120
<211> 25
<212> DNA
<213> human metapneumovirus

<220>
<223> probe no 79

41/52

<400> 120	
atcagtttca atcaaagaga gtgag	25
<210> 121	
<211> 25	
<212> DNA	
<213> human metapneumovirus	
<220>	
<223> probe no 80	
<400> 121	
taaagcaagc aatcaaagtc atgga	25
<210> 122	
<211> 25	
<212> DNA	
<213> human metapneumovirus	
<220>	
<223> probe no 81	
<400> 122	
cccattgtaag aagaagagtc taccg	25
<210> 123	
<211> 20	
<212> DNA	
<213> human metapneumovirus	
<220>	
<223> probe no 82	
<400> 123	
actcaagccc acagcatcca	20
<210> 124	
<211> 23	
<212> DNA	
<213> human metapneumovirus	
<220>	
<223> probe no 83	
<400> 124	
ctcaaacagtc cacagaaggc tcc	23
<210> 125	
<211> 26	
<212> DNA	
<213> human metapneumovirus	
<220>	
<223> probe no 84	
<400> 125	
attgttttag taatttgtac aatctc	26
<210> 126	
<211> 26	
<212> DNA	
<213> human metapneumovirus	
<220>	
<223> probe no 85	
<400> 126	
acaagttgat tctggaattc aggaaaa	26
<210> 127	
<211> 25	
<212> DNA	

42/52

<213> human Metapneumovirus

<220>

<223> human Metapneumovirus
probe A2

<400> 127

cgagcatgtt agactcaaaa atgca

25

<210> 128

<211> 23

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 33 multiplex assay

<400> 128

atgtatccgt ccaagctgag tta

23

<210> 129

<211> 26

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 34 multiplex assay

<400> 129

attggtttag taattggtag aatctc

26

<210> 130

<211> 1027

<212> DNA

<213> human Influenza A virus

<220>

<221> gene

<222> (1)...(1027)

<223> human Influenza A virus
strain A/Hong Kong/1180/99(H3N2)

accession number af386771

<400> 130

agcaaaagca	ggtagatatt	gaaagatgag	ccttctaccc	gaggtcgaaa	cgtatgttct	60
ctctatcgtt	ccatcaggcc	ccctcaaagc	cgaaatcgcg	cagagactg	aagatgtctt	120
tgtctggaaa	aacacagatc	ttgaggtctt	catggaatgg	ctaaagacaa	gaccaatccct	180
gtcacctctg	actaagggga	tttttagggtt	tgtgttcacg	ctcacgtgc	ccagttagcg	240
aggactgcag	cgtagacgtt	ttgtccaaaa	tgcctcaat	ggaaatgggg	atccaaataa	300
catggacaaaa	gcagttaaac	tgtatagaaaa	acttaagagg	gagataacat	tccatggggc	360
caaaggaaaa	gcactcagg	attctgtctgg	tgcaatgtcc	atgtgcattgg	gcctcataata	420
caataggatg	ggggctgtaa	ccactgttaat	ggcatttggc	ctggtatgtt	caacatgtga	480
acagattgt	gactcccaagc	acaggtctca	taggcaatg	gtggcaacaa	ccaatccatt	540
aataagacat	gagaacagaa	tgggtttggc	cagcaatcata	gctaaggcta	tggagcaaat	600
ggctggatca	agttagcagg	cagcggaggc	catggagatt	gctagtctagg	ccaggcaaat	660
ggtgccggca	atggagagccg	ttgggactca	tcctacttcc	agtactggtc	taagagatga	720
tcttcttgaa	aaatttcgaga	ccttacgaa	acggatgggg	gtgcagatgc	aacgatca	780
gtgacccgcgt	tgttgttgc	gcgcgtatca	tggggatctt	gcacttgcata	tgttgatcc	840
ttgatcgctt	ttttttcaaa	tgcatctatc	gactcttcaa	acacggccctt	aaaagagggc	900
cttctacgga	aggagtactt	gagtctatga	ggaaagaata	tcgaaaaggaa	cagcagaatg	960
cttggatgc	tgaccacagt	cattttgtca	gcataaagg	ggagtaaaaa	actacccctgt	1020
tttctact						1027

<210> 131

<211> 987

<212> DNA

<213> human Influenza A virus

<220>

<221> gene

<222> (1)...(987)

<223> human Influenza A virus

43/52

strain A/Charlottesville/31/95 (H1N1)
accession number af398876

<400> 131	60
atgagtcctc taaccgaggt cgaaaacgtac gttctctcta tcgtcccgta aggccccctc	120
aaagccgaga tcgcacagag actttaagat gtccttgctg gaaagaacac cgatcttgag	180
gctctcatgg agtggctaaa gacaagaccg atccctgtcac ctctgactaa ggggatttta	240
ggattttgtgt tcacgctcac cgtgcccagt gaggcaggac tgcacgctag acgccttgctc	300
caaaaatggcc ttaatgggaa tggggatcca aataaataatgg acagagcagt taaactgtat	360
agaaaagctt agaggggatg aacattttcat ggggccaatgg aataatggact cagttattct	420
gctgggtcac ttggccagtt tatgggcctc atataacaaca ggatgggggc tggaccacc	480
gaatcagcat ttggccgtat atgcgcaccc tggtaacaga ttgtggactc ccagcataaag	540
tctcataggc aaatggtaac aacaaccaat ccatttaataa gacatggaga aagaatgggt	600
ctggccagca ctacagctaa agctatggag caaaatggctg gatcggatgt acaaggcagct	660
gaggccatgg aggttgcgtag tcaggccagg caaaatggctg agggcaatggag agccattggg	720
actcatctt gctcttagcac tggtctgaaa aatgatcttc ttggaaaattt gcaggccctat	780
cagaaacggc tgggggtgca gatgcaccaac ttcaatgtat cctcttgggtt tggccgcaag	840
tatcatttggg attgtgcacc tggatattgtt gattatgtat cgcccttttt tcaaataatgc	900
ttatcgtatc tttaaacacacg gtctgaaaatgg agggccctct acggaggag taccagagtc	960
tatgagggaa gaatatcgag aggaacacca gaatgtgtg gatgctgacg aaggtcattt	987
tgtcagcata gagctggagt aaaaaaac	

<210> 132

<211> 1076

<212> DNA

<213> human Influenza B virus

<220>

<221> gene

<222> (1)...(1076)

<223> human Influenza B virus
strain B/Nagoya/20/99

<400> 132

atgtcgctgt ttggagacac aatttgcctac ctgttttcat tgacggaaga tggagaaggc	60
aaagcagaac tagcagaaaa attacactgt tggttgcgtg gaaagaatt tgacctagac	120
tctgccttgg aatggataaa aaacaaaaaa tgcttaacty atataaaaaa agcactaatt	180
ggtcctctta tctgtttttt aaaaaacaaa gacaagaaaa gaaaaaaaag attcatcaca	240
gagcccttat cagaatggg aacaacagca aaaaaaaa aaggcctgtat tctagcttag	300
agaaaaaatga gaagatgtgt gagctttcat gaagcatttg aaatagcaga aggcctatgaa	360
agctcagcgc tactatattt tcttcatgttgc atgtacccgt accttggaaa ttattcaatg	420
caagtaaaac taggaacgcgt ctgtgccttg tgcgaaac aacatcaca ttccacacagg	480
gctcatagca gagcagcgcgt atcttcagtgt cctggatgtg ggcgagaaat gcaaatggc	540
tcagctatga acacagcaaa aacaatgtat ggaatggaa agggagaaga cgtccaaaaaa	600
ctggcagaag aactgcaaaac caacattgtt gttgtggat ctcttggatc aagtcaaaag	660
aatggggaaag gaatttgcaaa ggtatgtatgg gaatgttcaatg agcagagctc tatggaaaat	720
tcagctcttg tgaagaaaataa cctataatgc ttgaaaccatt tcagatttctt tcaattttgtt	780
cttttatctt atcagctctc catttcatgg ctggaaacat agggcatttg agtcaaataaa	840
aaagggagt aaacatgaaaa atacgaaatgg aatggccaaa taaagagaca ataaacagag	900
aagtatcaat ttggagacac aatttacaaa aaaaatccca ggcacaaagaa acaatgaagg	960
aagtgccttc tgacaacata gaagtatttg gttgaccacat agtgatttg gggctttctt	1020
ctgaagagat aataaaaaatgg ggcaaaacag ttttggaggt agaaaaatttgc cattaa	1076

<210> 133

<211> 1725

<212> DNA

<213> human Respiratory Syncytial Virus

<220>

<221> gene

<222> (1)...(1725)

<223> human Respiratory Syncytial Virus
strain B1
accession number af013254

<400> 133

atggagctgc tgatccacag gttaagtgcata atcttccata ctcttgctat taatgcattt	60
tacctcacct caagtgcagaa cttaaactgtgag gatgtttacc aatcgacatg tagtgcagg	120
agcagagggtt attttatgtgc tttaagaaca ggttgcgtata ccagtgcatt aacaatagaa	180
ttaaataataa taaaagaaaaac caaatgtcaat ggaactgtaca cttaaatggaa atttataaaa	240
caagaattttg ataagtataa gaatgcgtg acagaattac agctactttt gcaaaacaca	300
ccagctgcac acaaccggggc cagaagagaa gcaccacagt atatgtacttata	360

44/52

accactaaaa	acctaaaatgt	atcaataaggc	aagaagagga	aacgaaggatt	tctgggcttc	420
ttgrrtaggtg	taggatctgc	aatagcaagt	ggtatagctg	tatccaaagt	tctacacccrt	480
gaaggagaag	tgaacaagat	caaaaatgc	ttgttatctt	caaacaaggc	tgtagtccgt	540
ctatcaatgt	gggtcagtgt	ttaaccaggc	aaagtgttag	atctcaagaa	tiacataaaat	600
aaccaattat	taccatagat	aatcaacag	agctgtcgc	tctccaacat	tgaacacgtt	660
atagaattcc	agcagaagaa	cagcagattt	ttggaaatca	acagagaattt	cagtgtcaat	720
gcaggtgtaa	caacaccc	aagcaacttac	atgttaacaa	acagtggattt	actatcattt	780
atcaatgata	tgcctataac	aatatgtcag	aaaaatattt	tgtcaagca	tgttcagata	840
gtaaggaac	aaaggatttt	tatcatgtct	ataataaagg	aaagaatctt	tgcataatgtt	900
gtacagctac	ctatctatgg	tgtaatagat	acacccgtt	ggaatttaca	cacatcacct	960
ctatgcacca	ccaacatcaa	agaaggatca	aatatgttt	taacaaggac	tgatagagga	1020
ttgttatgtt	ataatgcagg	atcgatattc	ttctttccac	aggctgacac	ttgttaaagia	1080
cagtccatc	gagatatttt	tgacactatg	aaacgttttga	cattaccaag	tgaagtccgc	1140
ctttgtaa	ctgacatatt	caatttcaag	tatgacttgc	aaattatgac	atcaaaaaca	1200
gacataagca	gctcagtaat	tacttctt	ggagctatag	tgtcatgtca	ttgtaaaaact	1260
aaatgcactg	catccaaacaa	aaatctgtgg	attataaaga	cattttctaa	ttgttgcgtac	1320
tatgtgttca	acaaggagg	agatactgtt	tcagtggca	acactttata	ctatgtaaaac	1380
aagcttggaa	gcaagaacct	ttatgtaaaa	ggggaaacctt	taataaatta	ctatgaccc	1440
ctatgtttt	cttctgtatga	ttttgtatgc	tcaataatctt	aagtcaatga	aaaaatcaat	1500
caaagttag	cttttatttgc	tagatctgtat	gaatttactac	ataatgtaaa	tactggcaaa	1560
tctactacaa	attatgtat	aactacaattt	attatagtaa	tcattgttagt	attgttatca	1620
ttaatagcta	ttgttttgc	ttgttattgc	aaagccaaaa	acacaccgt	tacactaagc	1680
aaagaccaac	taagtggaaat	caataatattt	gcattcagca	aatag		1725

<210> 134

<211> 1575

<212> DNA

<213> human Parainfluenza 1 virus

<220>

<221> gene

<222> (1)...(1575)

<223> human Parainfluenza 1 virus strain
Washington/1964
accession number nc003461

<400> 134

atggccgggc	tactaagtac	ttttgacaca	tttagttcca	ggagaagtga	gaggcatcaat	60
aagtctggcg	gaggagcaat	tatacctgtt	caaagaagta	ccgtttctgt	tttcacattt	120
ggcccggatgt	tgacatgtt	tgcaatgttt	ttatataatg	caaccactt	tttagcccac	180
tcattggaca	cagataaaaca	acactctca	agaggaggat	ttttgtatc	actccttgc	240
atggctaca	gtatgtccgg	gttatatctc	actacaaacg	gtgtcaatgc	tgatgtcaag	300
tatgtgtat	acaatataaga	gagagatctt	aaaagaacaa	aaacagatgg	tttgcattgtc	360
aaaacaagag	atcgaggat	tgaagaaaca	acagatgtt	tgttggacc	tatgtatcaac	420
aagaacccat	tgttccaagg	gcaaaagagag	aatgcggatc	tagggcatt	gtttcagaca	480
tatggatatac	ctgcatgtct	cgagctata	atagttcaag	tttgatagtt	tttgcgttaaa	540
gccataaaca	gtatgtgtgg	tctaaagaaaa	ggatttctca	atagatttga	agcattcaga	600
caggatggaa	ccgtttaaaag	ttccctggtc	ttcacaggag	acacagtgt	aggtatttgg	660
gcagtgtat	ggtcacaaca	aagcttagta	tctttatgtt	ttagaaacact	gtgtactatg	720
aacacatcca	ggtcagat	aactacattt	gagaagaaca	ttcagattgt	aggaaaattac	780
ataagagatg	caggattatgc	atcttttcgt	aacaccatca	agtatgtt	agaaacgaa	840
atggccccc	tgacactatc	atatctgtat	ccagatataaa	acaaatttgg	agcccttgc	900
gatatctatc	tatcaaagggg	agccccggcc	ccttttatat	gtatacttgc	agaccccgat	960
catggagact	ttggccctgg	aaactatcca	gcactgttgg	gtctggcaat	gggcgttgc	1020
gtgggtacaaa	acaaaatgtat	gcaacatgtat	gtactgttgg	gaacatattt	ggacatggaa	1080
atgttctatc	ttggacaatgc	tgtatgtttt	gatgttgcatt	ccaaatctcg	cagtgtctcg	1140
gaggaaagac	taggtgttgc	agatacagca	aaagagagac	taagcaccca	tctgacaaaac	1200
ctttcaggag	gggatgtgtgc	gtaccacaag	cctacagggt	gtggagctat	agaagtggca	1260
attgtatata	cagacataac	attttggatc	gaggacactg	ctgatgggg	aaacaagaac	1320
tggacaaaatg	acacatgt	aaatgttgc	aatcactcg	tgcacaccc	cacaatcag	1380
attcgttgc	cagaagaatgt	tgtatgtttt	aaatgtatgt	aagatgttac	tgatatagaa	1440
aacaagattt	caccaaggct	ggccgacaga	aaacagagac	taagccaggc	aaacaataaa	1500
cgagacacca	gcagtgtatgc	tgactatgt	aatgtatgt	atgttacagc	ggctgcagg	1560
ataggaggaa	ttttaa					1575

<210> 135

<211> 1548

<212> DNA

<213> human Parainfluenza 3 virus

<220>

<221> gene

<222> (1)...(1548)
<223> human Parainfluenza 3 virus
strain GP
accession number ab012132

<400> 135	atgttgtagcc	tatTTgtatac	atTTaatgca	cgtaggcaag	aaaacataac	aaaatcagecc	60
	ggTggagctta	tcatttctgg	acagaaaaat	actgtttcta	tatTTgtct	tgaccgaca	120
	ataatgtggat	ataatgtggaa	aatgacatac	gcttccttct	ttttatctca	ttcactggat	180
	aatggagaaac	aacatgcaca	aaggggcaggg	ttccctgggt	ccttattatc	aatggcttat	240
	gccaatccag	agctctaccc	aacaacaaaat	ggaagtaaig	cagatgtceaa	gtatgtcata	300
	tacatgtatcg	agaaaagatct	aaaacggccaa	aagtatggag	gattttgtgt	taagacgaga	360
	gagatgtgtat	atgacaaagac	aactgttgg	atatttggaa	gtgaccttgg	ttgtatcag	420
	gaaatctatgt	tgcagaaacgg	aagaaaaacat	tcaacaattt	aagaccttgt	ccacacattt	480
	gggttatccat	catgtttagg	actctttata	atacagatct	ggatagttct	gttcaaaagct	540
	atcacttagta	tctcagggtt	aagaaaaaggc	tttttccccc	gatttggaaagc	tttcagacaaa	600
	gatggaaatcg	tgcaggccgg	gctggttattt	agccgttgaca	cagtgtatcc	gatttgggttca	660
	attatgcggt	ctcaacagag	cttggtaact	ctttaggttg	aaaattttat	aacaatgtaaat	720
	actagcggat	atgaccccttc	aaccatgaaa	aagaatataat	aaattttttgg	taactatata	780
	agagatgcag	gttctcgttc	attcttcaat	acaatcagat	atggaaatttg	gactagaatg	840
	gcagctttga	cttctatccac	tctcagacca	gacatcaata	gattaaaagc	tttggatggaa	900
	ctgtatrtat	caaaagggacc	acgcgttct	ttcatctgtt	ttctcagagaa	tcccatatcat	960
	gggtggatgtt	caaaaggccaa	ctatcttgc	atatggagat	atgcataatggg	agtggcagtt	1020
	gtacaaaata	gagccatgca	acagtatgt	acgggaagat	catatctgg	tattgatatg	1080
	ttccagctag	gataaagcgt	acgacgtgtat	gctgaagctc	agatgagctc	aacactagaa	1140
	gatgaatcttg	gatgtacata	ccggatgtaaa	gaaaggcttgc	agagacatat	aaaggacata	1200
	aatatgttcac	agacatctt	ccaaaaacca	acaggcttgcgt	cagccatagaa	gatggcaata	1260
	gatgaagtcag	cagaacaaatt	cgaacataga	tcatgtcaag	aaacggatgtt	aaacaccccaa	1320
	tcatctataa	ttcaaatatgc	ttgggcagaa	ggaaacagaa	gcgtatgtcg	gactgagcaa	1380
	gatacagaat	ctgacaaatat	caacactggaa	caacaaaaca	tcatgagacag	actaaacaaag	1440
	agactcaacg	aaaagaagaaa	acaaaggcagt	caaccaccta	ccaaatcccc	aaacagaacg	1500
	aatcaggacg	aaatagatga	tctgtttat	gcattttggaa	gcaactaa		1548

<210> 136
<211> 2910
<212> DNA
<213> human Adenovirus

<220>
<221> gene
<222> (1)...(2910)
<223> human Adenovirus
strain 105
accession number ai293903

<400>	136	atggctaccc	cttcgatgat	gccgcagtgg	tcttacatgc	acatctcgaa	ccaggacgccc	60
tcggagttacc		tgagccccgg	gtctgggtgcag	tttgcggcg	ccacccggac	gtacttcgc		120
ctgaaataaca		agtttagaaa	ccccccatgg	gcgcctatgc	acgacgtgac	cacagacccgg		180
tcccagcggt		tcacgcgtcg	gttcatccct	tggttgcgg	aggataccgc	gtactcgatc		240
aaggcgccgt		tcacccctggc	tggtgggtgac	tttgatatggc	ttccacgtac			300
tttgacatcc		gcccgggtgtc	ggacaggggc	cctacttca	agccctactc	tggcaactgccc		360
tacaacgcctc		tagctcccaa	gggcgtctcc	aactccgttg	atgtgggaaca	aaaaggaaat		420
acggccggcc		gggttggccga	gtgtgaagaa	gaagaggaa	atgaagatga	agaagaggaa		480
gaggaaagagc		aaaacgcgtcg	agatcaggct	actaagaaaa	cacatgttta	tgcccaggct		540
cctttgtctg		gagaaacaat	tacaaaaaagc	gggctacaaa	taggatcaga	caatgcagaa		600
acacaacgtt		aacctgttata	tgcagatctc	tcctatccac	cagaacactca	aattggcggaa		660
tctctaggta		acgcgaactgt	tgtctaatgca	ggggaggagga	gagtgtttaa	aaaaaaacaact		720
cccatgaaac		catgtctatgg	atctttatgc	aggcctacaa	atcccttttgg	tggccaaatcc		780
gtccctgggtc		cggatgaaaaa	aggggggtgcct	cttccaaagg	tttgcatttgc	attcttctca		840
aatactactt		ttttgttacgaa	ccggcgttacaggc	aatgcctacta	aacccaaaatgt	gggtgttgatc		900
agtgaagatg		ttaatttttgg	aacccccagac	acacatctgt	tttacaaaacc	tgaaaaaaagggt		960
gatggaaaatg		ctaaagcttat	gtttgggttcaa	caatctatgc	aaacacagacc	caattacatc		1020
gcttttcaggg		acaatttttat	tggcctaaatg	tattataaca	gcactggcaa	catgggtgttt		1080
cttgcgtgttc		aggcatcgca	gtctaaatggcc	gtggtagatt	tgcacagacag	aaacacacagag		1140
ctgtccctatc		aacttttgc	tgatccat	ggtgatgatgg	ttagatattt	ttctatgttgg		1200
aatcagggtt		tagacgacta	tgaccccgat	gttagaatca	ttgaaaaacc	ttgaaactgag		1260
gatgaatttgc		caaattttattt	tttcccttctt	gggggttattt	gggttaacttga	cacccatcaa		1320
gcttattttaagg		ctaatggcaa	tggcgacgg	gataatggaa	atactacatg	gacaaaaagat		1380
gaaaatttttgc		caacacgttaa	tggaaataggaa	gtgggttaca	actttttccat	ggaaaattttaac		1440
cttaatttttgc		acccatgtgg	aaattttctt	tacttccata	tttgcataata	ccctggccagat		1500
aagctaaaaat		acaaccccccac	caacgttqaa	atatcttqaca	accccaacac	cttcaactac		1560

46/52

atgaaacaagg	gagtgggtggc	tcctgggctt	gtagactgct	acattaaccc	tggggcgccgc	1620
tggtcctcgg	actacatggc	caacgttaat	ccctttaacc	accaccgcaa	tgcgggcctg	1680
cgttaccgc	ccatgttgtt	gggaaaacgga	cgctacgtgc	ctttcacat	tcaggtgccc	1740
caaaagtttt	ttgcctttaaa	aaaccccttc	ctcctgccc	gtcatacac	atatgaatgg	1800
aacttcagg	aggatgttaa	catggttctg	cagagctctc	tggaaaacga	ccttagagtt	1860
gacggggcta	gcattaaagtt	tgacagcatt	tgtctttacg	ccacacccctt	ccccatggcc	1920
cacaacacgg	cctccacgc	ggaagccat	ctcagaaatg	acaccaacga	ccagtcctt	1980
aatgactacc	tttccgcgc	caacatgc	tatccacata	ccgccaacgc	caccaacgtg	2040
cccatcttca	tcccatcg	caactgggc	gcatttcgc	gttgggcctt	cacacgttg	2100
aagacaaaagg	aaaccccttc	cctgggatca	ggctacgacc	cttactacac	ctactctggc	2160
tccataccat	accttgacgg	aaccttctat	cttaatcaca	cctttaagaa	gttggccatt	2220
acttttgaci	cttctgttag	ctggccggc	aacgaccgc	tgttactcc	caatgagtt	2280
gagattaagg	gctcagttga	cgggggaggg	tataacgtag	ctcagtgc	catgacaaaag	2340
gactgtttc	tagtgcagat	gttggcaac	tacaatattg	gttaccagg	cttttacatt	2400
ccgaaagct	acaaaagaccg	catgtactcg	ttcttcagaa	acttccagcc	catgagccgg	2460
caagtgtgtt	acgatactaa	atacaagat	tatcagcagg	tttgaattat	ccacccagcat	2520
aacaatcg	cttcgttagg	ctacactcg	cccacccatgc	gcgagggaca	agcttacccc	2580
gtaatgttc	cctacccccc	aataggccaa	accgcggtrt	atagttttatc	ccagaaaaag	2640
tttcttgcg	accgcacccct	gtggcgcatc	ccattttcca	gttactttat	gtccatgggt	2700
gcgcacacg	acctgggcca	aaaccttctc	tacgcaact	ccgcccacgc	gctagacatg	2760
accttggagg	tggatcccat	ggacgagcc	acccttctt	atgttttgtt	tgaagtctt	2820
gacgtgttcc	gtgtgcacca	gcccaccc	ggcgtcatcg	agaccgtgt	cctgcgcacg	2880
cccttctcg	ccggcaacgc	cacaacataa				2910

<210> 137

<211> 810

<212> DNA

<213> human Enterovirus

<220>

<221> gene

<222> (1)...(810)

<223> human Enterovirus

strain Coxakievirus B1
accession number m16560

<400> 137

cggcccttga	atgcggctaa	tccttaactgc	ggagcacata	ccctcaaaacc	agggggcagt	60
gtgtcgtaac	ggggcaactct	gcagcggaaac	cgactacttt	gggtgtccgt	gtttcatttt	120
attccatatac	tggctgtctt	ttgtgacaat	tgacaggttt	ttaccatata	gttattggat	180
tggccatccg	gtgactaaca	gagcaattat	atatctttt	gttgggttta	taccacttag	240
cttggaaagag	ttttaaaacat	tacatctcat	cattaaacta	aatacaacaa	aatgggggct	300
caagttatcaa	cacaaaagac	tggagcacat	gagaccgggc	tgaatgc	cgggaaatcc	360
atccatccatt	acacaaaacat	aaactactat	aaagatgtcg	catccaactc	agccaaacaga	420
caggatttca	ctcaagaccc	aggtaaattt	actgagccag	tgaaggacat	tatgatcaaa	480
tcgatgtccag	cattgttgc	ccccctgtcc	gaagagtgt	gtttagatgt	cagggttcga	540
tcaataaccc	tcgggaactc	cactatcaca	acacaggagt	gtgctaattgt	tgtgttggg	600
tatgtgtgt	ggccagaata	tttgaaggac	aatgaagcca	caggcgagga	ccaaaccaaca	660
caatccgcg	tggccacatg	tggtttctc	actttagat	ccgtgcagt	gatgaagaat	720
tcagcagggtt	gggtgtggaa	gttaccaggat	gcactttcac	aaatgggggtt	gtttggacaa	780
aatatgcagt	accactactt	aggggagaaca				810

<210> 138

<211> 681

<212> DNA

<213> human Rhinovirus

<220>

<221> gene

<222> (1)...(681)

<223> human Rhinovirus

strain 14
accession number k02121

<400> 138

taacccttaga	gccttatgccc	acgatccagt	ggttgtttaagg	tcgttaatgt	caattccgggg	60
acgggaccga	ctacttttggg	tgtccgtgtt	tctcatattt	tcttatgttc	120	
acagcatata	tatacatata	ctgtgtatcat	gggcgttcag	gtttctacac	agaaaaagtgg	180
atctcacgaa	aatcaaaaaca	ttttgaccaa	tggatcaaatt	cagactttca	cagttataaa	240
ttactataag	gatgcagcaa	gtacatcatc	agctggtcaa	tcaactgtcaa	tggacccatc	300
taagtttaca	gaaccaggta	aaagatctcat	gcttaagggt	gcaccagcat	tgaatttcaacc	360
caatgttgag	gcctgtggtt	atagtgtat	agtacaacaa	atcacactcg	ggaatttcaac	420

47/52						
aataacaaca	caagaaggag	ccaacgctgt	tgtgtgttat	gctgaatggc	cagagtacct	480
tccagatgtg	gacgctagtg	atgtcaataa	aacttcaaaa	ccagacactt	ctgtctgtag	540
gttttacaca	ttggatagta	agacatggac	aacaggttct	aaaggctggt	gctggaaatt	600
accagatgca	ctcaaggata	tgggtgtgtt	cgggcaaaaac	atgttttcc	actcactagg	660
aagatcaggt	tacacagtac	a				681
<210> 139						
<211> 21						
<212> DNA						
<213> human Influenza A virus						
<220>						
<223> primer no 12 multiplex assay						
<400> 139						
cttctaaccg	aggtcgaaac	g				21
<210> 140						
<211> 24						
<212> DNA						
<213> human Influenza A virus						
<220>						
<223> primer no 13 multiplex assay						
<400> 140						
agggcatttt	ggacaaagcg	tcta				24
<210> 141						
<211> 20						
<212> DNA						
<213> human Influenza B virus						
<220>						
<223> primer no 14 multiplex assay						
<400> 141						
ttacactgtt	ggtttcggtgg					20
<210> 142						
<211> 20						
<212> DNA						
<213> human Influenza B virus						
<220>						
<223> primer no 15 multiplex assay						
<400> 142						
gccagttttt	ggacgtcttc					20.
<210> 143						
<211> 23						
<212> DNA						
<213> human Respiratory Syncytial Virus						
<220>						
<223> primer no 16 multiplex assay						
<400> 143						
aacagtttaa	cattaccaag	tga				23
<210> 144						
<211> 23						
<212> DNA						
<213> human Respiratory Syncytial virus						
<220>						
<223> primer no 17 multiplex assay						
<400> 144						
tcattgactt	gagatattga	tgc				23

48/52

<210> 145
<211> 26
<212> DNA
<213> human Parainfluenza 1 virus

<220>
<223> primer no 22 multiplex assay

<400> 145
tctggcggag gagcaattat acctgg 26

<210> 146
<211> 26
<212> DNA
<213> human Parainfluenza 1 virus

<220>
<223> primer no 23 multiplex assay

<400> 146
atctgcatca tctgtcacac tcgggc 26

<210> 147
<211> 22
<212> DNA
<213> human Parainfluenza 1 virus

<220>
<223> human Parainfluenza 1 virus
primer P1

<400> 147
gtatgggtga gaaacgaaga tg 22

<210> 148
<211> 22
<212> DNA
<213> human Parainfluenza 1 virus

<220>
<223> human Parainfluenza 1 virus
primer P2

<400> 148
ttgttaccaca gcaacaccca tt 22

<210> 149
<211> 26
<212> DNA
<213> human Parainfluenza 3 virus

<220>
<223> primer no 24 multiplex assay

<400> 149
aacaggaaac tatgtgcag aacggc 26

<210> 150
<211> 26
<212> DNA
<213> human Parainfluenza 3 virus

<220>
<223> primer no 25 multiplex assay

<400> 150
gatccactgt gtcaccgctc aatacc 26

<210> 151
<211> 25
<212> DNA
<213> human Parainfluenza virus

49/52

<220>		
<223>	humna Parainfluenza virus	
	primer P3	
<400>	151	
	tcttgcttca ttcttcaata caatc	25
<210>	152	
<211>	23	
<212>	DNA	
<213>	human Parainfluenza 3 virus	
<220>		
<223>	human Parainfluenza 3 virus	
	primer P4	
<400>	152	
	aattccatca gagttttaa tct	23
<210>	153	
<211>	18	
<212>	DNA	
<213>	human Adenovirus	
<220>		
<223>	primer human Adenovirus P5	
<400>	153	
	actccctcga tgatgccg	18
<210>	154	
<211>	26	
<212>	DNA	
<213>	human Adenovirus	
<220>		
<223>	primer no 26 multiplex assay	
<400>	154	
	cctacgcacg atgtgaccac agaccg	26
<210>	155	
<211>	26	
<212>	DNA	
<213>	human Adenovirus	
<220>		
<223>	primer no 27 multiplex assay	
<400>	155	
	gtgttgttagg cagtgccgga gtaggg	26
<210>	156	
<211>	21	
<212>	DNA	
<213>	human sars Coronavirus	
<220>		
<223>	primer SARS no P5	
<400>	156	
	ctaacatgct taggataatg g	21
<210>	157	
<211>	21	
<212>	DNA	
<213>	human sars Coronavirus	
<220>		
<223>	human sars Coronavirus	
	primer P6	

50/52

<400> 157	
caggtaagcg taaaactcat c	21
<210> 158	
<211> 24	
<212> DNA	
<213> human Sars Coronavirus	
<220>	
<223> human Sars Coronavirus	
primer P7	
<400> 158	
atgaatttacc aagtcaatgg ttac	24
<210> 159	
<211> 22	
<212> DNA	
<213> human Sars Coronavirus	
<220>	
<223> human Sars Coronavirus	
primer P8	
<400> 159	
cataaccagt cggtagctt ac	22
<210> 160	
<211> 16	
<212> DNA	
<213> human Enterovirus/human Rhinovirus	
<220>	
<223> primer no 28 multiplex assay	
<400> 160	
ctactttggg tgtccg	16
<210> 161	
<211> 19	
<212> DNA	
<213> human Enterovirus/human Rhinovirus	
<220>	
<223> primer no 29 multiplex assay	
<400> 161	
ggtaattcca ccaccanc	19
<210> 162	
<211> 23	
<212> DNA	
<213> human Influenza A virus	
<220>	
<223> probe no 30 multiplex assay	
<400> 162	
tcttcaggc tctgtgcgtat ctc	23
<210> 163	
<211> 23	
<212> DNA	
<213> human Influenza B virus	
<220>	
<223> probe no 31 multiplex assay	
<400> 163	
agctcagcgc tactatattg tct	23

51/52

<210> 164
<211> 23
<212> DNA
<213> human Respiratory Syncytial virus

<220>
<223> probe no 32 multiplex assay

<400> 164
ccttccagct tggttacata gta

<210> 165
<211> 23
<212> DNA
<213> human Parainfluenza 1 virus

<220>
<223> probe no 35 multiplex assay

<400> 165
aagtaccgtt tctgtcttca cat

<210> 166
<211> 23
<212> DNA
<213> human Parainfluenza 3 virus

<220>
<223> probe no 36 multiplex assay

<400> 166
cctgcactgt tccatcttgt ctg

<210> 167
<211> 18
<212> DNA
<213> human Adenovirus

<220>
<223> probe no 37 multiplex assay

<400> 167
cgcgtaactcg tacaaggc

<210> 168
<211> 23
<212> DNA
<213> human Rhinovirus

<220>
<223> probe no 38 multiplex assay

<400> 168
attcagcata acacacaaca gcg

<210> 169
<211> 23
<212> DNA
<213> human Enterovirus

<220>
<223> probe no 39 multiplex assay

<400> 169
cctgtgggtt cattgtccctt caa

<210> 170
<211> 558
<212> DNA
<213> human Herpesvirus 2

<220>

52/52

<223> modified human Herpesvirus 2
 internal control
 multiplex no 1

<400> 170
 ttacactgtt ggttcggtgg cgactttgcc agcctgtacc ccagcatcat ccaggccccac 60
 aaccctgtgt tcagtagctt cccctgcgg cccgaggccg tcgcgcaccc ggaggccggac 120
 cgggactacc tggagatcga ggtggggggc cgacggctgt tcttcgtgaa ggcccacgtt 180
 cgcgagagcc tgcgtggcat cctgcgtgcg gactggctgg ccatgcgaaa gcagatccgc 240
 tcgcggatcc cccagagcac ccccgaggag gccgtccctcc tcgacaagca acaggccgc 300
 atcaagggtgg tgcgtggcat cgtgtacggg ttacccgggg tgcagcacgg tcttcgtccc 360
 tgcctgcacg tggccggcac cgtgacgacc atcgccgcgt agatgtctct cgcgacgcgc 420
 gcgtacgtgc acgcgcgctg ggcggagttc gatcagctgc tggccgactt tccggaggcg 480
 gccggcatgc gcgcggccgg tccgtactcc atgcgcatca tctacgggga cacggactga 540
 agacgtccaa aaactggc 558

<210> 171

<211> 554

<212> DNA

<213> human Herpesvirus 2

<220>
 <223> modified human Herpesvirus 2
 internal control
 multiplex no 2

<400> 171
 ctactttggg tgcgtggcgt tttgccagcc tgcgtacccag catcatccag gcccacaacc 60
 tgcgtccatcg tgcgtctcc cttgcggcccg aggcgcgtgc gcacccgtggag gcccaccggg 120
 actacccgtt gatcgagggtg gggggccgcg ggctgttctt cgtgaaaggcc cacgtacgcg 180
 agagccgtct ggcgtccatcg ctgcgcgtact ggctggccat gcaaaaggcag atccgcgtcg 240
 ggatccccca gggccaccccg gaggaggccg tcctccgtca caagcaacag gcccacatca 300
 aggtgggtgtg caactcgggtg tgcgtttca cccgggtgcgac gcacggcttt ctgcctgtcc 360
 tgcacgtggc cggccaccgtg acgaccatcg gcccgcgat gctccctcgcc acgcgcgcgt 420
 acgtgcacgc ggcgtggccg gagttcgtatc agctgtggc cgcactttccg gaggccgcgg 480
 gcatgcgcgc cccctgggtccg tactccatgc gcatcatcta cggggacacg gactggctgg 540
 tggtgaaat tacc 554

<210> 172

<211> 23

<212> DNA

<213> human Herpesvirus

<220>
 <223> Internal Control probe no 42
 multiplex assay

<400> 172
 acaccgagg tgcacaccacc ttg